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Abstract 
 
Chinese hamster ovary (CHO) cells are the predominant host cell type used in the 
production of recombinant therapeutic proteins. They are chosen as hosts, because of 
their ability to create, fold and modify proteins in a manner that makes them compatible 
with the human immune system. Moreover, CHO cells are tried and tested model 
organisms for bioprocess platforms, meaning regulatory body approval for new 
therapeutics is relatively easy to achieve. CHO cells are inherently genetically unstable, 
which can lead to a decline in productivity and poses a threat to product quality 
heterogeneity of stable cell lines. The primary aim of this thesis was to characterise 
genomic instability of a CHOK1SV cell line and measure directly the impact this 
genetic instability has on the fidelity of recombinant plasmid copies. The impact of this 
would be two-fold: Firstly, an accurate quantification of genetic instability type and 
frequency would be established. Secondly, the techniques used to characterise genetic 
instability would be evaluated as tools for the detection of instability in cell line 
development processes.  
 
Microsatellite analysis and karyotype analysis were used to assess CHO cell genomic 
instability at the base pair / gene copy number (GCN) level and the chromosome level 
respectively. Microsatellites were found to be effective markers for genetic drift and cell 
line relatedness. However, there was no substantial evidence of microsatellite 
mutational change, and so it could not be concluded that microsatellites are an effective 
marker for deficient DNA replication / DNA damage or mismatch repair. Microsatellite 
change did not correlate with changes in GCN or cell specific productivity (qP). There 
was substantial evidence of chromosomal aberration from Karyotype analysis, which 
showed considerable levels of aneuploidy and chromosome breakage/fusion events. It 
was concluded that CHO cells have an inherent chromosomal instability and that 
karyotyping is a promising tool for genetic instability cell line development 
assessments. However, there was no substantial association found between changes in 
CHO karyotype and changes in qP or GCN. 
 
In order to generate a stable GFP cell line for the investigation of recombinant plasmid 
genetic instability it was necessary to optimise an electroporation protocol. Preliminary 
	 xvii	
experiments indicated that standard industry conditions were suboptimal and so a 
Design of Experiments (DoE) – based strategy was used to optimise electroporation. 
Final optimal conditions (termed 320-26) improved transfection efficiency by 17%. 
 
The final results chapter outlines a novel single-molecule real time (SMRT) sequencing 
analysis platform, which maximises the sensitivity of the technology, enabling mutation 
calling from individual molecules at a 0.01% frequency. One mutation was present at 
high levels throughout the study, a C à T transition in the bacterial origin of 
replication, which is assumed to have originated from the original plasmid stock. There 
was no evidence of mutations arising in plasmid cloning or as a result of the pre-
integration CHO cell environment. Substantial levels of point mutation were found in 
recombinant plasmid copies. Mutations were randomly distributed along the length of 
the plasmid and were apparently not influenced by natural selection.  G and C residues 
were mutated to a greater extent than A and T residues, with G.C à A.T transitions 
predominating. This final assessment of CHO cell genetic instability shows the 
requirement for product quality checks during cell line development.
	 xviii	
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Chapter 1 
 
Introduction 
 
 
This chapter will present the wider subject knowledge surrounding the work presented 
in this thesis in order to provide context and reason for it. A summary of 
biopharmaceutical industry development, production processes and example 
achievements are given to highlight how advances have been made, processes have 
been optimised and some of the areas in which processes can still be improved upon. 
The chapter is written to broadly introduce the biopharmaceutical industry with a 
skewed focus towards the concepts investigated and discussed in this thesis and outlines 
how advancement of these areas could lead to the production of better drugs, more 
quickly and cheaply. A brief review of the more specific material surrounding each 
chapter will be presented in more detail at the start of each chapter.  
 
1.1. The Biopharmaceutical Industry 
 
Biological sources have long been exploited for therapeutic use, such as the use of the 
smallpox virus by Edward Jenner in 1796 to combat cowpox, which established 
vaccination therapy as a medical treatment (Baxby, 1999); the serendipitous discovery 
of penicillin in Staphylococcus by Alexander Fleming in 1928 marking the advent of 
antibiotic medicine (Ligon, 2004); the therapeutic potential of naturally occurring 
proteins such as insulin and antibodies (Walsh, 2000). These biological sources have 
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been shaped by millions of years of evolution, and harnessing them can offer a novelty 
and high degree of specificity to medical treatment. 
 
Cell cultivation methods have been developed over the last century to such an extent 
that they can be used as production factories for these biologics. The creation of 
permanent and immortal cell lines, which are able to be grown and phenotypically 
manipulated in sub-culture has enabled the progression of large-scale industrial 
bioprocesses (Kretzmer, 2002). The development of mammalian cell culture on this 
scale was largely driven by the need for human viral vaccines in the 1950s and has 
continued to be the primary cell type used for the production of biological therapeutics. 
This is because the specific protein folding and modification systems they employ are 
compatible with human cellular components and immune system (Butler, 2005, Dinnis 
and James, 2005).  
 
Initially only products native to cell type could be produced, so just a small range of 
usable molecules were obtainable and only at the low concentrations yielded naturally. 
Therefore, only a limited number of therapies could be established (Kretzmer, 2002; 
Walsh, 2000). However, during the early 1970’s techniques were developed to 
covalently link DNA molecules regardless of their base-pair sequence, giving rise to 
recombinant DNA technology. Insertion of target DNA into mammalian cell hosts 
became possible, facilitating the linkage of exogenous and endogenous DNA within the 
cell (Lobban and Kaiser, 1973, Kretzmer, 2002). Moreover, the fusion of continuously 
proliferating myeloma cells with antibody producing lymphocytes gave rise to 
hybridoma cells capable of both continuous proliferation and antibody production 
(Kretzmer, 2002, Kohler and Milstein, 1975). Through genetic engineering or fusion, 
using specific antibody-producing lymphocytes, many more proteins could be produced 
and on a larger scale, which meant that recombinant therapeutic proteins found greater 
medical application. The first recombinant therapeutic protein to be made available 
from recombinant DNA technology was human insulin (Humulin, Genentech) for 
diabetes treatment in 1982, produced in Escherichia coli (E. coli). However, many 
therapeutic proteins have a higher, cell type-specific, structural and molecular 
complexity than insulin, and so need to be cultivated within a mammalian host; the first 
of these products was tissue plasminogen activator (tPA) in 1987, which is an 
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anticoagulant primarily used in the treatment of heart attack and stroke (Butler, 2005, 
Kretzmer, 2002, Pineda et al., 2012). 
 
Furthermore, engineering strategies have enabled proteins to be refined by modification, 
which led to the production of more therapeutically efficient products. For example, 
changes to the sequence of insulin stopped the interaction of insulin molecules with 
each other, thus creating a faster acting and more efficacious product (Kretzmer, 2002, 
Walsh, 2000, Olsen et al., 1996). Since the development of these technologies and the 
identification of more biomolecules with potential therapeutic applications a wider 
range of biologics have been produced in sufficient quantities to allow their medical 
application (Walsh, 2000). 
 
The modern definition of a biopharmaceutical is an engineered protein or nucleic acid 
which can be used for in vivo diagnostic or therapeutic purposes (Walsh, 2002). The 
biopharmaceutical industry is currently thriving with 212 products on the market 
(Walsh, 2014). The top ten products in the USA are presented in Table 1.1a. In the USA 
alone sales in 2012 reached $63.6 billion, which was an 18.2% increase from 2011 
(Aggarwal, 2014). This illustrates the scale of growth in this industry. The major targets 
of these therapeutic products are cancer, infectious diseases, autoimmune disorders and 
cardiovascular disease (Walsh, 2005). A wide range of therapeutic molecules (Table 
1.1b) are used, the five most common being monoclonal antibodies (mAbs), hormones, 
growth factors and fusion proteins and cytokines. In particular, monoclonal antibodies, 
which generate $24.6 billion in US sales (approximately 39% of total biopharmaceutical 
sales), dominate the biopharmaceutical market (Aggarwal, 2014, Dinnis and James, 
2005). 
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Table 1.1. Biopharmaceutical Sales of Top Selling Products 
Therapeutics are given in terms of therapeutic names (a), product types (b) and biotech 
companies (c). (Adapted from Aggarwal, 2014) 
 
 
Nearly 50% of new biopharmaceutical products being approved are biosimilars (Walsh, 
2010), which are alternative versions of already existing products. When patents on 
biopharmaceutical products expire, competing biotech companies (top ten – Table 1.1c) 
are permitted to create their own version of a product. In some cases drugs are 
engineered to be more efficient than the original and can often be produced more 
cheaply. These drugs are called biobetters (Barbosa, 2011). Furthermore, the release of 
this information can advance general understanding and lead to the discovery of novel 
products (Covic and Kuhlmann, 2007, Mellstedt et al., 2008). The first of these products 
was Omnitrope (Sandoz), a biosimilar of the human growth hormone somatroptin 
(Moran, 2008). 
 
Biological therapeutics, such as mAbs, have aided the treatment of a large number of 
conditions and had a positive impact on the quality of life of many patients. Clearly, 
there is a high demand to make therapeutic proteins cheaper, more efficient and of high 
A  B  C  
Product 
Sales 
($ Billions) 
Product Type 
Sales 
($ Billions) 
Company 
Sales 
($ Billions) 
Humira 4.6 mAb 24.6 Roche 13.2 
Lantus 4.51 Hormones 16.1 Amgen 12.9 
Enbrel 3.9 Growth Factors 8.1 Sanofi 5.1 
Remicade 3.6 Fusion Proteins 5.8 Novo Nordisk 4.9 
Rituxan 3.5 Cytokines 4.9 J&J 4.7 
Neulastsa 3.5 Therapeutic 
Enzymes 
1.4 Abbott 4.6 
Novolog 2.97 Blood Factors 1.2 Biogen Idec 3.9 
Avastin 2.8 Recombinant 
Vaccines 
1.1 Lilly 3.6 
Humalog 2.08 Anti-coagulants 0.4 BMS 1.7 
Herceptin 1.9   Merck 0.9 
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quality to ensure that success in treatment can continue to be improved upon and 
become as widespread as possible (Dinnis and James, 2005, Shukla and Thommes, 
2010). 
 
1.2. Recombinant Protein Expression: Expression Systems 
 
The production of biologics by biopharmaceutical companies is governed by certain 
aspects of the production process, such as cost-effectiveness, efficacy, effectiveness, 
time to market and safety, amongst others. Therefore it is important to use expression 
systems flexible enough to provide a manufacturing platform capable of fulfilling all of 
these criteria for multiple biologics at an individual level (Ferrer-Miralles et al., 2009, 
Li et al., 2010). Due to the large variation in recombinant proteins with potential 
therapeutic functions and the additional complexity of protein folding and post-
translational modifications (PTMs), it is unlikely that there will be a naturally occurring 
expression system capable of making all biologics. Different expression systems are 
metabolically diverse from one another. Therefore particular expression systems are 
better adapted for particular applications (Andersen and Krummen, 2002, Ferrer-
Miralles et al., 2009). The cell types harnessed for biopharmaceutical production show 
great amenability to a range of culture conditions and desirable phenotypes, through 
both adaptive evolution and engineering techniques. This enables the production of a 
vast amount of biopharmaceuticals from a single organism (Mohan et al., 2008, Davies 
et al., 2013). 
 
1.2.1. Non-mammalian Systems and Important Characteristics. 
 
Prokaryotes have been utilised as biologic expression platforms for many applications, 
such as the production of Humulin by E. coli. Much of our initial understanding of 
molecular biology was centered around E. coli, so it is extremely well characterised. 
Therefore, our understanding of molecular genetics and the development of genetic 
tools for engineering were established in a prokaryotic background and so generating an 
engineered production organism is relatively straightforward. Moreover, it is easy to 
rapidly culture bacteria and produce large yields of recombinant product. Simple 
molecules such as hormones, interferons and interleukins are amongst the approved 
therapeutic products synthesised by E. coli (Ferrer-Miralles et al., 2009). However, 
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generally, their ability to produce complex humanised proteins is limited, because they 
naturally process proteins differently to a eukaryotic cell and so lack the ability to carry 
out complex eukaryotic processes. A humanised protein must be folded in the correct 
conformation and attain the correct PTMs, such as acetylation, carboxylation, 
amidation, glycosylation and phosphorylation. Such modifications affect the efficacy of 
a protein through properties such as specificity, stability and activity (Walsh and 
Jefferis, 2006). The differences between proteins produced by prokaryotes and 
eukaryotes is enough to cause an immunogenic reaction when a potential therapy is 
administered, because the immune system would likely recognise these differences and 
elicit an immune response (Ferrer-Miralles et al., 2009).  
 
Glycosylation is the most influential PTM in terms of therapeutic specificity, because it 
is the most commonly found PTM in eukaryotic organisms, with over 50% of all human 
proteins being glycosylated (Walsh and Jefferis, 2006). Protein glycosylation affects 
protein folding, secretion, degradation, cell signaling, immune function and 
transcription, so is likely to have a significant impact on a proteins therapeutic function. 
The potential variation in glycosylation profiles makes it a more varied and 
consequently more complicated attribute than the proteome itself, which means that 
each organism’s glycosylation profile can be extremely specific (Lauc et al., 2010). 
Therefore, it is essential to make sure a host expression system is capable of producing 
a recombinant protein with a glycosylation profile compatible with humans so it does 
not provoke an immune response (Ferrer-Miralles et al., 2009). Protein glycosylation 
pathways do exist in prokaryotes, and these can be engineered into, and implemented, in 
an E. coli system. However, there are distinct differences between this form of 
glycosylation and that which occurs in a mammalian system. If prokaryotes could be 
engineered to produce humanized glycosylation forms then they would likely come to 
the fore in biopharmaceutical production (Abu-Qarn et al., 2008, Valderrama-Rincon et 
al., 2012). 
 
Therefore, for the time being, eukaryotes are better candidates for the production of 
therapeutic proteins, especially complex ones, because their metabolism allows them to 
produce these proteins with the correct specificity in structure and PTMs so not to elicit 
an immune response (Walsh and Jefferis, 2006, Ferrer-Miralles et al., 2009, Andersen 
and Krummen, 2002). The eukaryotic production systems able to carry out the protein 
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folding and PTMs needed to produce humanised proteins are yeast, insect, plants and 
mammalian cells (Walsh, 2006). Plants can be utilised as production vehicles for 
recombinant proteins both in the form of transgenic plants and plant cell culture. 
Commercially, plants have been able to successfully produce animal proteins. 
Recombinant plant technology offers high yields, low cost, low chance of pathogen 
contamination and the protein can be produced in storage organs such as seeds to ease 
purification (Sharp and Doran, 2001, Giddings et al., 2000). However plant-based 
recombinant technology is less developed than other expression systems and attaining 
regulatory approval for engineered plants is a challenge. Until a robust, tested and 
trusted infrastructure is in place it is unlikely that plants will challenge mammalian cells 
as a production platform (Hellwig et al., 2004, Fischer et al., 2012).  
 
Yeasts, like plants, are able to produce high yields of recombinant protein at a low cost. 
Furthermore, like E. coli they exhibit quick growth and are extremely well characterised 
and understood, because they formed the basis of our understanding of the eukaryotic 
cell cycle, amongst other processes. The two most utilised strains for recombinant 
protein production are Saccharomyces cerevisiae (S. cerevisiae) and Pichia pastoris (P. 
pastoris) (Demain and Vaishnav, 2009). The glycan structure in mammalian and yeast 
cells is the same as it arrives at the Golgi. However, the mammalian Golgi elicits 
various trimming and extension reactions, resulting in a sialylated glycan structure. On 
the other hand, rather than trim, yeast adds further mannose groups thus resulting in 
recombinant protein unsuitable for therapeutic use. Despite this, P. pastoris is a 
promising expression system. Through a series of engineering strategies it is capable of 
producing proteins with humanized glycosylation profiles. This along with its good 
growth characteristics and protein secretory mechanisms makes P. pastoris a capable 
production system. It has already been successfully engineered to produce proteins such 
as insulin precursor, interleukin 2 and tumour necrosis factor amongst others 
(Macauley-Patrick et al., 2005, Demain and Vaishnav, 2009, Berlec and Strukelj, 2013, 
Hamilton and Gerngross, 2007). 
 
Whilst these expression systems have all shown promise they are not yet producing to 
the same quality or quantity as the industry standard of mammalian cells (Dinnis and 
James, 2005). Non-mammalian cells are more likely to stimulate an immune response, 
because of their lack of specificity in PTMs (Raju, 2003). For example, plants 
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consistently add α1,3-fucose and β1,3-xylose sugars, which elicit immunogenic 
responses in humans (Walsh and Jefferis, 2006). Furthermore, there needs to be further 
development and understanding before these alternative expression systems could offer 
a potential replacement to mammalian cells. For example, P. pastoris, which is arguably 
the best non-mammalian production system, still needs a great deal of process 
optimisation. Yields produced are still three to five-fold less than the gold standard of 
mammalian cell systems and the heterogeneity and stability of glycosylation is still 
something that needs to be proven in its consistency. However, it is believed that yeast 
systems will reach these standards, the confidence of which is reinforced by the 
endorsement of the technology by Merck & Co by taking over Glycofi technology in 
2006 (Beck et al., 2010). Although these technologies show promise, it is mammalian 
systems that predominate the production of humanised therapeutic proteins, despite 
being expensive and slow in comparison to alternative systems (Demain and Vaishnav, 
2009). Moreover, it is likely that process outputs would need to show considerable 
improvements for companies to consider the replacement of the mammalian systems for 
which the industry has been moulded upon. 
 
1.2.2. Mammalian Expression systems 
 
Mammalian cells currently dominate the biopharmaceutical market with 60-70% of 
recombinant therapeutic proteins being produced by mammalian cell culture. To put this 
into context, biopharmaceutical sales currently constitute 27% of total drug sales and 
are growing at a rate 7-fold higher than the pharmaceutical sales overall (Wurm, 2004, 
O'Callaghan and James, 2008, Walsh, 2014, Aggarwal, 2014). Therefore mammalian 
cell culture is a hugely important platform in the drug market. As described previously 
this is largely due to their ability to correctly fold and assemble large, complex 
molecules and carry out the appropriate PTMs to make a protein suitable for therapeutic 
application in humans both in terms of their therapeutic activity and safety. Also, as 
higher eukaryotes, mammalian cells are able to recognise secretion signal sequences in 
the recombinant gene and the mammalian cell machinery is able to mediate the 
successful secretion of the recombinant gene product (Barnes et al., 2000, Page, 1988). 
A great amount of research and development has, and continues, to be carried out on 
mammalian cell culture, cell biology and cell engineering. There are a variety of 
mammalian cell types currently being used and developed for recombinant protein 
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production, including Chinese Hamster Ovary (CHO), Mouse Myeloma (NS0), Baby 
Hamster Kidney (BHK) and Human Embryonic Kidney (HEK-293) (Wurm, 2004). The 
choice of cell line is largely down to its ease of large-scale culture, high growth rates, 
cell specific productivity (qP), titers and their ability to produce a efficacious and safe 
product (O'Callaghan and James, 2008). CHO expression systems are the most widely 
used, which is due not only to their protein folding and PTMs, but also to their ability to 
be cultured quickly and robustly on a large scale, their simplicity in transfection and 
recombinant gene integration, and their ease of product approval by the FDA (Jayapal et 
al., 2007, Wurm and Hacker, 2011, Wurm, 2004). 
 
Cell line engineering is an area of research and development that has resulted in process 
improvements in the manufacturing of biological therapeutics in mammalian cells in 
terms of increased recombinant gene expression, product quality and cell attribute 
improvement. For example increased sialylation was achieved by increased expression 
of sialyl transferase and the production of non-fucosylated products by creating FUT8 
knockout cell lines. These changes have led to the production of specific and more 
efficacious proteins, increasing their therapeutic potential (Zhu, 2012, Bork et al., 2009, 
Shields et al., 2002, Iida et al., 2006, Wong et al., 2010). In another example, 
engineering against late cell culture conditions that can induce apoptosis, such as 
nutrient and oxygen depletion and the accumulation of harmful bi-products, was 
achieved by overexpression of Bcl family members and E1B-19K. This significantly 
increased mAb productivity and created cells that are more robust to these conditions 
(Dorai et al., 2010, Dinnis and James, 2005, Zhu, 2012). In a further example, 
engineering strategies have been used to improve production of difficult to express 
proteins. This could serve to increase the number of proteins with therapeutic potential 
finding commercial application. Pybus et al. (2014) varied the mAb LC: HC ratio and 
the expression of foldases, chaperones and unfolded protein response (UPR) 
transactivators to subvert UPR induction, thus increasing mAb productivity in a product 
specific manner. In general, as the understanding of the mechanistic processes of the 
cell increases more engineering targets can be identified and researched (Dinnis and 
James, 2005). 
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1.3. Recombinant Protein Expression: The Process in Mammalian Cells 
 
1.3.1. Stable Gene Expression 
 
Stable gene expression (SGE) is the term used to describe permanent expression of a 
recombinant protein by a cell host. This is achieved by introducing a plasmid DNA 
vector containing the recombinant gene of interest, which facilitates its integration into 
the host organism’s genome. Subsequently, highly expressing clonal populations are 
generated, expanded and used for screening and further analysis (Makrides, 1999).  
 
There is a very well established platform (Figure 1.1) for the stable expression and 
subsequent production of recombinant proteins in mammalian cells (Jayapal et al., 
2007, Wurm, 2004). After a potential therapeutic product has been identified its DNA 
sequence is determined and the gene of interest is inserted into a plasmid along with a 
selection gene, which will give recombinant cells a survival advantage to ensure their 
propagation.  Carefully optimised genetic regulatory elements are included to govern 
gene expression. Mammalian cells are transfected with multiple copies of this plasmid 
and a small number of these will integrate into the mammalian host genome (Wurm, 
2004, Li et al., 2010). After a brief recovery period a selection agent is administered to 
the cells so that only cells with the selection gene, and subsequently the recombinant 
gene, survive. Therefore non-recombinants are gradually removed from the population. 
After selection the cell population will consist of a heterogeneous stable pool of 
expressing cells. Clonal populations are made by isolating single cell survivors, which 
are cultivated and expanded into, theoretically, homogenous cell lines. The clonal cell 
lines are tested for attributes desirable in a recombinant protein-expressing cell line. 
These attributes include high qP, growth characteristics in shaking flask and bioreactor 
conditions, and product quality. Eventually one cell line is taken forward for long term 
large-scale production and a cell bank is generated and frozen for future use. This 
process can take more than 6 months. Despite the success of this platform research, 
development and optimisation continue to improve this process (Wurm, 2004, Jayapal 
et al., 2007, Li et al., 2010, Kim et al., 2012, Birch and Racher, 2006). During this 
process clonal cell lines are expanded over multiple passages and go on to be cultured in 
laboratory-scale bioreactors to assess and optimise growth in these conditions. 
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Eventually, the cultures are scaled up to industrial bioreactor size for commercial 
production (Jayapal et al., 2007). 
 
This thesis focuses on upstream processes. However, for completeness, a brief summary 
of downstream processes is given here. It is important that optimised upstream methods 
are followed by efficient extraction and purification of recombinant proteins from cell 
culture. A large proportion of yield can be gained or lost by effective downstream 
methods and as a result have a large impact on manufacturing costs (Shukla et al., 
2007). The final product must be free from any impurities of the cell, bioreactor or the 
purification procedure itself. These impurities include protein A, media components, 
DNA, host cell protein, viruses and endotoxins (Shukla et al., 2007, Kelley, 2007). The 
downstream process will differ with each product, but there is a common industrial 
approach used. Briefly, the standard platform for mAb purification is as follows: Cells 
and cell debris are removed through centrifugation and depth filtration, which is 
referred to as cell culture harvesting. After this the mAb is captured directly by protein 
A affinity chromatography, binding specifically to the Fc region of the antibody and 
removes cell impurities such as DNA and host cell protein. This provides more than 
98% purity in a single step and is responsible for a large reduction in volume. Elution is 
carried out using low pH, serving as a viral inactivation step. The solution is neutralised 
before the polishing steps. Polishing typically consists of ion-exchange 
chromatographic techniques that help remove leftover impurities. After a viral filtration 
step an ultrafiltration/diafiltration process mediates the transfer of the product into its 
formulation buffer (Shukla et al., 2007, Shukla and Thommes, 2010). 
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Figure 1.1: Stable Cell Line Generation 
The figure briefly summarises the stable cell line generation process, as described in the 
text. 
 
 
1.3.2. Transient Gene Expression 
 
Transient gene expression (TGE) is an alternative method to generate producing cells, 
which offers very quick production of small amounts of protein rather than slow 
production of large amounts of protein. It is the quickest and least expensive way of 
producing recombinant protein (Wurm, 2004, Makrides, 1999). In TGE the ability of 
the multiple plasmid copies to produce recombinant protein extrachromosomally is 
utilised in order to rapidly assess aspects of the production process such as vector 
design and product efficacy. Therefore, this process is quick because there is no need to 
screen for successful genome integrations. TGE lasts around 10 days, because 
expression is rapidly lost when the plasmid copy number becomes diluted due to cell 
division and lost in line with plasmid half-life (Rita Costa et al., 2010, Barnes et al., 
2003, Baldi et al., 2007). Generally, TGE is used for initial analysis and characterisation 
Create Optimal Plasmid 
Vector
Transfection / Plasmid 
Integration
Selection / Screening for 
selective gene (by addition 
of selection pressure)
Creation of Clonal cell 
populations
Screening of Clonal 
populations for high 
producers / fast growers
Single cell line taken 
forward for production
Chapter 1: Introduction 
	 13	
of the cell line, recombinant protein and the plasmid vector used to express it, so that 
the process can be reviewed before taking a system and product into long-term cell 
culture. For example, different combinations of vector elements such as promoters and 
enhancers can be tested and optimised (Makrides, 1999). Process evaluation using the 
TGE process can take as little as three days and the parameters, which are evaluated as 
having been most successful, are taken on to produce long term stable cell lines (Wurm, 
2004). TGE is also being developed as a recombinant protein production method in its 
own right, being able to produce milligram to gram quantities in just a few days via 
large-scale transfection processes (Derouazi et al., 2004, Wurm, 2004, Zhu, 2012). If it 
can be done on a larger scale TGE can be used more in product process development 
meaning that SGE is not needed until the later stages of the bioprocess. This means that 
development can be done more quickly and is less resource intensive (Steger et al., 
2015). 
 
HEK293 and CHO cells are the most commonly used cell lines for TGE, with HEK293 
cells having the ability to produce the highest titers of recombinant protein. However 
even between two mammalian cell types, such as HEK293 and CHO, growth 
characteristics can differ and varied products can be manufactured from the same 
construct, because of the specific processing that occurs in an organism (e.g. PTMs). 
Most manufacturing is done via SGE and ideally the host system should be consistent 
throughout the production process. Due to the fact that CHO produce the majority of 
recombinant products via SGE, a great amount of research and development is trying to 
improve yields from TGE in CHO so that consistency can be maintained for the best 
producing mammalian cell type. For example, engineered CHO cell lines expressing T 
antigen and the presence of genetic elements such as OriP or SV40 Ori allows the 
prolonged episomal presence of the plasmid. Also, culturing cells with DMSO and in 
hypothermic conditions has helped raise the yields achieved through TGE in CHO cells 
(Agrawal et al., 2013, Makrides, 1999, Wurm, 2004). 
 
1.3.3. Expression Vector and Selection System 
 
The expression vector primarily used for gene expression in mammalian systems is a 
DNA plasmid, which exists extrachromosomally and is designed to contain various 
elements that enhance transcription and translation (Wurm, 2004). A plasmid is often 
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linearised before transfection to enhance integration efficiency, but this is not essential, 
as it will be linearised in the nucleus before integration (Rita Costa et al., 2010, Wurm, 
2004). Typically, the plasmid will contain strong promoter and enhancer elements 
upstream of the gene of interest to drive its high expression. The function of a promoter 
is to be bound by transcription factors to initiate transcription. One such promoter is the 
cytomegalovirus (CMV) promoter and is the most widely used to drive strong 
expression in industrial platform processes. Promoters can be constitutively active, 
induced or repressed if a finer level of control is required over gene expression. 
Enhancer sequences are positioned further upstream and influence the activity of the 
promoter (Rita Costa et al., 2010, Makrides, 1999). Genetic elements are often included 
to elicit desirable RNA processing and stability. For example the SV40 Poly (A) tail is 
included to increase RNA stability as well as its role in transcription termination (Rita 
Costa et al., 2010). Moreover, genes in plasmid vectors do not contain introns like a 
regular gene would, but one is usually inserted to ensure transport of the mRNA from 
the nucleus to the cytoplasm, increasing the rate of translation. This is because during 
pre-mRNA splicing into mRNA the exon junction complex is added, which is thought 
to enhance the mRNA’s transport from the nucleus into the cytoplasm (Tange et al., 
2004, Wurm, 2004). Different organisms have a specific tRNA pool in their cells, which 
means that some anticodons are more common than others. Therefore to optimise 
translation gene sequences are usually codon-optimised to enhance protein production 
(Wurm, 2004). Sequences will also be altered so they do not contain cryptic poly(A) 
tails or splice sites and will be carefully assembled in such a way to avoid unwanted 
RNA folding (Birch and Racher, 2006). The expression of the selection gene will be 
driven by a weak promoter to make the selection process more stringent. Thus any 
given cell will need to contain recombinant plasmid copies capable of high expression. 
One example of this is the SV40 promoter (Kim et al., 2011, Rita Costa et al., 2010). 
The plasmid also contains bacterial elements such as antibiotic resistance gene and 
origin of replication for plasmid replication in a bacterial host prior to mammalian cell 
introduction (Birch and Racher, 2006, Rita Costa et al., 2010). 
 
In monoclonal antibody assembly the reaction kinetics are greatly influenced by the 
stoichiometric ratio of the heavy and light chains. To ensure efficient ratios the delivery 
of each gene can be optimised.  Typically, two methods have been used to attempt this: 
In the first, two plasmids can be used each containing one of the light or heavy chains 
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and the ratio is maintained by proportion of each plasmid going into the cell via co-
transfection. The problem with this method is that the plasmids will integrate into 
different genomic regions that are capable of different levels of gene expression. This is 
known as the position effect and will be discussed later in this section. Therefore, gene 
delivery of optimal gene ratios does not necessarily lead to optimal ratios of gene 
expression (Wurm, 2004, Rita Costa et al., 2010). The second method uses a single 
vector containing both genes, which can be under the same promoter or promoters with 
slightly different expression capabilities to try and encourage an optimal ratio for any 
given antibody. The problem with this method is that there is not yet a diverse enough 
range of readily available promoters for use in these vectors. However, recent studies 
have identified a range of synthetic promoters that could offer bespoke stoichiometric 
gene expression for any given protein (Brown et al., 2014). Moreover, the plasmid 
sequence often undergoes recombination resulting in gene loss. The choice of method 
differs in different systems and with different products (Rita Costa et al., 2010, Kim et 
al., 2011).  
 
A common system used industrially utilises the glutamine synthetase (GS)- vector 
(Figure 1.4), in which the gene for the GS enzyme is used as the selection gene (Barnes 
et al., 2000). For monoclonal antibody production this plasmid contains codon-
optimised genes for the antibody light and heavy chains and for GS. It also contains the 
strong viral CMV promoter upstream of the light and heavy chains and the weaker 
SV40 promoter upstream of the GS gene. Poly(A) tails are positioned downstream of 
each gene and introns are included to facilitate mRNA processing as mentioned 
previously. The β-lactamase ampicillin resistance gene (Amp) and the bacterial origin 
of replication are included for selection and replication in bacteria prior to transfection 
(Kim et al., 2011, Brown et al., 1992). GS is an enzyme which catalyses the production 
of glutamine from glutamate and ammonia and this is the only enzyme capable of 
glutamine synthesis in the cell. Therefore, cells cultured in media lacking glutamine will 
have more efficient growth when they have obtained the plasmid vector sequence (Jun 
et al., 2006). NS0 cells are often used with this system because they do not produce 
glutamine. CHO cells, on the other hand, can produce endogenous glutamine. However, 
the application of methionine sulphoximine (MSX), an inhibitor of GS, means this 
system is still applicable to CHO cells. The sequential addition of MSX to the cultured 
cells steadily increases the cell’s need for more GS to overcome MSX’s inhibitive 
Chapter 1: Introduction 
	 16	
effect, which causes the GS gene to be amplified within surviving cell population. 
Therefore the sequential addition of MSX indirectly amplifies the gene copy number of 
the mAb genes, which will result in the generation of more cells capable of producing 
higher amounts of recombinant protein. This is because cells, which do not contain 
amplified copies of the recombinant construct will not survive. (Jun et al., 2006, Barnes 
et al., 2001, Brown et al., 1992). More recently, CHO GS-knockout cell lines have been 
generated in order to prevent endogenous GS production. This removes the reliance 
upon the selection pressure to generate productive cell lines and has led to shorter 
process development times and higher levels of production (Fan et al., 2012). 
 
 
Figure 1.2: GS vector  
Each gene contains the coding region, intron and poly(A) tail. The SV40 viral promoter 
is used for the GS gene, whereas the CMV promoter is used for the light chain (LC) and 
heavy chain (HC) genes. The ampicillin resistance gene and bacterial origin of 
replication elements are contained for bacterial selection and replication. (Taken, with 
permission, from Kim et al., 2011). 
 
 
 
Another system utilizes the dihydrofolate reductase (DHFR) gene, which codes for an 
enzyme involved in nucleotide metabolism. In this case, specific CHO cell lines have 
been engineered to be DHFR-deficient. In the same way as MSX in the GS system, 
methotrexate (MTX) concentration in cell culture is sequentially increased in the DHFR 
system. This inhibits the production of hypoxanthine and thymidine, which are essential 
to the cell. Therefore, the DHFR and recombinant gene are amplified within the 
surviving cell population due to this treatment. The GS system is favoured because only 
one round of amplification is needed, so the process only takes 3 months, whereas the 
DHFR system, needing multiple rounds of amplification to achieve the required 
silencing by methylation. Methylation of cytosines within
promoter CpG islands may inhibit transcription factor
binding to cognate DNA sequences (Siegfried and Simon,
2010). Methylated CpG’s also recruit methyl-CpG-binding
proteins that inhibit transcription through recruitment of
transcriptional co-repressors and chromatin remodeling
(Clouaire and Stancheva, 2008; Klose and Bird, 2006; Wade,
2001). Alternative mechanisms of transgene silencing have
also been reported, such as (in amplified cell lines) repeat-
induced gene silencing (Garrick et al., 1998; McBurney et al.,
2002), or more generally histone modifications (hypoace-
tylation) (Richards and Elgin, 2002).
To design improved strategies for the generation of stable
cell lines, and to enhance our ability to distinguish stable
from unstable cell lines early in the cell line development
process, it is clear that we require an enhanced under-
standing of the underlying causes of production instability.
This study is a detailedmolecular analysis of 12 GS-CHO cell
lines, 2 producing a recombinant IgG1 monoclonal antibody
(Mab) and 10 producing a total of 5 different recombinant
IgG2 Mabs during extended sub-culture in the presence
of selective pressu e. We demonstrate that production
instability derives from two primary mechanisms: (i)
epigenetic—methylation-induced transcriptional silencing
of the CMV promoter driving Mab gen transcription and
(ii) genetic—progressive loss of recombinant Mab gene
copies in a proliferating CHO cell population. The latter
mechanism is far more prevalent than the former, although
production stability is clearly a cell line-specific phenom-
enon, where discrete mechanisms may overlap to yield a
unique inter-relationship between epigenetic modification,
genetic stability and productivity.
Materials and Methods
Cell Line Construction
Twelve suspension-adapted GS-CHO cell lines (A1-A2, B1-
B10) each producing a recombinant Mab were generated
using standard methodology (Porter et al., 2010). Briefly,
transfections were performed by electroporations of the host
cell line CHOK1SVTM (Lonza Biologics) with a linearized
plasmid vector (Lonza Biologics) encoding the glutamine
synthetase (GS) selection marker, Mab light chain (LC) and
Mab heavy chain (HC) genes in that order 50 to 30 (Fig. 1).
After transfection and initial selection in 50mMmethionine
sulphoximine (MSX; Sigma-Aldrich, Poole, UK), single cell
clones were generated either by capillary cloning (cell lines
A1, A2, B3–B10) or by single cell sorting using FACS (cell
lines B1, B2). Both cloning processes have been validated at
Pfizer to result in a> 95% probability of clonality. Cell lines
B1 and B2 express an IgG1 Mab, whilst the remaining cell
lines express a total of 5 different IgG2Mabs. Mab expression
vector constructs differed with respect to HC sequence,
where cell lines A1, A2, B1, B2, B3, and B7 utilized a non-
codon optimized HC sequence and cell lines B4, B5, B6, B8,
B9, and B10 were generated using a HC sequence that had
been codon-optimized along the entire sequence. Mab LC
constant domain and GS sequences were identical in all cell
lines.
Routine Culture Conditions
All cell lines were routinely sub-cultured in CD-CHO
medium (Invitrogen, Paisley, UK) supplemented with
25mM methionine sulphoximine (MSX; Sigma-Aldrich,
Poole, UK) in vent-capped Erlenmeyer flasks (Corning
Incorporated, Acton, MA). Cell lines A1 and A2 were seeded
at 2! 105 cells mL"1 and sub-cultured every four days and
maintained at 378C under 5% (v/v) CO2 in a shaking
incubator. Cell lines B1–B10 were sub-cultured every three
or four days and were seeded at 3! 105 viable cellsmL"1 and
maintained at 36.58C under 5% (v/v) CO2. Cell count and
viability was determined using a Vi-CELLTM Cell Viability
Analyzer (Beckma Coulter, CA). Cell line generation
number (i.e., population doublings) was calculated as
described in Greenwood et al. (2004). For the purpose of this
study the generation number was set to zero when cells were
Figure 1. Schematic representation of the vector(s) used to generate recombinant IgG-producing GS-CHO cell lines A1–A2 and B1–B10. Two Mab expression vector
constructs were used to generate the cell lines, each based on the construct shown. The vector constructs consisted of heavy chain (HC) and light chain (LC) cDNA cassettes each
under the control of separate human cytomegalovirus (CMV) promoters (PCMV), with the glutamine synthetase (GS) selection marker driven by the SV40 promoter (PSV40). The two
vectors differed only in the HC sequence; the vector used to generate cell lines A1–A2 and B1, B2, B3, and B7 contained the non codon-optimized HC sequence, whereas the vector
used to generate cell lines B4, B5, B6, B8, B9, and B10 contained the optimized HC sequence which had been codon optimized along the entire length of the HC sequence. For all
vectors the LC sequence was identical. Intron and polyA sequences are indicated, as are the b-lactamase ampicillin resistance gene (Amp) and the bacterial origin of replication
(Ori). For all cell lines the vector was linearized prior to transfection using a single restriction enzyme site located within the Amp gene.
2 Biotechnology and Bioengineering, Vol. xxx, No. xxx, 2011
Chapter 1: Introduction 
	 17	
productivity, is a 6 month process (Barnes et al., 2000, Barnes et al., 2001, Jun et al., 
2006, Wurm, 2004).  
 
1.3.4. The Position Effect 
 
The site at which plasmid DNA integrates into the mammalian cell genome has a large 
impact on the expression of the recombinant gene, which subsequently has a large 
impact on recombinant protein production. This is known as the position effect, which 
is largely due to epigenetic effects (Wurm, 2004). Epigenetic characteristics are 
heritable components of an organism’s genome, which can change expression, but are 
not coded by the DNA sequence itself. Gene expression depends on the DNA sequence 
of a coding regions regulatory elements, such as the promoter and enhancers, their 
activation and the structure of the chromosomal location at which those DNA sequences 
are located (Wolffe and Matzke, 1999). Indeed, the structure of chromatin can be open 
and easily accessible to transcription factors (euchromatin) or condensed by various 
modifications and bound proteins, leaving it far less accessible to transcription factors 
(Richards and Elgin, 2002, Mutskov and Felsenfeld, 2004).  
 
Therefore, the location at which a recombinant gene integrates with the host genome 
can greatly influence its level of expression (Wurm, 2004). There has been successful 
development of approaches to combat negative position effects (Wurm, 2004). For 
example boundary elements, such as insulators, are DNA sequences that surround the 
coding region and prevent interaction with outside effectors of expression, such as 
enhancers and heterochromatin. Therefore, these coding regions can function as an 
independent genetic unit within a chromosome (Geyer, 1997). Anti-repressor elements 
can be used to flank coding regions and stop the spread of heterochromatic features like 
methylation and hypoacetylation in order to preserve gene expression. Boundary 
elements such as these have been shown to enable the stable and long term expression 
of recombinant genes (Kwaks et al., 2003, Wurm, 2004). That being said, integration 
within heterochromatic regions and certain regions of euchromatin will still cause 
dampened or no expression (Lattenmayer et al., 2006). Therefore it is widely accepted 
that the successful development of gene integration targeting methods, whereby the 
plasmid DNA is targeted to a specific transcriptionally active genomic location 
(approximately 0.1% of the CHO genome), could make high gene expression more 
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consistent. This could greatly reduce the need for time consuming and expensive 
selection and screening steps (Lattenmayer et al., 2006, Zhou et al., 2010). 
Recombinases can be used to recombine sequences inserted into the plasmid with 
sequences in the genome known to be located in highly expressed areas (Wurm, 2004). 
Research in this field has shown promise, as shown by Zhou et al. (2010). In this work a 
reporter plasmid was transfected and single-copy gene expression was selected for in 
order to generate a cell population with transcriptionally active insertion sites. Next, a 
second plasmid, containing the gene of interest, was targeted to the initial insertion site 
using the FLP-FRT system. Successfully targeted integrants contained a second 
selection gene, reconstituted from sequences from both plasmids. Therefore, selection 
of desirable integrants could propagate the gene of interest within a transcriptionally 
active site. Finally, the DHFR system was used for gene amplification to produce high 
producing clones after very few rounds of amplification (Zhou et al., 2010). 
 
1.3.5. Transfection 
 
Transfection is the general term given to the introduction of nucleic acids into host cells 
and is used to promote expression of an exogenous product. Transfection can be termed 
stable or transient depending on whether the non-self DNA is expressed permanently 
(as described previously) or for a short period of time, respectively. Broadly, 
transfection methods are categorized into three types: biological, chemical and physical. 
None of these methods are considered the best for all systems, as each have their 
advantages in different situations (Wurm, 2004, Kim and Eberwine, 2010).  
 
Biological methods of transfection are carried out through viral delivery. Clearly 
viruses, by nature, have an evolved inherent ability to introduce foreign DNA to a host 
and typically this is done with a high transfection efficiency (Kim and Eberwine, 2010, 
Douglas, 2008). Despite this efficiency, gene delivery has moved away from viral-
mediated transfection methods due to safety concerns with viral toxicity, manufacturing 
limitations and plasmid size constraints (Douglas, 2008, Mehier-Humbert and Guy, 
2005). 
 
Chemical methods of transfection rely on the interaction of positively charged 
chemicals and negatively charged DNA, leading to the formation of DNA-chemical 
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complexes. Examples of this include DNA-Calcium phosphate co-precipitation, cationic 
lipid complexes, such as with lipofectamine, and cationic polymer based transfection 
such as with polyethylenimine (PEI). In each case the ratio of DNA to the chemical of 
choice needs to be optimised for any given system (Douglas, 2008, Rita Costa et al., 
2010). These complexes are able to form electrostatic interactions with the cell 
membrane, possibly with the help of cell surface proteins and other moieties, to enter 
the cell via endocytosis. The exact mechanism for this is yet to be elucidated. Indeed, 
the mechanism by which the chemical-DNA complexes leave the endosomes is also yet 
to be discovered. In the case of lipofection it is thought the complexes bind or 
destabilize the membrane in order for translocation to take place (Rita Costa et al., 
2010, Rehman et al., 2013). Whereas, it is thought that PEI soaks up protons within the 
endosome due to its large buffering capacity, leading to an increase in endosomal pH. 
This causes an osmotic swelling of the endosome due to the rapid influx of protons and 
chloride ions, which subsequently causes it to burst and release the PEI-DNA 
complexes into the cytosol. Moreover, it is postulated that the buffering capacity of PEI 
protects PEI-DNA complexes once they reach the liposomes by neutralizing the 
lysosomal compartment. Therefore the nucleases, which are active at a low pH, do not 
degrade the complexed DNA. It is also believed that PEI may facilitate the entry of 
DNA vector into the nucleus (Rita Costa et al., 2010, Tait et al., 2004, Akinc and 
Langer, 2002). The calcium phosphate method is relatively cheap, can be applicable to 
many cell types and generates cells with high productivity (Rita Costa et al., 2010). 
However, despite being able to transfect a high plasmid copy number, the efficiency 
with which this method can create recombinant cell lines is low (0.05-0.1%), even with 
attempts at increasing efficiency with DMSO. Moreover, it cannot be used in serum-
free processes, such as with CHO cells, which is the largest biologic producer. 
Therefore, the calcium phosphate method it is not as widely used in the 
biopharmaceutical processes described in this chapter (Rita Costa et al., 2010, Chenuet 
et al., 2008). Lipofection and PEI mediated transfection are simple techniques, which 
can be carried out in serum or serum-free conditions with high transfection efficiencies. 
PEI is the preferred choice for large-scale bioprocesses due to its comparatively low 
cost (Rita Costa et al., 2010, Rehman et al., 2013, Baldi et al., 2007, Reed et al., 2006).  
 
There are a variety of physical transfection methods used for gene delivery. For 
example, mechanical methods such as microinjection and particle bombardment have 
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proven useful in single cell and tissue work respectively. However the laborious, costly 
and low throughput nature of these techniques are amongst the reasons they have not 
been popularized in the bioprocesses described in this review (Mehier-Humbert and 
Guy, 2005). Electroporation is a simple and very quick method for gene delivery into 
the host cell. It involves subjecting the cells to a pulsed electric field in order to disrupt 
the membrane potential (voltage gradient) across the plasma membrane. As a result, 
aqueous pores are created and exist transiently in the lipid bilayer, through which 
plasmid DNA can enter the cell (Canatella et al., 2001, Rita Costa et al., 2010). 
Electroporation is the transfection methodology used in this thesis and will be discussed 
in detail in the next section. 
 
Different transfection procedures are typically used for transient gene expression and 
stable gene expression. Electroporation is a commonly used transfection methodology 
for stable gene expression due to its ease, cost and potential for high-throughput. DNA-
PEI polymers are more commonly used for transient transfection. The main reason for 
this difference is that electroporation typically transfects DNA into milliliter quantities 
of cell culture, which can be cloned and scaled up. On the other hand transient gene 
expression is short-lived, because extrachromosomal plasmid DNA becomes diluted 
and eventually lost. Therefore, to fulfill high yield needs production must be 
instantaneously large-scale. PEI mediated transfection can be carried out on a large 
scale and immediately yield large volumes of transiently producing cells and as a result 
is predominantly used to fill this niche (Zhu, 2012). However, recent advances in flow 
electroporation technology, as with the MaxCyte® transfection system, allow for 
scalable electroporation to take place that offers a closed, sterile and disposable system 
(Fratantoni et al., 2003). Cells are suspended in a buffer and electroporation can be 
optimised on a relatively large scale at high efficiencies resulting in gram quantities of 
antibody (Fratantoni et al., 2004, Steger et al., 2015), which is in line with other leading 
transient systems (Bandaranayake and Almo, 2014).  
 
1.3.6. Electroporation 
 
Electroporation is a transfection methodology, which uses an electric field pulse(s) to 
transiently permeabilise the plasma membrane of a cell. This process is utilised in order 
to introduce molecules such as DNA into the cell (Gehl, 2003). For this to happen the 
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transmembrane potential needs to reach a threshold level, in which it is estimated that 
the electrical field across the membrane is approximately 108 V/m for a standard 
membrane width of 5 nm. To achieve this the minimum electrical field that needs to be 
applied is reported to be around 0.2-1V (Chen et al., 2006). When the threshold is 
reached the structure of the membrane is reconfigured and pores form, through which 
molecules can travel into the cell. Confirmation of these pores has been achieved by 
electron microscopy (Chen et al., 2006, Bio-Rad, n.d.). In the case of DNA, loading of 
the cell occurs through electrophoretic movement rather than by osmosis, because DNA 
is negatively charged. Therefore, there is a more direct relationship between the 
intensity of the electric field and the efficiency of DNA transfection than with 
uncharged molecules (Gehl, 2003, Sukharev et al., 1992). Furthermore, DNA interacts 
with the plasma membrane and helps facilitate pore formation during electroporation 
(Spassova et al., 1994, Gehl, 2003, Escoffre et al., 2009). In this study DNA is 
linearised to promote higher levels of genome integration. Linear DNA has lower 
transfection efficiencies than circular and supercoiled DNA and so may need stronger 
optimal electroporation conditions (Schmidt et al., 2004). As stated, the transmembrane 
potential must be increased for the destabilisation of the membrane to take place. A 
variety of factors have an impact on this (Gehl, 2003). One of these factors is electrical 
field strength. This is the measurement of electrical intensity within the electroporation 
chamber and is affected by the voltage applied to the chamber and the distance between 
the two electrodes. This is summarised by equation 1.1, where E is electric field 
strength (V/cm), V is Voltage and d is the distance between electrodes (cm) (Gehl, 
2003, Bio-Rad, n.d.). 
 
 ! = #/%                                      Equation 1.1. Electric Field Strength 
 
 
Also, cells with different radii have different transmembrane potential thresholds. 
Larger field strengths are needed to permeabilise smaller cells (Escoffre et al., 2009, 
Gehl, 2003). The angle between the membrane and the electrode (i.e. the electric field) 
also affects the dynamics of electroporation. The inside of the cell is negatively charged. 
Therefore the pole of the cell facing the anode will be permeablised first and to a greater 
extent, because this is where the transmembrane potential will be exceeded earliest. The 
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pole facing the cathode will be permeabilised second and to a lesser extent. Even though 
overall permeabilisation is greater at the cell pole facing the anode, DNA enters the cell 
to a greater extent at the pole facing the cathode due to the direction of electrophoretic 
forces. The permeabilised area increases in size with higher field strengths and the 
extent of permeabilisation within this area is determined by the duration, and number of 
pulses (Gehl, 2003, Escoffre et al., 2009). The temperature at which electroporation is 
carried out affects the dynamics of the transfection process. A lower temperature may 
help increase cell viability due to the heating effect caused during electroporation. 
Moreover, the process by which pores are resealed would be slowed and so DNA, 
potentially, has longer to enter the cell. However, a higher temperature would facilitate 
pores to reseal more quickly, which might in turn increase overall cell viability. 
Moreover, differences in temperature result in differences in conductivity and 
subsequently sample resistance. Therefore, it is important to use an optimal temperature 
which strikes a balance between these characteristics (Bio-Rad, n.d.). Although the 
extent to which these factors impact on electroporation are reasonably well defined, the 
exact mechanisms by which the membrane is destabilised and DNA traverses the 
membrane are yet to be fully elucidated (Bio-Rad, n.d., Escoffre et al., 2009). 
 
Typically, there are two waveform types that are used for DNA electroporation: 
exponential decay and square wave (Jordan et al., 2008, Jordan et al., 2013) (Figure 
1.3). In exponential decay electroporation the voltage rapidly increases to a peak and 
decreases exponentially over time (Equation 1.2.): 
 
 #& = 	#(	[*+ ,-. ]                         Equation 1.2. Exponential Decay Waveform 
 
 
Where Vt is voltage at time = t (msec), V0 is the voltage upon discharge, R is circuit 
resistance (ohms) and C is circuit capacitance (µF). The time voltage takes to decrease 
is dependent upon the capacitance and resistance of the circuit (Jordan et al., 2013, Bio-
Rad, n.d., Jordan et al., 2007). The total resistance is a product of the resistance of the 
electroporation system being used and the resistance of the sample. The sample 
resistance is affected by a number of factors. Essentially, these factors impact on the 
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overall consistency of the sample being electroporated. They include sample volume, 
temperature, inter-electrode gap, ionic-strength of the extracellular medium, 
conductivity of the cell membrane and cytoplasm, cell density and the purity, 
concentration and size of nucleic acid being transfected. The resistance will impact on 
the transmembrane potential and as a result the voltage delivery parameters required to 
destabilise the membrane (Escoffre et al., 2009, Jordan et al., 2007). The resistance of 
the electroporation system being used can be set manually, and in the case of this work, 
is in line with manufacturer instructions. The capacitance of the circuit describes the 
ability of the circuit to store electric charge and is used as the changeable variable when 
experimentally altering the length of an exponential pulse. This is also manually set 
(Bio-Rad, n.d.). The time constant (τ) (Equation 1.3.), given in milliseconds, is the term 
used to describe the rate of voltage decay and is given as the time taken for the pulse to 
reach approximately 37% (1/e) of its initial intensity, which is derived from equation 
1.2. This is the standard measure of pulse length for exponential decay electroporation 
(Bio-Rad, n.d., Jordan et al., 2007). 
 
 τ = R	x	C                                           Equation 1.3. Time constant 
  Figure 1.3. Electroporation Waveforms 
A) This plot depicts the decay of an exponential pulse derived from Equation 1.2, 
whereby the voltage is decreasing at an exponential rate, influenced by the 
capacitance and resistance of the circuit. The time constant (τ) is given as the 
numerical measurement of pulse length (Equation 1.3.). 
B) This plot depicts the square wave waveform, derived from Equation 1.4., with 
two pulses. A voltage is discharged for a determined amount of time (t). The 
pulse droop is represented by the dotted line and is derived from Equation 1.5. 
 (This figure is adapted from Bio-Rad (n.d.), page 47, Figure 4.1.) 
A B 
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Square wave electroporation involves the active truncation of a pulse, which is 
maintained at the same voltage for a set amount of time and provides the option of 
delivering multiple pulses (Equation 1.4.) (Bio-Rad, n.d., Jordan et al., 2008). 
 
 ln #( − #& = 	 &7	8	9                                      Equation 1.4. Square Wave Waveform 
 
For square wave electroporation the pulse length is not given as the time constant, but is 
instead given as an actual pulse length in milliseconds that has been set manually with 
the electroporation device. The pulse truncation gives a squared waveform rather than 
the curved waveform of an exponential decay pulse. In reality the voltage at the end of a 
square wave pulse is always slightly less than the initial voltage. This slight voltage 
decay is referred to as the droop (%) and is largely influenced by the resistance and 
capacitance of the circuit, as well as the time set for the pulse length (Equation 1.5.) 
(Jordan et al., 2007, Bio-Rad, n.d.). 
 
 :;<<= = >?+>,>?                                       Equation 1.5. Square Wave Droop 
 
 
1.4. CHO Cell Genetic Instability 
 
The Chinese Hamster (Cricetulus griseus) has long been used as a laboratory example 
specimen. In 1957 Theodore Puck isolated and cultured cells from the ovary of a 
Chinese Hamster. They were found to be robust, quick and easy to culture and so CHO 
cells became an established immortal cell line. Genetic instability has always been an 
inherent feature of CHO cells and they were often used as a model system in studying 
karyotype heterogeneity and chromosomal aberrations (Jayapal et al., 2007). 
 
Immortal mammalian cell lines are typically genetically heterogeneous (Wurm, 2004). 
In the cell culture environment, as opposed to a mammalian cell’s natural environment 
in the organ of the organism itself, the selection pressures are different. Initially, the 
only genes under evolutionary constraint are those that influence cell growth and 
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viability. Therefore, many genes, which do not have a great influence on these growth 
characteristics, become neutral in the context of evolution. Subsequently, these genes 
are no longer fixed by natural selection, meaning that when mutations occur they may 
be more likely to remain in the subsequent generations. These genes will become 
polyallelic and survival of alleles will be random. This is known as genetic drift 
(Kimura, 1955, Kimura, 1979). This inherent ability to develop genetic heterogeneity 
allows for the straightforward and quick evolution of cells towards particular 
phenotypes, which are desirable for the process of producing recombinant proteins, by 
imposing particular constraints. Indeed, these genomes are relatively malleable and so 
can be moulded to fit many purposes. For example, cells have been evolved to be 
cultured without serum with high cell densities and viabilities, which is desirable 
because of the potential immunogenic contaminants found in serum (Sinacore et al., 
2000). Cells have also been adapted to be able to grow in the presence of compounds 
such as lactate and ammonia, so that when they are produced as bi-products of the 
production process cells are not affected by their toxicity (Prentice et al., 2007). The use 
of a selection gene and an inhibitor (discussed in the section 1.3.3) is another example 
of exploiting this rapid evolution to produce cells which have more expressive or 
greater number of copies of the recombinant gene to achieve higher yields of 
recombinant protein production (Wurm, 2004). Through many generations of cell 
culture and adaptive evolutionary engineering strategies, a number of phenotypically 
and genetically distinct CHO cell lines have been created, which exhibit drastic genetic 
differences to the original Chinese hamster genome (Derouazi et al., 2006, Wurm, 
2013). 
 
In the process of stable cell line generation a cloning step is carried out to create 
homogenous populations of cells, through the generation of new populations from a 
single cell. Despite this process there is a great deal of phenotypic variability observed 
between cells in these apparently clonal cell populations, because rapid phenotypic drift 
generates a mixed population (Barnes et al., 2006). Genetic heterogeneity is a relatively 
uncontrollable and unpredictable phenomenon, which can greatly affect host cell 
performance in the production process (Kim et al., 2011). When a population of cells is 
evolved towards a particular phenotype, such as protein production or to optimise 
growth characteristics, it stands to reason that the cells selected for use in the production 
process are those cells that achieve the desirable phenotype first and can do it most 
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efficiently (Figure 1.4). To achieve this change in phenotype there has to be a change in 
the genetic elements of the cell capable of causing differential expression. The selected 
cells have achieved this change in genetic elements first and so are likely to be the most 
genetically unstable. Therefore, potentially, instability itself is selected for and so 
perhaps it is no surprise that during long-term culture cells tend to deviate from what is 
desirable, because they are inherently unstable (Heller-Harrison et al., 2009). 
Alternatively, this could be due to a particular cell acquiring “high-producing” 
mutations where other cells have acquired less high-producing mutations, because 
mutation is random. However, if cells are heterogeneous for the many attributes tested, 
then it is likely that cells are also heterogeneous in terms of genetic stability. It is likely 
that the properties of a high-producer are attributable to both of these factors. This 
theory is supported by findings from Liu et al. (2010), in which a dysfunctional state of 
DNA mismatch repair was induced for the purpose of creating a pool of genetically 
diverse cells for subsequent phenotypic selection. Inherent instability is a desirable 
characteristic in the generation of a cell line, but becomes undesirable in the latter stages 
where desirable phenotypes can be lost. A better understanding of instability is required 
before this problem can be screened for or solved. 
 
Indeed, CHO cells are believed to have a so-called “mutator” phenotype (Kim et al., 
2011). In particular, CHO cells are very karyotypically unstable in the form of 
homologous recombination-based rearrangements, especially in response to gene 
amplification steps (Yoshikawa et al., 2000, Derouazi et al., 2006). Instability has also 
been seen through the loss of recombinant gene copies (Kim et al., 2011), and at the 
base pair level (Zhang et al., 2015), which has been shown to contain a plethora of 
single nucleotide polymorphisms (SNPs) (Lewis et al., 2013). A large number of cell 
doublings are required to create a working cell bank of a recombinant protein-producing 
cell line that is suitable for the start of long-term cell culture, and then subsequently to 
scale up cell numbers for production processes. The inherent instability of these cell 
lines often causes productivity to be greatly decreased or even lost during this period, 
which can subsequently lead to rejection of cell lines for production purposes (Heller-
Harrison et al., 2009, Barnes et al., 2003). Clearly this is unwanted, because a lot of 
resources have gone into a cell line’s development (Barnes et al., 2003). Changes in 
productivity have been firmly correlated with changes in the transcript level of the 
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recombinant gene, which can be a result of changes in gene expression or changes in 
recombinant gene copy number (Yang et al., 2010, Kim et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Selection of Genetic Instability Phenotype 
The schematic illustrates three populations of two different cell lines at different times 
over the course of a screening process for a desirable phenotype (red). Cell line 1 is 
more genetically unstable, so acquires mutations more quickly, which generates genetic 
heterogeneity. Some of these mutations are lost (yellow - neutral) or retained (red – 
desirable) through random sampling or selection. Cell Line 2 is more genetically stable 
so acquires mutations at a slower rate and as a result will take longer to achieve the 
desirable phenotype. Cell line 1 is more likely to be chosen for production processes, 
but may be more likely to lose productivity further down the line, because of its 
inherent genetic instability. Perhaps Cell line 2 would be more likely to retain a 
desirable phenotype once it has been achieved. 
 
Time 
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Epigenetic regulation is responsible for some of this change in gene expression. For 
example, it has been shown that DNA methylation correlates with loss in protein 
productivity. Specific CpG islands within the CMV recombinant gene promoter can 
become methylated in regions used as transcription binding sites, which has the result of 
diminishing gene expression (Yang et al., 2010, Kim et al., 2011). Some studies show 
that loss in productivity is almost solely down to loss in gene expression through 
methylation (Yang et al., 2010), whereas others show that the predominant cause is 
recombinant gene loss (Barnes et al., 2007). Kim et al. (2011) showed that a reduction 
in recombinant gene copy number has been correlated to loss in productivity. In this 
study instability was present in high and low producing cell lines, such at gene copies of 
the heavy chain, light chain and GS gene were uneven, despite the initial 1:1:1 ratio in 
the plasmid vector. In the productively unstable cell lines light chain genes were lost to 
a greater proportion than heavy chain and GS genes. Potentially, this is because the light 
chain gene is surrounded by more repetitive sequences, so a homologous recombination 
event is more likely to happen around this gene than the others (Kim et al., 2011). 
 
The position effect could influence both of these factors that cause changes in gene 
expression. Plasmid integration near inactive regions can make the transgenic region 
itself become inactive through silencing (Wurm, 2004). The position effect could also 
impact on gene copy number; For a plasmid to become integrated there needs to be a 
gap created by genomic breakage for the plasmid sequence to integrate. There are 
certain hot spots for DNA damage and subsequently for areas creating these genomic 
gaps. Therefore, plasmids could be more likely to insert into a region prone to genomic 
breakage and thus be more at risk of rearrangements. Insertion sites are likely to have 
different levels of inherent stability and capacity for gene expression (Denissenko et al., 
1997, Barnes et al., 2007, Kim et al., 2011). 
 
Once some cells within the population have acquired lower productivity attributes it is 
thought they have a growth advantage over high producing cells because of the lessened 
metabolic burden of not producing recombinant protein. Therefore, these low producing 
cells can take over the population because of their growth advantage, causing the cell 
line’s overall production to decline. If genetic instability can be understood and 
controlled then this phenomenon can be prevented (Barnes et al., 2007). 
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This instability does not only impact upon cell productivity, but can also have adverse 
effects on product quality. During the cell line development process cell lines are 
assessed for product quality attributes, such as protein aggregation, charge variants, 
glycosylation variants, and sequence variants, in line with regulatory body requirements 
(Ren et al., 2011, Zhu, 2012). It is crucial that these attributes remain consistent to 
ensure the safety and efficacy of a recombinant therapeutic product (Zhang et al., 2015). 
An underlying instability can lead to phenotypic heterogeneity in all if these quality 
attributes (Ren et al., 2011, Davies et al., 2013). Other than sequence variants, which 
will be analysed in this thesis (chapter 5), an example of one of these influential 
phenotypes is glycosylation. It has been shown that cell lines become heterogeneous in 
N-glycan processing of recombinant products, which can have an impact on the 
pharmacokinetics and biological function of a recombinant protein (van Berkel et al., 
2009, Zhu, 2012, Davies et al., 2013). Sequence variants have been discovered in a 
large proportion of clonal cell lines, and have been shown to directly cause changes to 
the amino acid sequence of a recombinant protein (Zhang et al., 2015). Evaluation of 
these product quality attributes on product efficacy and immunogenicity presents a 
technical challenge and so if cell lines carrying these undesirable attributes can be 
identified early in cell line development, they can be eliminated as a candidate cell lines 
for production processes (Zhang et al., 2015, Davies et al., 2013). 
 
 
1.5. Advancements and Future Directions 
 
Advancements in the production of biological therapeutics can be measured in different 
ways, such as increased product titers, increased cell qP, product quality consistency, 
time to market and the variety of products able to be produced by a given system, 
amongst others. This chapter has already summarised some of the key areas in which 
changes have been, and continue to be, made. For example; vector design for an 
increased and tailored production, cell engineering strategies to boost productivity and 
growth, transfection method variety and optimization, advancements in TGE for more 
insightful and faster screening processes, research into targeted integration for more 
consistent and predictable levels of gene expression, improvement of downstream 
methodologies for higher titers and product purity, and improvements in gene selection 
systems such as the GS knockout cell line. These improvements have already led to 
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volumetric productivity being increased from 0.5 to 2-10 g/L in large-scale bioprocesses 
(Datta et al., 2013). 
 
1.5.1. Systems Biology and Omics technology 
 
The overall concept of systems biology is the shift from looking at biological organisms 
purely at the molecular level to investigating whole-organism biology. Clearly, 
molecular techniques are needed to study processes mechanistically and in detail, but 
the idea is to integrate all of these defined isolated reactions and processes into a 
working model of a dynamic cellular network (Westerhoff and Palsson, 2004). As well 
as integrated analysis, development of high-throughput technologies has allowed the 
study of cellular functions on a global scale in which large datasets can be analysed 
together. The term ‘omics’ is used to describe this (Westerhoff and Palsson, 2004, 
Kildegaard et al., 2013). Omics includes the study of the entirety of a cell’s genes 
(genomics), mRNA (transcriptomics), proteins (proteomics), metabolism 
(metabolomics), metabolic flux (fluxomics) and glycosylation profiles (glycomics) 
(Datta et al., 2013, Kildegaard et al., 2013). All of this information together allows for a 
better understanding of cellular complexity in a way that is more than just a sum of its 
parts, but as the interacting and ever-changing environment that it is. Discoveries here 
can lead to a wide range of useful engineering targets to facilitate cell line 
improvements (Kildegaard et al., 2013; Westerhoff and Palsson, 2004).  
 
1.5.2. Synthetic Biology 
 
Synthetic biology aims to apply understanding of genetic elements and their interactions 
to the engineering of novel genetic constructs that offer novel or improved functionality 
to a host (Lienert et al., 2014). Logical parallels were derived from electrical circuit 
design such that genetic circuits could be built in a similar modular fashion with 
functional components such as switches, oscillators and feedback loops (Khalil and 
Collins, 2010, Lienert et al., 2014). These so-called building blocks can be taken from 
different organisms and combined in a way that would not occur naturally to create 
truly novel functions. This can be achieved through the interaction of different genes 
and recombinant proteins, and through the creation of advanced proteins that contain 
sequence components from different origins (Purnick and Weiss, 2009, Lienert et al., 
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2014). In one study a library of synthetic promoters was created based upon a 
bioinformatics sequence analysis of promoter sequence abundance. It was determined, 
via the use of synthetic reporters, that promoters designed in this fashion could reach 
expression at twice the level of the CMV promoter and could consistently and precisely 
control gene expression in CHO cells over two orders of magnitude. Through doing this 
the importance of different promoter sequence components were accurately defined 
(Brown et al., 2014).  
 
1.5.3. Screening Tool 
 
There is a rising demand for a wider variety of therapeutics that can be produced in 
abundance. Therefore, as our understanding and capacity for process optimisation 
increases it is important that there is the capability of assessing production platform 
attributes in a high throughput manner quickly and cheaply (Browne and Al-Rubeai, 
2009). For example, an essential step in the production process is the transition from a 
heterogeneous pool of producing cells to the generation of clonal cell lines, which can 
be assessed for desirable attributes. Initially, this was achieved by limited dilution 
cloning methods, which are slow and laborious (Browne and Al-Rubeai, 2007). 
Fluorescence-activated cell sorting (FACS) methods allowed for a more high-
throughput process and enabled the selection of cells by their productivity through the 
assessment of cell surface protein expression, saving time in the clonal screening 
process (Browne and Al-Rubeai, 2009). More recently clone picking has been 
automated through the use of mechanical systems such as the ClonePix from Genetix. 
The ClonePix quantifies secreted protein immoblised in semi-solid medium on a single 
cell level, providing a better indication of total cellular protein than protein expressed 
on the cell surface as with FACS (Nakamura and Omasa, 2015, Browne and Al-Rubeai, 
2009). After clonality has been established multiple clones are grown and assessed for 
their growth and productivity characteristics in a high-throughput plate format. The best 
of these clones are taken forward for expansion and further testing (Le et al., 2015, Noh 
et al., 2013). Cell line stability and heterogeneity as well as product quality are also key 
attributes of concern at this stage and will be discussed separately in chapters 4 and 5. 
 
TGE, as discussed previously, is an extremely useful process in which process 
parameters can be optimised quickly and cheaply, because it is not as laborious or 
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expensive as SGE. This means that new candidates and their variants can be tested, 
different cell lines compared, vectors can be varied and optimised and different media 
formulations can be analysed in a high-throughput manner. This is an extremely useful 
platform in predicting how processes will function in stable production (Pham et al., 
2006, Baldi et al., 2007, Andersen and Krummen, 2002). Clearly, the development of 
screening tools in TGE processes can help streamline the production process.  
 
 
1.6. Project Aims 
 
This chapter has summarized the platforms and bioprocesses utilised for the production 
and recovery of recombinant therapeutic proteins with a focus on genetic instability. As 
described, there are still many gaps in our biological and process knowledge, the 
understanding of which can facilitate the improvement and optimisation of these 
processes. As our knowledge base widens the number of options for bioprocesses 
increases. For example, a wider variety of proteins can be produced, through a number 
of engineering strategies, different vector designs, via different transfection 
technologies and using different selection methods. Options are also increased in that 
bioprocess characteristics can be more acutely tested and analysed at each stage of the 
process. Clearly it is important that we have the ability to test these attributes 
efficiently.  
 
This thesis focuses on the characterisation and understanding of three aspects of the 
bioprocesses described above and the potential application of the findings through more 
optimised methodologies or potential bioprocess screening tools. 
 
Chapter 3 discusses the effect of CHO cell genetic instability and heterogeneity on 
therapeutic protein production bioprocesses. The chapter aims to characterise the extent 
of this stability at the base pair and chromosomal level and demonstrate the potential 
need for a screening tool for genetic stability of clonal protein-producing cell lines. 
 
Chapter 4 shows the optimisation of electroporation, which was needed for the 
generation of stable GFP cells in chapter 5. In doing this it was discovered that standard 
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industry conditions could be vastly improved in a product and platform specific manner 
using design of experiments (DoE) methodology. 
 
Chapter 5 discusses the difficulties in maintaining product quality throughout the 
production bioprocess, specifically in the form of sequence point mutation. Firstly, the 
chapter aims to assess recombinant DNA sequence integrity at different stages in 
generating a GFP-producing cell population. The second aim is to validate an 
alternative analysis of the Pacific Biosciences PacBio RSII single-molecule sequencing 
platform to facilitate a higher resolution of mutation detection. 
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Chapter 2 
 
Materials and Methods 
 
This chapter provides a detailed description of the materials and methods used to 
complete the experiments described in results chapters three, four and five.  
 
Microbial work and molecular biology techniques were carried out in a separate lab to 
mammalian cell culture to ensure cell culture sterility. Any materials or vessels to be 
used in culturing of mammalian cells were sterilized with 70% ethanol and work was 
conducted within a laminar flow hood. Materials used were of high purity and, where 
necessary, underwent appropriate filtering and autoclaving procedures.  
 
2.1. CHO Cell Culture 
 
2.1.1. Cell Culture Maintenance 
 
CHOK1SV derived suspension cells (cell line CHO269M, Pfizer, NY, USA) were 
cultured in CD-CHO medium (Thermo Fisher Scientific, MA, USA) supplemented with 
6mM L-glutamine (Thermo Fisher Scientific, MA, USA) in vented Erlenmeyer flasks 
(Corning, Surrey, UK). Cell culture volumes used were 20-25% of Erlenmeyer flask 
total volume. Flasks were incubated at a temperature of 37 °C, in 5% (v/v) CO2 and 
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shaking at 140 rpm. Cells were routinely subcultured at a seeding density of 0.2 x 106 
cells/mL on a 3-4 day schedule. A Vi-Cell cell viability analyser (Beckman-Coulter, 
High Wycombe, UK) was used to determine the average cell viability, concentration 
and diameter via an automated Trypan Blue exclusion assay in which non-viable cells 
are permanently stained. Cells were subcultured up to a maximum of 25 times in order 
to minimise genetic diversity, apart from for the generation of stable cell lines (detailed 
in section 2.6) 
 
The cell culture growth characteristics; cell doubling time (equation 2.1.), generation 
number (equation 2.2.) and cell specific growth rate (µ) (equation 2.3.) were calculated 
using the equations below: 
 Cell	Doubling	Time = /01	/2 	34567 89: /0167 89: /2                             Equation 2.1. 
 Generation	Number = /0∙67 89: /0167 89: /2/01/2 345                Equation 2.2.   
 A = 67 89: /0167 89: /2/01/2                                                              Equation 2.3. 
 
Where t is time, f is final and VCD is viable cell density.  
 
2.1.2. Cryopreservation and Cell Bank Generation 
 
Master and working cell banks were created for the CHO269M cell line received from 
Pfizer (NY, USA); Two days after subculture (mid-exponential phase) cells were 
pelleted by centrifugation at 130 x g for 8 minutes and resuspended at a concentration of 
1 x 107 cells/mL in CD-CHO media containing 7.5% DMSO (Sigma Aldrich, Dorset, 
UK). 1 mL aliquots were assorted into NUNC cryovials (ThermoFisher Scientific, MA, 
USA) and stored in a “Mr. Frosty” container (Nalgene, Roskilde, Denmark), filled with 
100% isopropanol, at -80 °C overnight to allow slow freezing of cell solutions. 
Cryovials were then transferred to a liquid nitrogen freezer (-196 °C) for long-term 
storage. To revive cells from liquid nitrogen storage, cells were rapidly thawed at 37 °C. 
Subsequently, the cell solution was added to 30 mL of pre-warmed media and a sample 
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taken for determination of viability and VCD. Cells were then incubated at standard 
culture conditions. These cells are labeled “Day 0”.  Cells are subcultured after two 
days of subculture and subsequently follow the standard subculture regime. Cells are 
acclimatised to these conditions for three subcultures before being used for any 
experimental work. 
 
2.2. Plasmid DNA Amplification and Preparation 
 
2.2.1. Transformation and Plasmid Amplification 
 
A phCMV C-GFP FSR Vector (Genlantis, CA, USA) plasmid was transformed into 
Library Efficiency® DH5α™ Escherichia coli (E. coli) competent cells (Thermo Fisher 
Scientific, MA, USA); DH5α™ cells were thawed on ice and mixed with 25 ng of 
plasmid DNA, incubated for 30 minutes on ice, heat shocked at 42 °C for 45 seconds 
and then returned to ice incubation for a further 2 minutes. Cells were then diluted 1:10 
in LB-Broth (Thermo Fisher Scientific, MA, USA) and incubated for 1 hour at 37 °C. 
The cells were then spread on to LB-Agar (Thermo Fisher Scientific, MA, USA) plates 
containing Kanamycin (Sigma Aldrich, Dorset, UK) at a concentration of 50 ug/mL. 
Plates were incubated at 37 °C overnight. A colony was picked and used to inoculate 5 
mL LB-Broth containing 50 ug/mL Kanamycin to generate a starter culture, which was 
incubated at 37 °C, 200 rpm for 8 hours. Starter cultures were then used to inoculate 
larger volumes of Kanamycin containing LB-Broth for bulk amplification, which were 
incubated at 37 °C, shaken at 200 rpm for 12-16 hours.  
 
2.2.2. Plasmid Extraction and Purification from E. coli  
 
A Gigaprep kit (Qiagen, Manchester, UK) was used to lyse E. coli cells and purify 
amplified plasmid DNA, following the manufacturers protocol. Briefly; kit buffers are 
used between centrifugation steps to lyse cells via alkaline lysis and precipitate a large 
proportion of cellular components. The remaining supernatant is applied to an anion 
exchange resin column, which binds plasmid DNA and the remaining impurities are 
removed through wash steps. The plasmid DNA is then eluted using nuclease free water 
(Thermo Fisher Scientific, MA, USA) for short-term storage or Tris-EDTA buffer 
(Thermo Fisher Scientific, MA, USA) for long-term storage, both at -20 °C. 
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2.2.3. Caesium Chloride Extraction from Transfected Mammalian Cells 
 
Cells were pelleted by centrifugation at 2500 x g for 5 minutes, washed in PBS (Sigma 
Aldrich, Dorset, UK), resuspended in 250 uL of a resuspension solution (50 mM Tris-
HCl - Thermo Fisher Scientific, MA, USA; 10 mM EDTA - Thermo Fisher Scientific, 
MA, USA; 100 ug/mL RNase – QIAGEN, Manchester, UK) and lysed with 250 uL 
1.2% SDS (Sigma Aldrich, Dorset, UK) supplemented with 20 uL Proteinase K 
(Thermo Fisher Scientific, MA, USA). The solution was mixed by inversion and 
incubated at room temperature for 5 minutes before adding 350 uL precipitation 
solution (3M CsCl - Sigma Aldrich, Dorset, UK; 1M potassium acetate - Sigma 
Aldrich, Dorset, UK; 0.67M acetic acid - Thermo Fisher Scientific, MA, USA). The 
precipitation solution was mixed by inversion, incubated for 15 minutes on ice and 
centrifuged at 15,000 x g for 15 minutes. Supernatant was applied to a Miniprep column 
(Qiagen, Manchester, UK) and centrifuged at maximum speed for 1 minute. 750 uL 
wash buffer (80 mM potassium acetate - Sigma Aldrich, Dorset, UK; 10 mM Tris-HCl 
ph7.5 - Thermo Fisher Scientific, MA, USA; 40 uM EDTA - Thermo Fisher Scientific, 
MA, USA; 60% ethanol - Thermo Fisher Scientific, MA, USA; diH2O) was added to 
the column and centrifuged at maximum speed for 1 minute. DNA was eluted from the 
column using 50 uL nuclease-free water (Thermo Fisher Scientific, MA, USA) via a 
final centrifugation at maximum speed for one minute. Samples were pooled using the 
miVac DNA concentrator (Genevac Ltd, Ipswich, UK). 
 
2.2.4. BluePippin Purification 
 
Validation of the Blue Pippin system (instrument and reagents - Sage Science, MA, 
USA) was carried out with the assistance of demonstration from a Sage Science 
representative, Will Deacon. Purification was carried out using pulsed field 
electrophoresis cassette BLF7150, which uses a 0.75% agarose gel and an external S1 
marker. The instrument was set to purify DNA of a target length of 5.3 kb, with a 
maximum range of purification between 4.25 kb and 6.35 kb. Target DNA was purified 
after 145 minutes of running the gel. For purification of DNA samples to undergo 
sequencing, Blue Pippin purification was carried out by GATC Biotech (Konstanz, 
Germany), which targeted 5 kb DNA fragments, with a maximum range of purification 
of 3 kb. 
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2.2.5. Restriction Digestion of Plasmid DNA 
 
500 ug plasmid DNA, 1x CutSmart™ Buffer (New England Biolabs, UK) diH2O and 
2000U AflII restriction endonuclease (New England Biolabs, UK) were mixed and 
incubated for 2 hours at 37 °C. The endonuclease was denatured by incubating the 
restriction solution at 65 °C for 25 minutes. An ethanol precipitation was carried out to 
purify the linearised plasmid DNA, which was resuspended in Tris-EDTA buffer 
(Thermo Fisher Scientific, MA, USA) at a concentration of 1.3 mg mL-1 for storage at -
20 °C.  
 
2.3. Post-preparation Assessments of Plasmid DNA 
 
2.3.1. Agarose Gel Electrophoresis 
 
Plasmid DNA was run on 0.8% agarose Tris-acetate-EDTA (TAE) (Sigma Aldrich, 
Dorset, UK) gels mixed with ethidium bromide (Sigma Aldrich, Dorset, UK)  for ~90 
minutes alongside a Hyperladder I (Bioline, UK) molecular weight ladder. Images were 
taken under UV light using a Biospectrum Imaging System (UVP, CA, USA). 
 
2.3.2. Nanodrop Quantification of DNA 
 
A Nanodrop 2000 (Thermo Scientific, MA, USA) was used to determine DNA 
concentration and purity. The Beer Lambert Law (Equation 2.4) calculates the 
absorbance of a DNA sample, which in turn can be used to calculate the concentration 
of DNA samples (Equation 2.5), using light path length and extinction coefficient of 
DNA (0.02 ug ml-1 cm-1) at a wavelength of 260 nm. 
 B =∈ DE                                                 Equation 2.4 
 E = FGH2I.I5                                                    Equation 2.5 
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Where A is absorbance, ε is molar extinction coefficient (L mol-1 cm-1), b is path length 
(cm) and c is concentration (mol L-1). The purity of samples was determined by the 
260/280 ratio, where a ratio between 1.8 and 1.9 was indicates purity. 
 
2.4. Electroporation 
 
CHO cells were centrifuged at 130 x g for 8 minutes two days after subculture, at which 
point they had reached a VCD between 0.8 x 106 and 1.2 x 106. Cell pellets were then 
washed with 20 mL CD-CHO (Thermo Fisher Scientific, MA, USA) and centrifuged 
again at 130 x g for 8 minutes. Cells were resuspended in pre-warmed media (CD-CHO, 
L-Glutamine - Thermo Fisher Scientific, MA, USA) at a concentration of 1.68 x 106 
cells mL-1. 40 uL (50 ug) linearised phCMV C-GFP plasmid DNA (Genlantis, CA, 
USA) in Tris-EDTA (Thermo Fisher Scientific, MA, USA) buffer was added to a 4 mm 
electroporation cuvette (Bio-Rad Laboratories, CA, USA) followed by 595 uL cell 
solution (1 x 106 cells). During preliminary parameter optimisations to determine the 
constant conditions of the optimisation process, cells were electroporated using standard 
Pfizer Conditions: 300 V, 900 uF, exponential decay pulse. Post-optimisation, 
electroporation was conducted using 320-26 conditions: 320 V, 26 ms, exponential 
decay (time constant protocol). All electroporations were carried out on the Gene Pulser 
Xcel electroporation system (Bio-Rad Laboratories, CA, USA). Electroporated cells are 
immediately diluted with 500 uL media and transfered to a 6-well plate (ThermoFisher 
Scientific, MA, USA) containing 2 mL pre-warmed media for static, humidified 
incubation at 37 °C and 5% (v/v) CO2 for 24 hours. 
 
2.5. Generation of Stable GFP Cells 
 
The phCMV C-GFP plasmid contains a neomycin resistance gene. Therefore G418, a 
neomycin analogue, can be used to select for cells with genome-integrated plasmid, so 
that over time the cell culture will be populated only by stably producing GFP cells. 
Protocols were derived from a combination of the electroporation protocol optimised 
above, Lonza reference guides and an in-house GFP stable cell line generation protocol 
(Lonza, 2012). 
G418 is known to have batch to batch and cell line to cell line inconsistencies, so a dose 
response study was carried out to ascertain the minimum concentration needed to 
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prevent cell growth for each batch used. A dose response study was set up in which 
CHO cells were subcultured at 0.2 x 106 cells/mL into 50 mL Cultiflasks (Sigma 
Aldrich, Dorset, UK) containing CD-CHO (ThermoFisher Scientific, MA, USA), 6mM 
L-glutamine (ThermoFisher Scientific, MA, USA)  and G418 disulphate salt (Sigma 
Aldrich, Dorset, UK) at concentrations spanning 0-1.5 mg/mL. Cultiflasks were 
incubated at 37 °C, 5% (v/v) CO2, shaking at 170 rpm. Cell viability and concentration 
were determined daily for 5 days. 
 
Electroporation was carried out using 320-26 conditions, using 1 x 107 cells and 
transferred into T-75 flasks (ThermoFisher Scientific, MA, USA) for static, humidified 
incubation. After 24 hours, 0.8 mg/mL and 0.9 mg/mL G418 disulphate salt (Sigma 
Aldrich, Dorset, UK) was added to cultures for G418 batches 1 and 2 respectively. 
G418 is known to be relatively unstable at 37 °C, so during this static incubation phase, 
media was replaced every 3-4 days. When cultures reached a viable cell density of > 0.5 
x 106 cells/mL, cells were transferred to 30 ml Erlenmeyer flasks with 0.2 x 106 
cells/mL for standard shaking conditions, supplemented with G418 and 1x HT 
supplement (ThermoFisher Scientific, MA, USA). Cell viability and VCD was 
measured using the Vicell and GFP fluorescence was recorded by flow cytometry after 
each subculture. Fluorescence-activated cell sorting (FACS), carried out at the 
University of Sheffield Flow cytometry core facility, was used twice for the top 90% 
and 20% of GFP positive cells respectively in order to generate a high-producing cell 
population. 
  
2.6. Flow Cytometry 
 
Cells were centrifuged at 130 x g for 8 minutes and resuspended in PBS (Sigma 
Aldrich, Dorset, UK) for flow cytometric analysis. An Attune® Autosampler 
(ThermoFisher Scientific, MA, USA) flow cytometer and Attune® Autosampler 
software (ThermoFisher Scientific, MA, USA) was used to analyse cell samples for 
GFP fluorescence via excitiation with a 488 nm laser, and detection with a 530/30 band 
pass filter. Photomultiplying tube (PMT) sensors were optimized at 900 mV for GFP 
detection and 1200 and 2400 for forward scatter (FSC) and side scatter (SSC) 
respectively. A viable cell population was gated in accordance with FSC and SSC. Non-
transfected cells were used to measure cell auto-fluorescence and used to set a bi-
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marker gate to distinguish between GFP and non-GFP producing cells, so that 99% of 
cells were in the negative gate in a non-transfected cell sample (Figure 2.1). For each 
sample 10,000 cells were measured. 
 
 
Figure 2.1. Flow Cytometry Gating Example 
Viable cells were gated using FSC and SSC (A). Bi-marker gates were set according to 
cell auto-fluorescence of negative controls (B) to ascertain the percentage of cells that 
are fluorescing in positive samples (C). 
 
 
 
2.7. Response Surface Methods 
 
Design expert 9.0.4 was used to design and analyse experiments for the optimisation of 
electroporation parameters. For one preliminary experiment for the optimisation of 
sample volume was carried out using a one factor RSM model. The remaining RSM 
optimisations were carried out using rotatable central composite designs. For each 
model the data is analysed in this order: 1. In terms of the response range ratio, which 
reveals if any data transformations would make data easier to interpret. In this case a 
A 
B C 
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Box-Cox plot for power transforms would instruct on which type of transformation to 
carry out. 2. A fit summary is presented in terms of a sequential model sum of squares 
(SMSS), lack of fit tests and model summary statistcs (MSS): standard deviation, R 
squared, adjusted R squared, predicted R squared and predicted residual sum of squares 
(PRESS). This fit summary suggests which type of model best fits the data in terms of 
polynomials. 3. Based on this information the appropriate model is set to fit the data. 4. 
An ANOVA describes the significance of the model and the significance of each factor 
within this model. Moreover, the lack of fit is again presented. 5. Diagnostic tests are 
viewed and analysed to check for residual abnormalities. 6. Graphical representations of 
the models are plotted for visualising the response surface. 7. The optimisation function 
then utilises the predictive capacity of the model to generate an optimal set of 
parameters for a given set of requirements. 
 
2.8. Microsatellite Analysis 
 
2.8.1. Stable Cell Line Generation – 2  
 
Ten GS-CHOK1SV cell lines (B1-B10), producing recombinant mAb were generated 
by Peter M. O’Callaghan and Minsoo Kim as desbribed in Kim et al. (2011), according 
to standard methodology (Porter et al., 2010). CHOK1SV (Lonza Biologics) cells were 
electroporation with a linearised GS vector containing a mAb light and heavy chain (LC 
and HC). Cells containing genome-integrated plasmid were selected for by 50 uM 
methionine sulphoximine (MSX; Sigma-Aldrich, Dorset, UK). Clones were made by 
capillary cloning (B3-B10) or by FACS-facilitated single cell sorting (B1 and B2). Cell 
lines B1 and B2 expressed IgG1 mAb, whereas cell lines B3-B10 expressed a range of 
different IgG2 mAbs. Cell lines B4, B5, B6, B8, B9 and B10 were transfected with a 
codon-optimised HC sequence along its entire length, whereas cell lines B1, B2, B3 and 
B7 were transfected with a non-codon optimised HC sequence. LC and GS genes were 
identical throughout. 
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2.8.2. Cell Culture 
 
Cells were cultured by Peter M. O’Callaghan and Minsoo Kim in the conditions 
described in (Kim et al., 2011). Briefly, cell lines B1-B10 were subcultured using a 3-4 
day regime, in which they were seeded at 0.3 x 106 viable cells/mL. CD-CHO medium 
(ThermoFisher Scientific, MA, USA) with a supplement of 25 uM MSX (Sigma-
Aldrich, Dorset, UK) was used. Cells were incubated at 36.5 °C. All other cell culture 
conditions are in line with those described in section 2.1.1. 
 
2.8.3. Microsatellites and Primers 
 
Peter O’callaghan and Claire Bennett identified and designed primers for six 
microsatellites in the CHO genome (Table 2.1). 
 
Microsatellite Sequence Forward Primer Reverse Primer Source 
10.1 (CA)n GCCTAGGCTCAAAC
AAGCAC (20) 
TATAAGACACAAG
TAGTGAGTG (22) 
(Aquilina et al., 
1994) 
11.1 (CA)n TTTTCCAAGTATGTG
CTTCCCTG (20) 
AAACAAGGTTCAG
TGGGATAGC (22) 
(Aquilina et al., 
1994) 
21.1 (CA)n TTTCCCAAAGAAGTC
ATATGCC (22) 
CCTTCCTGCAATCT
CAAGATG (21) 
(Aquilina et al., 
1994) 
GNAT2 (TTC)n CAATGTTACTCTATC
CCATCCTGG (24) 
GTAAGGCTCCTGTC
TGTGAGACAG (24) 
(Baron et al., 1996) 
GT-23 (CA)n ATCTGAAGTTAAAAT
GAAGTTG (22) 
CTCTGTGGGTATGC
ACATAG (20) 
(Hinz and Meuth, 
1999) 
BAT25 (T)n GAGGAGTGCCACAA
ATCAAAGCTAG (25) 
CCCAGATTTTCAGA
TTTTAACCATG (25) 
(Liu et al., 2010) 
 
Table 2.1. Microsatellites and Primers 
The table contains a list of the microsatellites used in this study, their base composition, 
the forward and reverse primer sequences used for each microsatellite and the literary 
source, which provided a previous example of microsatellite use. 
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2.8.4. Sample Preparation 
 
Genomic DNA samples from 1 x 108 cells were prepared using the Agilent DNA 
extraction kit (Agilent Technologies, CA, USA) according to manufacturer instructions. 
PCR was carried out using the Hot Start Taq plus kit (QIAGEN, Manchester, UK) 
according to manufacturer instructions, using the primers shown in table 2.1 to amplify 
microsatellite DNA. 
 
2.8.5. Capillary Gel Electrophoresis 
 
This was outsourced to Steven Haynes of the Core Genomics Facility at the University 
of Sheffield Medical School. The following was a protocol provided: 1 ul of PCR 
amplified sample was mixed with 8.7 ul of formamide and 0.3 ul of LIZ600 size 
standard per sample, which was then transferred to plates and centrifuged to the bottom 
of each well. The plate was then transferred on to the heating block, heated to 95°C, for 
3 minutes. The plate was then incubated on ice for 5 minutes. The 3730 genetic analyser 
(ThermoFisher Scientific, MA, USA) was used to separate fragments by size using 
automoated capillary gel electrophoresis. 
 
2.8.6. Statistical Analysis in R 
 
Statistical analysis using ANOVAs, Tukey’s multicomparisons tests, F tests, power 
transformations (Box-Cox plots), T-tests and graphical representation was carried out 
using R software.  
 
2.9. Karyotype Analysis 
 
Genomic samples were prepared as described in section 2.9.4. Karyotype analysis was 
outsourced to Duncan Baker of the Sheffield’s Children’s Hospital genetic diagnostics 
service in which for each cell line 30 cell squashes were viewed by giemsa staining, and 
karyotypes were noted when they existed in 3 or more of the cells within this squash, 
because this is the number thought to be enough to represent a new clone of cells. 
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2.10. Single Molecule DNA Sequencing 
 
2.10.1. Sample Preparation 
 
The linearised stock and transfected / non-integrated samples discussed in chapter 5 
were prepared using protocols described in sections 2.2.2 and 2.2.4 respectively. The 
transfected / non-integrated sample underwent an additional purification step using 
BluePippin (Sage Science) technology as described in section 2.2.5. For integrated 
genomic recombinant plasmid DNA samples genomic DNA was prepared using a 
Blood and Cell Culture DNA kit (QIAGEN, Manchester, UK) according to 
manufacturer protocols. Briefly, cells were centrifuged, washed and resuspended in PBS 
(Sigma Aldrich, Dorset, UK). Cells were then lysed and DNA purified using the buffers 
and Genomic-tip 20/G column provided. Recombinant plasmid DNA was then 
amplified via PCR. Primers (Table 2.2) were designed using SnapGene software (GSL 
Biotech LLC, Chicago, USA) to amplify the plasmid sequence in quarters to generate 
~1.25 kb fragments. 
 
Fragment Forward Primer Reverse Primer 
1 TTAAGGCGTAAATTGTAAGCGTTAAT
ATTTTG 
CGCTTCAGTGACAACGTCGAG 
 CAATAGGCCGAAATCGGCAAAATCC CAATAGCAGCCAGTCCCTTCC 
2 GCTCGACGTTGTCACTGAAGC GGAAGGGACTGGCTGCTATTG 
 CACTAGAAGGACAGTATTTGGTATCT
GC 
GTGGCCTAACTACGGCTACAC 
3 GAGCTACCAACTCTTTTTCCGAAGG  GAATCCGCGTTCCAATGCAC 
 GGTTTGTTTGCCGGATCAAGAG CGTTCCAATGCACCGTTCC 
4 GTGCATTGGAACGCGGATTC  GATACATTGATGAGTTTGGACAAACC
AC 
 GGAACGGTGCATTGGAACG GATACATTGATGAGTTTGGACAAACC
ACAAC 
Table 2.2. phCMV C-GFP Plasmid Primers 
(Sigma Aldrich, Dorset, UK) 
 
 
The PCR mix contained: 250 ng plasmid DNA, 0.5 ul Phusion high fidelity DNA 
polymerase (New England Biolabs, UK), 1 ul NTP mix (New England Biolabs, UK), 10 
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ul Polymerase Buffer (New England Biolabs, UK), 2.5 ul of forward and reverse 
primers, diH2O to make final volume 50 ul. The Veriti 96-well thermal cycler 
(ThermoFisher Scientific, MA, USA) was used for PCR. Samples were heated to 98 °C 
for 30 seconds, then cycled 40 times through 98 °C for 10 seconds, 65.4 °C for 30 
seconds and 72 °C for 38 seconds, followed by a final heating of 72 °C for 10 minutes 
before being held at 4 °C. Amplified DNA fragments were then purified using a 
QIAquick PCR purification kit (QIAGEN, Manchester, UK) according to manufacturer 
instructions. Briefly, DNA is purified using a series of centrifugation steps facilitated by 
the use of the buffers and spin column provided. The success of the PCR and 
purification was checked by agarose gel electrophoresis. Resulting samples were 
resuspended in Tris-Hcl (pH 8.0) buffer (Sigma Aldrich, Dorset, UK) and pooled 
together for DNA sequencing. 
 
2.10.2 PacBio RSII SMRT Sequencing 
 
Single molecule real time (SMRT) sequencing was outsourced to GATC Biotech 
(Konstanz, Germany). Briefly, samples are ligated to hairpin adapter sequences to 
create a SMRTbell template. Individual SMRTbell templates are sequenced by a single 
polymerase to generate sequence reads containing multiple versions of the template (see 
explanation in chapter 5). Sequencing is conducted using a PacBio RSII instrument 
(Pacific Biosciences, CA, USA). 
 
2.10.3 SMRT Sequencing Analysis 
 
Primary analysis was outsourced to Phillip Lobb of Pacific Biosciences (CA, USA) who 
generated consensus sequences from individual molecules. Secondary analysis. BLASR 
software was used to align these consensus sequences to the reference sequence. R was 
used to call mutations and comment on coverage. The script can be found in Figure 
A26. Details of this analysis can be found in chapter 5. 
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Chapter 3 
 
CHO Cell Genomic Instability and 
Heterogeneity 
 
 
3.1. Introduction 
 
3.1.1. Chapter Summary 
 
This chapter provides further introduction to the subject of genetic instability, which 
was discussed in section 1.5. The chapter focuses on the inherent genomic instability 
and heterogeneity of CHO cells, and so looks into genetic changes on a global scale. 
The development of methodologies that are capable of characterising and quantifying 
this genomic instability would be extremely useful for cell line development platforms, 
because it would enable the detection and elimination of cell lines with a predisposition 
to genetic instability and so reduce the chance that production cell lines suffer declines 
in productivity over long-term cell culture. This study aimed to characterise genomic 
instability at the base pair and gene copy number level through microsatellite analysis, 
and at the chromosomal level using karyotype analysis.  Ten monoclonal antibody-
producing cell lines, which had previously been shown to suffer changes in cell 
productivity as a result of changes in recombinant gene copy number, were used so that 
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the genetic changes discovered in this study could be directly compared with changes in 
productivity and gene copy number found in a previous study (Kim et al., 2011). 
 
There was significant microsatellite allelic variation between the ten cell lines, and there 
were marginal changes in microsatellite allele frequencies across different generations 
of individual cell lines. However, this variation could only be attributed to genetic drift, 
rather than mutational change, and so the study did not provide sufficient evidence to 
suggest that microsatellites could be used as markers for mutational change. There was 
substantial karyotypic change found in this study, both in the form of changes in 
chromosome number and breakage / fusion events. This genetic instability was not 
shown to directly correlate with changes in productivity or gene copy number, but it 
was concluded that karyotyping could be a useful tool to eliminate genetically unstable 
cell lines during cell line development. 
 
3.1.2. Forms of Genetic Instability 
 
If a cell is genetically unstable it undergoes genomic changes at a higher rate than a 
normal cell would, which can come in a variety of forms. There can be: sequence 
changes involving base substitution, insertion or deletion of one or a few nucleotides, 
gene copy loss, chromosome number changes from the loss or gain of a chromosomes 
resulting in aneuploidy, chromosome breakage resulting in loss of chromosome parts, 
chromosome translocations where two chromosomes fuse, and gene amplification 
(Lengauer et al., 1998). Cell proliferation is a tightly regulated process with many 
processes to coordinate. One of these aspects is DNA replication and segregation. DNA 
needs to be replicated accurately and efficiently segregated in order to maintain 
genomic integrity throughout many generations (Aguilera and Gomez-Gonzalez, 2008). 
There are many DNA damage sense and repair pathways and mechanisms to ensure this 
is the case and if it is not done efficiently mutations and aberrations occur (Jackson, 
2002). Clearly this can have its disadvantages, but on the other hand for selection or 
genetic drift to drive evolution there has to be genetic variation. Therefore mutation is 
needed for the evolution of cell lines towards desired phenotypes (Hastings et al., 2009, 
Aguilera and Gomez-Gonzalez, 2008, Sinacore et al., 2000). Unfortunately,  
information on the specific causes of genetic instability in CHO cells is lacking. 
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In the case of CHO cells and developing a producing cell line, genetic instability is an 
attribute that should be closely monitored. Protein folding, PTMs, protein expression 
and amino acid sequence are some of the key attributes which could be affected by 
genetic instability, which could have implications for product quality as well as gene 
expression (O'Callaghan and James, 2008). It has been shown that loss in recombinant 
gene copy number correlates with a decline in cell specific productivity. Perhaps it is 
this underlying genetic instability of CHO cells that causes recombinant gene loss and 
causes observed losses in productivity (Kim et al., 2011). Markers of genetic instability 
can be used to characterise the extent and type of genetic instability of a given cell line, 
which include the measure of chromosomal instability, point mutations and the cells 
response to DNA damage (Lengauer et al., 1998, Jackson, 2002). This study involves 
the investigation into chromosomal instability and microsatellite instability, which can 
be used to estimate changes at the base pair level, changes in gene copy number and be 
used for cell line identification. 
 
Chromosomal instability is a hallmark of the cancer phenotype, a marker of an unstable 
cell and has been shown to propagate further genetic instability (Mitelman et al., 2007). 
Chromosomal instability has been shown to cause defects in a wide range of cellular 
functions such as protein synthesis, protein folding, changes in cellular metabolism, 
gene expression, cell proliferation and increases in point mutations (Gordon et al., 
2012). One form of chromosome instability is aneuploidy, which is the alteration in 
chromosome number and involves the loss or gain of chromosomes in a daughter cell 
compared to its mother cell. This is predominantly due to a decline in mitotic fidelity, 
meaning that the cell is less able to carry out equal chromosome segregation (Thompson 
and Compton, 2011, Lengauer et al., 1998). Another form of chromosomal instability 
results in the rearrangement of chromosomes, which can come in the form of deletions, 
insertions, translocations, duplications, inversions, the formation of isochromosomes 
and the formation of marker chromosomes. These types of changes result from breakage 
and fusion of chromosomes (Thompson and Compton, 2011). Chromosome aberrations 
can cause changes in gene copy number and gene expression, which will inevitably 
influence cell homeostasis (Thompson and Compton, 2011, Gordon et al., 2012). CHO 
cells are known for their chromosomal instability, so it is a logical marker to use when 
measuring the genetic instability of a potential producing cell line (Derouazi et al., 
2006). 
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Microsatellites are short (1-6 nucleotide) DNA motifs repeated in tandem and are 
interspersed throughout the genome. They are very common, highly variable sequences 
with many length-based polymorphisms, and are a popular genetic marker (Ellegren, 
2004). Mutations causing changes in the number of repeats, and thus causing 
polymorphic lengths of microsatellite, are relatively frequent. They occur through a 
mechanism called slippage (Figure 3.1.). Due to the repetitive and homologous nature 
of microsatellites, complementary strands can misalign after denaturation during DNA 
replication. This can cause expansion or contraction of repeats depending on the 
orientation of the misalignment relative to the template strand, because the DNA 
polymerase does not synthesise the microsatellite to a length consistent with the 
template (Lai and Sun, 2003). If this mistake is not recognised by the DNA mismatch 
repair (MMR) systems then the new allele is carried through to subsequent generations. 
This causes a large amount of variation within populations. Microsatellite 
polymorphism is commonly used as measure of relatedness between subjects and can be 
used as a method of cell line identification. Moreover, microsatellite slippage is more 
common than other base pair-level mutation. Therefore, it is a sensitive marker of MMR 
fidelity and so can be used as a proxy for all genetic instability at this level i.e. base 
substitution and insertion / deletion mismatches, as well as gene copy number changes. 
Base-pair level mismatches can have a wide range of deleterious effects on cellular 
metabolism and so studying their frequency can give useful information on the genetic 
stability of a given cell line and its ability to sense and repair that damage (Lengauer et 
al., 1998, Kurzawski et al., 2004, Lai and Sun, 2003, Kunkel and Erie, 2005, Aquilina et 
al., 1994, Yu et al., 2015). 
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Figure 3.1. Replication slippage. 
Each numbered block represents one repeat of a microsatellite. The figure illustrates 
how DNA strands can become misaligned and as a result the microsatellite can undergo 
expansion (left) or contraction (right). 
 
 
3.1.3.  Chapter Aims and Hypotheses 
 
This investigation aims to characterise the extent of genetic change at the base pair, 
copy number and chromosome level through microsatellite and karyotype analysis. 
Hypotheses: 
• There would be significant nucleotide-level change over long-term cell culture. 
• There would be significant karyotype-level change over long-term cell culture. 
• This genetic change would correlate with observed changes in cell specific 
productivity and gene copy number 
• Heterogeneity would be present between cell lines and would be seen to develop 
over time. 
 
3.2 Results 
 
The hypothesis generated by Kim et al (2011) was that repetitive sequences within the 
GS vector are subject to homologous recombination-based gene loss. This was 
supported by the fact that light chain genes, which are surrounded by more repetitive 
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elements, were lost to a greater extent than heavy chain and GS genes. Vector design, 
genomic location of recombinant gene integration (position effect) and underlying cell 
line genomic stability are all postulated to influence this phenomenon. The work 
presented here aims to build on the work of Kim et al (2011), with an investigation into 
the hypothesis that the underlying background genetic instability is significant and 
could strongly influence recombinant gene loss and, subsequently, a decline in qP. The 
same ten (B1-B10) GS-CHOK1SV mAb-producing cell lines used in the Kim et al. 
(2011) study, sampled at the same low and high generation numbers, were used to 
analyse cell line genetic instability at the base pair and chromosome level. A brief 
summary of the workflow of the experiments and analysis carried out in this chapter is 
provided in figure 3.2. 
Figure 3.2. Chapter 3 Workflow 
The flow chart begins with the chapter premise, which originates from the 10 cell lines 
studied by Kim et al. (2011) and the need to assess their genomic instability. This is 
done at the base pair / GCN level by microsatellite analysis and at the chromosome 
level by karyotype analysis. Microsatellite analysis involved the study of allelic 
heterogeneity amongst the 10 cell lines and how allele frequency changes over time. 
Karyotyping considers changes in chromosome number and form. Both of these tools 
are then assessed in their ability to report on genomic instability as well as their 
correlation with changes to qP and GCN. 
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3.2.1. Microsatellite Analysis 
 
Microsatellite instability was used as a marker of overall genetic instability at the base 
pair level to assess the heterogeneity of these cell lines and their genetic stability over 
time. Six microsatellites (GNAT2, 10.1, 21.1, 11.1, GT-23 and BAT25) were used as 
markers to genetically characterise each of the ten cell lines (B1-B10). Samples from 
each cell line were taken at both a low and high number of generations after cloning. A 
summary of the exact sampling generations, production stability and gene copy number 
(GCN) is shown in Table 3.1.  Microsatellites were amplified by PCR and analysed by 
capillary gel electrophoresis in order to determine the extent of microsatellite 
polymorphism in each cell line. Genemapper® (Applied Biosystems) and Peak 
Scanner® (Applied Biosystems) software were used to determine the number (number 
of peaks) and frequency (peak height) of alleles for each microsatellite (Figure 3.3). 
Peak height is sample specific and so cannot be compared between different samples. 
Therefore, peak heights were converted to percentages to normalise the data. This 
profile of different allele frequencies in a given cell line will hereafter be referred to as 
the allele frequency distribution. Table 3.2 shows the number of alleles for each 
microsatellite. Each microsatellite was sampled in duplicate, except for GT-23, which 
was sampled in triplicate. Due to sampling errors there is no data available for 
microsatellite 11.1 in cell line B6. 
 	
 
 
Table 3.1. Gene Copy Number and qP Changes in Cell Lines B1-B10 
The data in this table is adapted from data generated in (Kim et al., 2011). The table shows the generation number for each cell line, referred to as 
“low” or “high”, changes in qP both as a percentage and rate, and changes in gene copy number for the heavy chain, light chain and GS gene in 
terms of percentage and rate. 
 Generation Number Change in qP Recombinant GCN Change (%) Recombinant GCN Change (rate) 
(generation-1 x 103) 
Cell Line Low High Percentage Rate 
(generation-1 x 102) 
HC LC GS HC LC GS 
B1 20 72 - 32.6 - 0.80 - 17.9 - 48.1 - 13.6 - 3.8 - 12.6 - 2.8 
B2 20 84 - 24.7 - 0.46 - 11.5 - 38.9 - 1.8 - 1.9 - 7.7 - 0.3 
B3 16 57 - 3.7 - 0.09 0 8.7 - 5.6 0.0 2.0 - 1.4 
B4 23 103 - 23.8 - 0.31 - 15.4 - 34.9 - 12.9 - 2.1 - 5.3 - 1.7 
B5 19 95 0.0 0.00 - 20.0 - 31.3 - 22.8 - 2.9 - 4.9 - 3.4 
B6 14 82 - 1.8 - 0.03 - 11.1 - 9.6 - 15.9 1.6 - 1.5 2.2 
B7 2 77 - 13.9 - 0.22 - 13.8 - 7.9 - 19.2 - 2.0 - 1.1 - 2.8 
B8 16 76 - 44.4 - 0.93 - 43.2 - 57.5 - 45.9 - 9.4 - 14.2 - 10.2 
B9 12 93 - 70.7 - 1.47 - 72.8 - 83.2 - 81.0 - 15.9 - 21.8 - 20.3 
B10 11 92 6.3 0.07 24.1 3.0 19.7 2.7 0.4 2.2 
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Figure 3.3. Peak Scanner Software Allele Frequency Determination 
The figure illustrates how the allele frequencies for each microsatellite were determined 
using Peak Scanner® software. The three main peaks show that there are three alleles of 
the microsatellite GNAT2 (126bp, 129bp, 132bp). The peak height (H) determines the 
frequency of each allele (2305, 100675, 14066) in this cell line (B3 High). These were 
converted to percentages to enable comparisons between samples (8.5%, 39.5%, 52%). 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2. Number of Alleles per Microsatellite 
The table shows how many alleles were detected for each microsatellite as determined 
by Genemapper® (Applied Biosystems) and Peak Scanner® (Applied Biosystems) 
software. 
 
 
3.2.1.1. Microsatellite Heterogeneity Between Cell lines 
 
This first set of analyses gives an insight into the variation between cell lines within a 
given generation, which provides information on genetic drift and cell line 
heterogeneity. Subsequently, it was investigated whether any observed heterogeneity is 
Microsatellite Number of Alleles 
GNAT2 3 
10.1 4 
21.1 3 
11.1 6 
GT-23 6 
BAT25 4 
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seen to increase over long-term cell culture by comparing the variance at low and high 
generation numbers. 
 
It was decided that this analysis would be carried out on an allele-by-allele basis and so 
the dataset was split into 52 data subsets by categories of microsatellite, generation and 
allele. So, for example, one subset contained all the percentage values of total GNAT2 
microsatellite copies for allele 1 in each cell line at low generation number (GNAT2 – 
Low – Allele 1: 20 data points, two for each cell line). Before analysing the variance 
within these data subsets, it was necessary to establish whether their residuals were 
normally distributed in order to determine whether to carry out a parametric or non-
parametric variance test. A Shapiro-Wilk test was carried out to test for normality 
(Table A41), which shows data is normally distributed when p > 0.05. 6 of the 52 data 
subset residuals were not normally distributed and so Box-Cox plots for data transforms 
(Figure 3.4) were generated to ascertain the power transformation most likely to yield 
normal residuals in each case. The following power transformations were carried out: 
 
• BAT25 – High – Allele 1 1.57 
• 10.1 – Low – Allele 1 0.44 
• GT-23 – High – Allele 2 -9 
• 10.1 – High – Allele 3 -36.42 
• 10.1 – High – Allele 4 31.1 
• GT-23 – Low – Allele 6 -9.73 
 
Using these transformed percentage values the Shapiro-Wilk test was used again to 
check for data subset normality (Table A42). The data transformations resulted in five 
out of the six data subset residuals being normally distributed. However, one data subset 
(10.1 – High – Allele 4) still had non-normally distributed residuals. To assess 
microsatellite heterogeneity between cell lines, one-way ANOVAs were conducted for 
all data subsets to assess differences in allele frequency distribution, except for data 
subset 10.1 – High – Allele 4, which was assessed using a non-parametric equivalent 
rank test, the Kruskal-Wallis one-way analysis of variance. The p-values were then 
adjusted using a Benjamini Hochberg adjustment, to nullify the type I error risk from 
using multiple ANOVAs. 
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Figure 3.4: Box-Cox Plots for Power Transforms: Non-Normal Microsatellite Data 
The plots show the value of lambda (directly under peak) for a power transformation 
most likely to yield a normally distributed dataset. 
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Table 3.3 shows the p-values from all 52 variances tests, highlighting those that were 
significant (p < 0.05). 4 out of the 6 microsatellites (GNAT2, 21.1, 11.1, BAT25) show 
significant variance in allele frequency distributions between the low generation cell 
lines and between high generation cell lines. Figure 3.5 contains plots illustrating the 
allele frequency distributions, in which cell lines are represented by differentially 
coloured plot lines in individual plots for all microsatellite-generation number 
combinations. The plots show that the significant microsatellite variation revealed by 
the ANOVAs (GNAT2, 21.1, 11.1 and BAT25) is not randomly distributed.  
 
 
 
Table 3.3: Microsatellite Polymorphism: Variance Between Cell Lines 
The table contains the p-values from ANOVA tests describing the microsatellite allelic 
variance between B1-B10 cell lines at a low (A) and high (B) generation number. * 
represents significant variance. 
 
 
 
A) Low Generation      
Microsatellite Allele 1 Allele 2 Allele 3 Allele 4 Allele 5 Allele 6 
GNAT2 * 1.07E-07* 1.09E-10* 2.45E-11*    
10.1 0.738 0.738 0.738 0.738   
21.1 * 1.45E-04* 1.52E-08* 5.18E-12*    
11.1 * 5.46E-05* 2.78E-07* 1.59E-08* 1.05E-06* 5.48E-07* 2.47E-07* 
GT-23 0.854 0.854 0.854 0.854 0.854 0.854 
BAT25 * 6.80E-09* 7.03E-12* 7.31E-12* 2.32E-09*   
B) High Generation      
Microsatellite Allele 1 Allele 2 Allele 3 Allele 4 Allele 5 Allele 6 
GNAT2 * 8.87E-11* 6.08E-11* 8.12E-12*    
10.1 0.603 0.603 0.499 0.603   
21.1 * 9.09E-09* 1.23E-12* 6.59E-15*    
11.1 * 4.51E-06* 4.77E-06* 3.01E-06* 0.002* 1.61E-05* 6.01E-07* 
GT-23  0.060 0.094 0.094 0.094 0.094 0.094 
BAT25 * 1.24E-11* 5.49E-11* 1.12E-11* 2.69E-12*   
 	
Figure 3.5: Allele Frequency Distribution  
The plots show allele frequency for each cell line: Colours: B1 (black), B2 (blue), B3 (green), B4 (orange), B5 (dark gray), B6 (red), B7 (brown), 
B8 (cyan), B9 (dark green), B10 (yellow). The letters represent different clusters of cell lines that are similar in allele frequency distribution. 
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Instead, it is due to an apparent clustering phenomenon, whereby subgroups of cell lines 
have similar allele frequency distributions, which differ significantly to the allele 
frequency distributions of the other subgroup(s). Cell lines that belong to the same 
cluster with one microsatellite do not necessarily belong to the same cluster for other 
microsatellites. However, it is noteworthy that cell lines B1 and B2 as well lines B4, 
B5, and B8 are always the same cluster. Significantly variable microsatellites present 
the following clusters: 
• GNAT2: Low and High 
o A) B3, B6, B7, B9, B10. 
o B) B1, B2, B4, B5, B8.  
• 21.1: Low and High 
o A) B1, B2, B3, B6, B7, B9, B10. 
o B) B4, B5, B8. 
• 11.1: Low 
o A) B1, B2, B3, B4, B5, B8. 
o B) B7, B9, B10. 
• 11.1: High 
o A) B1, B2, B3, B4, B5, B8, B9. 
o B) B7 
o C) B10 
• BAT25: High and Low 
o A) B1, B2, B4, B5, B8. 
o B) B3, B6, B7, B9, B10. 
The clusters within these variable microsatellites remain the same from low to high 
generation, except for microsatellite 11.1, in which cell line B9 appears to change from 
cluster B to cluster A and cell line B10 forms its own cluster (C) in high generation 
cells. The plots illustrating those microsatellites that exhibited no significant 
microsatellite variation in the ANOVAs (10.1 and GT-23) show all 10 cell lines in the 
same cluster. As well as clustering, the shapes of clusters shift between low and high 
generations, which is indicative of change over long-term cell culture. For example, 
GNAT2 cluster A cell lines are more widely spread in the high generation plot in 
comparison with the low generation plot. 
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To further analyse the ANOVA results a Tukey’s multiple comparisons test was carried 
out to give a cell line by cell line breakdown of comparisons for each microsatellite. In 
the case of data subset 10.1 – High – Allele 4 a Kruskal Nemenyi test was carried out, 
which can be used in the same manner as a Tukey’s test for non-parametric data. These 
results are presented in Tables 3.4-3.9, whereby each comparison is represented by how 
many of the total alleles for each microsatellite were significantly different (p < 0.05) 
between cell lines. The tables support the conclusions drawn from Figure 3.6, whereby 
the significant variation shown by the ANOVAs is not randomly distributed, but is 
mostly down to an apparent clustering phenomenon, in which subgroups of cell lines 
have similar allele frequency distributions, which differ significantly to the allele 
frequency distributions of other subgroups. However, these tables also show that there 
is significant variation within these clusters as represented by the black and red dashed 
borders for clusters A and B respectively. Moreover, these tables show that, on a cell 
line-by-cell line basis, there is no significant variation between low and high generation 
cell lines for microsatellites 10.1 and GT-23. Microsatellites GNAT2, 21.1, 11.1 and 
BAT25 had significant generational allelic changes over long-term cell culture (orange 
shaded boxes), having 6, 11, 15 and 3 changes in the number of cell line-by-cell line 
allelic differences respectively. These allelic changes appear to be randomly distributed 
in microsatellites GNAT2, 21.1 and BAT25, whereas the changes appear exclusively in 
cell lines 9 and 10 in microsatellite 11.1. This supports the conclusions drawn from 
figure 3.6 and indicates that microsatellite change may have led to a breakaway of these 
cell lines from the initial clustering identified in low generation cell lines. Box plots 
illustrating these cell line-by-cell line differences are included in the appendix (Figures 
A27-32). Interestingly, these box plots reveal that the size of residuals for 
microsatellites 10.1 and GT-23 could be the reason for finding a lack of significant 
variance in the ANOVAs. 
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(3 Alleles) 3.4 
(4 Alleles) 3.5 
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(3 Alleles) 3.6 
(6 Alleles) 3.7 
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Tables 3.4-3.9: Tukey’s Multiple Comparisons Tests 
The tables provide the number of significantly different alleles for each cell line-cell 
line comparison at low and high generation numbers for each microsatellite. Low and 
high cell line comparisons are shown above and below the blacked-out cells 
respectively. The orange highlighted values represent the allele number values that have 
changed over long-term cell culture. Black and red dashed borders represent variations 
within A and B clusters respectively. 
(6 Alleles) 3.8 
(4 Alleles) 3.9 
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So far the analysis has indicated that cell line microsatellite heterogeneity may have 
increased from low to high generation. For example, the ANOVA p-values generally 
decreased from low to high generations, figure 3.5 showed greater dispersion of cell 
lines for higher generations and generally Tukey’s tests revealed that higher generation 
cell lines were more significantly different than lower generation cell lines. To confirm 
the validity of these inferences, an F Test was carried out to compare variances between 
low and high generation cell lines. The F test results are summarised in table 3.10. 
Generally, there was no significant difference in variances between low and high 
generations, except on two occasions with 10.1-Allele 3 and GT-23-Allele 1. Variance 
in microsatellite 10.1 and GT-23 was deemed not to be significant, so significant 
changes in variance here were not counted. This indicates that variance has not changed 
over long-term cell culture. 
 
Microsatellite Allele 1 Allele 2 Allele 3 Allele 4 Allele 5 Allele 6 
GNAT2 0.738 0.673 0.690    
10.1 0.211 0.117 0.031* 0.987   
21.1 0.787 0.971 0.974    
11.1 0.109 0.069 0.397 0.860 0.348 0.146 
GT-23 0.0398* 0.318 0.056 0.206 0.304 0.162 
BAT25 0.911 0.524 0.724 0.705   
Table 3.10: F Test for Variance Comparison Between Generations 
The table contains p-values generated from comparing variances between allele 
frequencies across low and high generations by F Tests (Table A43 contains the full set 
of p-values with variance ratios). * represents a significant change in variance. 
 
However, it has already been established that the main cause of significant variation 
between cell lines is due to the clustering phenomenon described previously and it could 
be the case that significant changes in variance between low and high generation were 
being masked by this large source of variation. Therefore, F Tests were carried out to 
assess the significant differences in variances between the clusters of cell lines 
identified in the low generation. The results of these F Tests are summarised in table 
3.11. This method was more able to identify significant variance differences between 
generations and the results show that heterogeneity appears to increase over long term 
cell culture. Differences in variance appears to be partially present for all 
microsatellites, apart from microsatellite 11.1 for which cluster B has significant 
differences in variance for all alleles. This supports the greater amount of change 
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determined previously in microsatellite 11.1 in comparison to other microsatellites. 
Again, for those variances deemed not significant by ANOVAs (10.1, GT-23, 
significant changes in variance should not be counted. 
 
 
Table 3.11: F Test for Variance Comparison Between Generations by Cluster 
The table contains p-values generated from comparing variances between allele 
frequencies across low and high generations by cluster, using F Tests (Table A44 
contains the full set of p-values with variance ratios). * represents a significant change 
in variance. 
 
 
3.2.1.2. Cell Line-specific Microsatellite Changes Over Time 
 
A more direct analysis, using T-TESTs, was carried out to assess the differences in 
allelic frequency distributions between low and high generations of individual cell lines. 
A Benjamini Hochberg p value adjustment was carried out to minimise type I error. A 
p-value less than 0.05 indicated a significant allele frequency distribution difference 
between early and late generations of a cell line. Table 3.12 shows the results of the T-
TEST in terms of how many alleles per cell line changed significantly for each 
microsatellite.
Microsatellite Cluster Allele 1 Allele 2 Allele 3 Allele 4 Allele 5 Allele 6 
GNAT2 A 0.088 0.086 0.049*    
 B 0.060 0.768 0.952    
10.1 A 0.211 0.117 0.031* 0.987   
21.1 A 0.007* 0.267 0.340    
 B 0.193 0.385 0.103    
11.1 A 0.006* 0.785 0.115 0.819 0.275 0.058 
 B 0.007* 0.002* 0.001* 0.003* 0.008* 0.001* 
GT-23 A 0.040* 0.317 0.056 0.206 0.304 0.162 
BAT25 A 0.115 0.939 0.874 0.165   
 B 0.011* 0.330 0.478 0.007*   
 	
 
 
Cell Line 
Changed Cell Lines (%) 
By Number Weighted Stability 
Microsatellite  Alleles B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 R N R N  
GNAT2  3 0 0 0 0 0 3 0 0 0 0 10 11.9 10 11.9 SS 
10.1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 S 
21.1 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SS 
11.1 6 0 0 0 0 0 0 0 0 2 0 10 10 3.33 3.33 NS 
GT-23 6 0 1 0 0 0 0 0 0 0 0 10 12.7 2.8 3.5 NS 
BAT25 4 0 1 0 0 0 0 0 0 0 0 10 12.7 10 12.7 SS 
Cell Line 
Change (%) 
R 0 33.3 0 0 0 16.7 0 0 16.7 0  
 
 
  
N 0 42.2 0 0 0 19.9 0 0 16.7 0 
Weighted 
Change (%) 
R 0 6.9 0 0 0 16.7 0 0 5.6 0 
N 0 8.7 0 0 0 19.9 0 0 5.6 0 
Stability S NS S S S SS S S NS S 
Table 3.12: T tests for Cell line-specific Microsatellite Changes over Time 
The table summarises cell line specific microsatellite allele frequency percentage comparisons and microsatellite-specific change between low 
and high generations. Cell line microsatellite stability is represented by percentage of microsatellite change and by weighted percentage change, 
which takes into account allele number. Percentages are given in raw (R) or normalised (N) (by generation number) form. Microsatellite stability 
is represented in the same manner. Stability categories based on normalised weighted percentages: (S – 0%), nearly stable (NS – 0-10%) and 
semi-stable (SS – 10-20%).  
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The percentage of cell line change in microsatellite was calculated using the number of 
microsatellites showing any instability (Cell Line Change (%)) and the weighted 
percentage of cell line microsatellite change was calculated by averaging the percentage 
of significantly unstable alleles for each microsatellite (Weighted Change (%)).  These 
percentage values (R) were then normalised (N) for generation by using the highest 
generation number as a reference point (B9 and B10 – 81 generations) Cell lines were 
categorized into stable (S – 0% change: B1, B3, B4, B5, B7, B8, B10), nearly stable 
(NS – 0-10%: B2, B9) and semi-stable (SS – 10-20%: B6) groups based on their 
normalised weighted percentage changes. As can be seen in Table 3.12 there was only a 
small amount of significant cell line-specific microsatellite change between low and 
high generation, which ranging between 0 – 19.9% weighted normalised percentage. 
Changes exhibited some cell line specificity, indicating that some cell lines were more 
genetically stable than others. It should be noted that figure 3.5 shows little change 
between early and late generations in allele frequency distribution, which is in line with 
the level of change shown in the T Tests. Individual microsatellite instability was 
calculated in the same manner, using percentage of cell lines (By Number) exhibiting 
change and a weighted (Weighted) percentage using an average of significantly unstable 
alleles. Microsatellites differed in their stability, ranging between 0-17% weighted 
normalised percentage, which would indicate that genetic instability is microsatellite 
(locus) specific. It should be noted that there were many T Test p – values that fell 
within the 0.05-0.1 range, meaning that they were nearly deemed to show significance 
(Table A45). More repeats may have revealed a higher level of microsatellite change. 
 
A correlation analysis was carried out using Pearson’s product moment correlation 
coefficient to establish whether the microsatellite instability observed in this study 
correlates with the qP and GCN changes observed by Kim et al. (2011) (Table 3.1). 
Both weighted and non-weighted percent changes in microsatellite were used for this. 
Table 3.13 contains the p-values from these correlation analyses, which show that there 
is no significant correlation between the observed microsatellite instability and changes 
in qP or GCN. 
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 Normalised Microsatellite 
Change 
Weighted Normalised 
Microsatellite Change 
Rate of HC GCN Change 0.688 0.950 
Rate of LC GCN Change 0.525 0.946 
Rate of GS GCN Change 0.763 0.895 
Rate of average GCN Change 0.635 0.971 
Rate of qP Change 0.543 0.919 
 
Table 3.13. Microsatellite Stability Correlation Analysis 
The table contains p-values from Pearson’s product moment correlation coefficients 
when comparing microsatellite changes with changes in GCN and qP. 
 
 
3.2.2. Karyotype Analysis 
 
CHO cells are known for having an unstable karyotype, which perhaps is not surprising 
considering it was originally isolated and cultured to study different forms of 
chromosomal aberration, amongst other things. Chromosomes can change in number to 
form aneuploid cells, or can change in form via breakage and fusion events with 
different chromosomes. The karyotypes of cell lines B1-B10 both at low and high 
generation were attained by viewing giemsa-stained cell squashes of cells from these 
populations. Approximately 30 cell squashes were analysed per sample. This was 
carried out by the Sheffield’s Children’s Hospital. Each chromosome was characterised 
and annotated in line with the methodology used by (Derouazi et al., 2006), which 
follows criteria set out in the established system for the karyotyping of CHO cells (Ray 
and Mohandas, 1976) and the International Standard Committee on Human Cytogenetic 
Nomenclature (Mitelman, 1995). Karyotypes of the ten cell lines were compared to the 
karyotype of parental CHO cell lines (Figure A33) as a standard. Chromosomes were 
identified and are referred to using the following nomenclature: 
 
• Numeric: According to wild type hamster chromosomes. 
• Derived (der(y)): Structurally rearranged chromosome derived from a known 
chromosome, where y = the name of the known chromosome type. In the case of 
chromosomal fusion, resulting in a chromosome made from two known 
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chromosomes, y is given as the known chromosome that is the largest 
constituent of the derived chromosome. 
• Isochromosome (Iso): Chromosome made from two identical arms of known 
origin. 
• Additional material of unknown origin (Add(y)): A chromosome in which 
chromosome y has fused with unidentifiable chromosomal fragment(s). 
• Z: Specific groups of morphologically altered chromosomes that have been 
previously identified in CHO cells. 
• Marker (Mar): Unclassifiable chromosome. 
 
The karyotype of the parental cell line contains 19 chromosomes. Even in the relatively 
small sample size of ~30 cells per culture sample, cell lines B1-B10 clearly deviate 
from the standard 19 chromosomes per cell (Table 3.14). Indeed, only three culture 
samples (B7 Low, B9 High and B10 Low) show complete homogeneity in chromosome 
number. This aneuploidy indicates that DNA replication is error prone, either in the 
form chromosome number moderation during mitosis or in the form of chromosome 
breakage or fusion events that generate modified chromosomes. Figure 3.6 shows the 
composite karyotype containing every chromosome type seen in cell lines B1-B10 
within this investigation, differentially colour-labeled according to whether they exist in 
wild type hamster cells (blue), are considered as common CHO chromosomes (i.e. 
parental - red), or are chromosomes novel to this investigation (black) (NB. “novel” 
chromosomes were counted as chromosomes not seen in the parental CHO karyotype 
and chromosome duplication events that appear to have occurred during stable cell line 
generation within this investigation). Figure 3.6 shows that these cell lines have 
undergone vast chromosomal change and show that this collection of cell lines have 
diverged from the parental cell line karyotype with 18 novel chromosomes being 
presented here, both in the form of duplications of common CHO chromosomes and 
modified chromosomes. There are 4 cases of novel (black) chromosome duplication, as 
indicated by the ‘+’ symbol. Novel chromosomes labeled ‘add’, ‘iso’, ‘der’ or ‘Mar’ 
represent those chromosomes that are generated as a result of breakage and fusion 
events. Marker (Mar) chromosomes in particular are postulated to derive from multiple 
breakage or fusion events, because their constituents cannot be recognised as a 
previously seen chromosome. This shows that improper segregation moderation and 
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breakage / fusion detection and repair are a consistent phenotype of these cell lines. A 
full list of cell line karyotypes can be found in table A46. 
 
 
Cell Line 
Number of Metaphase Cells with Chromosome Number n 
17 18 19 20 21 22 23 24 25 
B1 Low  1 28 1      
B1 High 1 3 20 5 1     
B2 Low  1 25 4      
B2 High  3 27       
B3 Low  1 27      1 
B3 High  2 28       
B4 Low   28 2      
B4 High   28 2      
B5 Low  2 27 1      
B5 High   29 1      
B6 Low 1 1 26 1 1     
B6 High  2 26 4 1     
B7 Low   30       
B7 High   15 14 1     
B8 Low   17 2 1     
B8 High  8 21 2 1     
B9 Low 1 3 21 2      
B9 High   30       
B10 Low   26       
B10 High  1 28 1      
 
Table 3.14: Chromosome Number in Cell Lines B1-B10. 
The table contains the chromosome numbers from the ~30 cell squashes obtained from 
cell culture samples of cell lines B1-B10 at both low and high generation numbers. 
 
 
 
 	
Figure 3.6: Composite CHO Karyotype from Cell Lines B1-B10 
The figure contains all chromosomes identified in the investigation. (Colours and terminology described in text) 
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Table 3.15 provides a summary of the chromosomal differences between the parental 
cell line and cell lines B1-B10. It contains all the novel chromosomes that were 
generated during the course of this investigation and also chromosomes that were 
present in the parental karyotype, but absent in some of cell lines B1-B10 (i.e. they have 
been lost - distinguished by *). Therefore, the table gives an impression of how unstable 
each cell line is in terms of how many abnormal chromosomal observations it contained 
(crosses) and how many changes in karyotype were observed between low and high 
generation numbers (orange highlight). In the instances where there was more than one 
karyotype observed in a given population of cells, the karyotype subpopulations are 
distinguished numerically aside the cell line-generation label. Data from Kim et al. 
(2011) regarding changes in qP are included in the right-hand columns. This table 
demonstrates that there were a large amount of abnormal chromosomes generated and 
that there have been many changes from the parental karyotype. There were no cell 
lines that maintained the parental karyotype in either generation. Moreover, 70% of cell 
lines B1-B10 showed changes in karyotype from low to high generation number. This 
indicates that CHO cells are largely unstable at the chromosome level, which has caused 
genetic heterogeneity between and within clonal cell lines. Interestingly, the cell lines 
that did not show any karyotypic changes between low and high generations showed 
some of the lower changes in qP and the two cell lines that demonstrated the largest 
changes in karyotype exhibited the largest changes in qP. However, this data is 
qualitative, and so firm conclusions regarding correlations cannot be made for potential 
cause and effect relationships. It is perhaps noteworthy that all cell lines lacking the 
marker10 chromosome showed no karyotypic changes in long-term culture, whereas 
add8 chromosome was found to be present in all of these non-changing cell lines. 
Moreover, chromosomes 1(x2), 2, der(4), 5, 8 / add8, 9, Z13 / isoZ13, Z8, Z4 /addZ4, 
Z2, marker1 and marker3 were found in all cell lines, so could perhaps be essential or 
contain essential elements. Also, no structural changes to original CHO chromosomes 
(blue) were observed in chromosomes 1, 2, 5 and 9, which may indicate that they 
contain essential genes and so if changed could have lethal results. Indeed, no 
duplication events are observed for chromosomes 1 and 9, which may indicate that 
changes in gene balance of these chromosomes cannot be tolerated.  
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0
-0.03
-0.22
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0.07
Table 3.15: Cell Lines B1-B10 – Differences to Parental Karyotype 
The table contains all the chromosomal differences between cell lines B1-B10 and the parental karyotype (Explained in text) 
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Table 3.16 presents the karyotype data slightly differently, whereby all the cell line 
populations / subpopulations with the same karyotype are grouped into the same 
‘cluster’. “L” and “H” refer to low and high generation cell lines respectively. Cell line 
sub populations with different karyotypes are distinguished in the same numerical 
format as in table 3.15. 
 
 
 
 
Table 3.16. Unique Karyotype Clusters 
The table combines together all cell line subpopulations with the same karyotype. 
Clusters that appear in both low and high generation cell lines, only low generation cell 
lines or only high generations are distinguished by orange, white and blue shading 
respectively. 
Cluster Cell Line Subpopulations 
1 B1-L, B2-L, B1-H-1, B2-H-1  
2 B3-L, B3-H 
3 B4-L, B5-L, B4-H, B5-H 
4 B6-L 
5 B7-L, B7-H-1 
6 B8-L-1, B8-H-1 
7 B8-L-2 
8 B9-L 
9 B10-L 
10 B1-H-2 
11 B2-H-2 
12 B6-H-1 
13 B6-H-2 
14 B7-H-2 
15 B8-H-2 
16 B9-H-1 
17 B9-H-2 
18 B10-H 
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The table shows that there were 18 distinct karyotypes present within cell lines B1-B10 
over the course of this investigation. Five of these karyotypes were only present in low 
generation cell lines (white), five karyotypes were present in both low and high 
generation cell lines (orange), and nine karyotypes are only present in high generation 
cell lines (blue). Therefore, in total there were fourteen distinct changes of karyotype 
between low and high generations (5 lost, 9 gained). Again, this supports the conclusion 
of gross genetic change at the chromosome level and demonstrates how this has led to 
an increased heterogeneity between cell lines B1-B10. 
 
The observed changes in karyotype and microsatellite frequency distribution were 
compared and there appears to be no apparent commonalities in terms of instability. For 
example, cell line B8 had several abnormal chromosomes in low generation cells and 
displayed karyotypic changes from low to high generation, but it was completely stable 
in terms of microsatellites. On the other hand, cell line B3 did not change in karyotype 
from low to high generation, but showed significant microsatellite instability (8.7% 
normalized weighted change). 
 
 
3.3. Discussion 
 
Phenotypic instability has been observed in the form of a decline in recombinant protein 
productivity and generation of product variants over long-term cell culture, which is a 
common and costly trait of current bioprocess platforms. Unfortunately, at present there 
are no predictive tools capable of indicating whether a given cell line may go on to 
show these undesirable traits (Kim et al., 2011, Derouazi et al., 2006; Zhang et al., 
2015). Clearly, it would be a great benefit if a cell line could be marked as stable or 
unstable in the developmental stages of testing new recombinant therapeutic candidates 
and their production, rather than investing time and resources into a cell line before 
discovering that it is productively unstable. This would save time, money and increase 
the overall efficiency of bioprocesses in terms of time to market and gaining consistent 
production titers. For such a tool to be put into place, there needs to be a firm 
understanding of the traits that can cause a cell to decrease in its productive capacity. 
Detectable markers of these instability-related traits, that are consistent and can be 
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called with confidence, need to be established to make it possible to efficiently evaluate 
and predict the relative stability of candidate cell lines.  
 
Broadly speaking, the molecular basis of production instability has most commonly 
been attributed to recombinant gene loss and a decline in the transcription of the 
recombinant gene (Kim et al., 2011). The relationship of gene copy number with 
productivity is relatively straightforward, whereby loss in gene copies correlates with a 
loss in productivity. This relationship may not be strictly linear, because the location of 
recombinant plasmid insertion dictates the expression capabilities of a given construct, 
but the correlation has been established. A decline in transcription of the recombinant 
gene is more complex. This can be due to methylation-based transcriptional silencing, 
changes to expression-determining sequences (promoter, open-reading frame and 
enhancer elements), translocation events to less active chromosomal regions, changes to 
other elements that impact upon transcription (transcription factors) or global 
transcriptional regulation changes.  
 
3.3.1. Microsatellite Analysis 
 
This study investigated microsatellite instability as a genetic marker for all mismatch 
repair-related changes, such as point mutations, insertions and deletions (Kunkel and 
Erie, 2005). Moreover, the slippage mechanism by which microsatellites are altered is 
similar to the proposed mechanism of recombinant gene loss suggested by Kim et al. 
(2011), whereby repetitive elements of sequence within the plasmid vector are subject 
to homologous recombination-based events, causing gene loss. Here, microsatellite 
instability was used to assess cell line-specific changes over time (two generational time 
points) and the relatedness of cell lines B1-B10, which were derived from the same 
parental cell line to measure developed heterogeneity.   
 
Microsatellite changes were analysed through the measurement of allele frequency 
distributions on an allele-by-allele basis. ANOVAs showed that amongst the low 
generation cell lines microsatellites GNAT2, 21.1, 11.1 and BAT25 showed significant 
variation in allele frequency distributions. It was shown that separate clusters of 
microsatellite-based relatedness were predominantly responsible for this observed 
variation, which indicates that most of this heterogeneity may have been derived from 
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the cell population of the parental cell line. These clusters were not the same in their cell 
line content for all microsatellites. However, cell lines B1 and B2 as well as cell lines 
B4, B5, and B8 were always in the same cluster, which is indicative of a closer level of 
relatedness between these cell lines compared to others. All cell lines remained 
within the same cluster from low to high generation number, except for microsatellite 
11.1. In microsatellite 11.1 cell line B9 changed from cluster B to cluster A and cell line 
B10 formed its own cluster, C, over long-term cell culture.  
 
A cell line-by-cell line analysis (Tukey’s multicomparisons test) confirmed the presence 
of these clusters, but also revealed that were was significant variance between some cell 
lines within certain clusters, which indicates development of heterogeneity that cannot 
exclusively be attributed to parental cell line derivation. Moreover, in cases where cell 
line-to-cell line comparisons changed in the number of significantly different alleles 
from low to high generation number, these changes were predominantly to an increased 
number of differences, which again would indicate an increasing heterogeneity over 
long-term cell culture.  
 
F tests were carried out between clusters at different generational time points to 
statistically measure for a change in heterogeneity over time. There was a significant 
generational difference between cluster variances, especially for microsatellite 11.1, 
which supports the conclusion that heterogeneity had developed over long-term cell 
culture, with microsatellite 11.1 showing the most dramatic change.  
 
T tests were used to determine cell line-specific changes in allele frequency distribution 
over long-term cell culture. These tests showed that there were minimal significant cell 
line-specific and microsatellite-specific changes in allele frequency distributions over 
long-term cell culture. Whilst this shows that cell lines differ in their level of stability, it 
is difficult to draw any firm conclusions from a dataset reporting so little change. 
Further study into these microsatellites with many more repeats may generate results 
that show more significant change. This is supported by the number of p – values 
generated from T Tests, which could be seen as ‘nearly significant’ (p = 0.05-0.1). 
Moreover, the fact that the different microsatellites showed different levels of instability 
supports the idea that genomic location impacts upon stability. Therefore, if 
microsatellites as stability markers were validated then they could elucidate ‘stable’ 
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targets for targeted recombinant DNA integration. The changes observed in 
microsatellite allele frequency did not correlate with changes in recombinant gene copy 
number or changes in cell specific productivity, which indicates that these 
microsatellites could not be used as a predictor of gene copy and production instability 
in these cell lines. However, this is not surprising given the small amount of change that 
was observed. 
 
This study has shown that microsatellite allele frequencies vary marginally, but 
significantly, over time and so, with further validation, could be used as a general 
marker of genetic instability. However, the variation was not an effective tool for 
predicting recombinant product stability. There were significant cell-line specific 
differences in microsatellite changes, which would indicate that microsatellites can 
distinguish stability between cell lines. Most of the change reported here is likely to be 
as a result of the slow but progressive nature of genetic drift, which gradually causes 
cell lines to differ in their allelic frequency distributions. Essentially, this is just an 
effect of random sampling over the generations (Kimura, 1955, Kimura, 1979). 
Therefore, microsatellites are a useful marker of allele frequency changes over time. 
Only microsatellite 11.1 showed signs of replication slippage occurrence, because of the 
more dramatic cluster changes observed. However, this cannot be concluded 
definitively, because no novel alleles of a different microsatellite length were detected, 
but rather a putative slippage event occurred causing a microsatellite change to a length 
that had already been seen. Therefore, no conclusive evidence was given that 
microsatellites could be used as a marker for base pair substitution.  
 
The fact that there was no correlation between microsatellite changes and changes in 
GCN or qP would indicate that these microsatellites are not a reliable marker of genetic 
instability at the gene copy number level and that base pair level changes did not 
significantly impact gene expression in these cell lines. However, the genomic location 
of a microsatellite has an impact on its stability just as the integration site of a 
recombinant plasmid has an effect on its production stability (Barnes et al., 2007). 
Therefore, given the fact that the genomic location of these microsatellites is not known 
and that their genomic context is likely to be different to that of integrated plasmid 
DNA, perhaps it is the case that microsatellites can be markers for overall genomic 
instability (Kurzawski et al., 2004), but cannot predict stability of integration sites 
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specifically. Furthermore, six microsatellites may not be enough to confidently assess 
instability at the base-pair level for a whole genome. This study showed that 
microsatellites adeptly showed the relatedness between different cell lines, as 
demonstrated by Yu et al., (2015). The allele frequency distribution plot (Figure 3.5) is 
the best illustration of this. These six microsatellites were able to characterise the ten 
cell lines through the adherence to frequency distribution clusters. Perhaps the use of 
more microsatellites would enable an exclusive identification pattern for each cell line. 
Overall, this study has highlighted the ways in which microsatellites can be analysed for 
markers of genetic instability in commercial cell lines and provides a useful platform for 
processing of future datasets, which might be more elucidating. 
 
3.3.2. Karyotype Analysis 
 
Cell lines B1-B10 were also assessed for their generational differences and cell line 
heterogeneity at the chromosome level through karyotype analysis. Both low and high 
generation cell lines were shown to be heterogeneous in terms of chromosome number, 
exhibiting a range of 17-25 chromosomes per cell. In all cases the modal chromosome 
number was 19, which was the parental cell line chromosome number. Cell lines B1-
B10 at low and high generations all contained chromosomes that were not present in the 
parental cell line. There were a total of 18 of these chromosomes generated within the 
cell culture period of this study.  70% of cell lines showed karyotype changes over long-
term cell culture, with a total of 14 distinct karyotype changes over long-term cell 
culture. It is difficult to compare GCN and qP instability with this genetic instability, 
because this data is qualitative. The number of chromosomal changes seen here does not 
necessarily correlate with changes in productivity, because it is difficult to quantify the 
impact of any single chromosomal aberration. Therefore, it is not feasible to directly 
project the chromosomal changes seen here on to the phenotypic changes observed 
these cell lines. Indeed, the genes that are affected by these aberrations and the  
subsequent downstream affects are not easy to interpret. Genetic and epigenetic effects 
can impact gene expression when genes are moved into different genomic locations 
(Gordon et al., 2012).  
 
Clearly this study has shown that these CHO cell lines are extremely unstable at the 
chromosome level, which is a hallmark of immortal and cancer cell lines. It has been 
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shown that chromosomal instability begets further chromosomal instability (Duesberg 
et al., 1998), so it is perhaps no surprise that changes were seen over long-term cell 
culture in cell lines that had already undergone karyotype change. In some cases 
chromosomal instability has been shown to be a predecessor for gene mutation and 
enzyme imbalance (Duesberg et al., 1998), which could also lead to production 
instability over long-term cell culture. As previously stated, CHO cells were initially 
used for the investigation of chromosomal aberrations (Jayapal et al., 2007) and since 
the start of their use in industrial bioprocesses have been manipulated, engineered and 
evolved towards desirable phenotypes, potentially at the cost of genetic fidelity 
(Sinacore et al., 2000, Heller-Harrison et al., 2009). Therefore, this instability is likely 
to be an inherent feature of all CHO cell lines. This may contribute to production 
instability, because hotspots of the CHO genome for DNA double-strand breaks are 
more likely to be integration targets for plasmid DNA. This could be a source of 
instability further down the line.  
 
It may be possible to engineer or evolve cell lines towards phenotypes that exhibit less 
genetic instability, but this is challenging, because the underlying mechanisms behind it 
are not fully understood. Practically speaking, assessments that enable the early 
detection of genetic instability may allow for the selection of cell lines less likely to 
undergo drastic genetic changes throughout the production process. Also, it has been 
shown here that some genomic regions including whole chromosomes, such as 
chromosome 1, are somewhat immune to the chromosomal instability presented here 
and microsatellite analysis has shown that some loci may be less prone to base pair 
change than others. Therefore, targeting plasmid insertion to these relatively stable 
regions may lead to a cell line more able to keeping its productive capacity. However, 
this may be a simplistic view, because recombinant protein production relies upon many 
genes, in terms of the level and the fidelity of their products, which are likely to be 
situated in different genomic loci. 
 
3.3.3. Conclusion 
 
This study aimed to characterise and quantify CHO cell genomic instability at the base 
pair and gene copy level through microsatellite analysis and at the chromosomal level 
using karyotype analysis, for the assessment of their validity as tools in the cell line 
Chapter 3: CHO Cell Genetic Instability and Heterogeneity 
	 84	
development process to minimise phenotypic instability. Overall, significant allelic 
variation in microsatellites could only be attributed to genetic drift, rather than 
mutational change, and so in this format is not suitable for assessing global instability. 
Potential studies, outlined in section 3.3.4, may provide more insight into the usefulness 
of microsatellites for this purpose. On the other hand, karyotype analysis showed that 
there is substantial change at the chromosome level, both in terms of chromosome 
number and breakage / fusion events. This high level of chromosome instability did not 
directly correlate with changes in qp or GCN, but it was concluded that karyotype 
analysis could be used to eliminate unstable cell lines during the cell line development 
process. 
 
3.3.4. Future Work 
 
This study has shown that microsatellites may be able to be utilised as a marker for 
genetic instability for mismatch repair related instability, such as point mutations, 
insertions and deletions. However, as stated in section 3.3.1, six microsatellites cannot 
fully diagnose instability at this level. A more comprehensive microsatellite instability 
analysis of the genome may allow for an increased resolution in investigating genomic 
instability at this level, in which a higher number of microsatellites would be used. A 
large number of microsatellites would need to be identified and characterized in terms 
of genomic location to ensure that genome coverage is as comprehensive as is possible.  
 
Section 3.3.1 also highlighted the difficulty in correlating a genome-wide state of 
instability with a locus-specific instability such as plasmid-related gene expression. 
Therefore, even if a large number of microsatellites were identified that covered the 
whole genome at an informative resolution, it would be difficult to validate their use as 
a genetic instability marker by investigating the stability of a single locus (i.e. an 
insertion site). Perhaps instead of using recombinant DNA expression to validate 
microsatellite instability a more global analysis using transcriptomics could be used, 
because logically a marker for global stability can be better verified by a global output. 
If transcriptomic analysis was carried out on cell lines B1-B10 at low and high 
generation then a quantification of overall gene expression change could be determined. 
If this change was to correlate with microsatellite instability using a comprehensive 
genome-wide array of microsatellites then this would validate microsatellite instability 
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as a marker for gene expression instability and it would heavily indicate that mismatch 
repair, or a lack thereof, impacts significantly upon gene expression. From this, an array 
of microsatellites could be used to assess cell line instability in the developmental stages 
of the production process with an aim to weed out unstable candidates. Furthermore, the 
transcriptomic data could be used to analyse genes known to be involved in the 
regulation of DNA replication and its fidelity to see whether expression rates differ 
from what might be expected. This could lead to engineering or evolution-based 
strategies to generate more stable cell lines. 
 
A stated above, the experimental format used in this study is perhaps not the best 
indicator of production stability, because this phenomenon is likely to be locus specific. 
One use of microsatellite instability analysis for a locus-specific purpose could be to 
design a plasmid vector carrying a recombinant protein that was also carrying 
microsatellites. If it is indeed a reliable marker for genetic instability, microsatellite 
change could be used as a tool, in this setting, to more accurately assess whether 
observed decline in recombinant protein production is due in any part to mismatch 
repair fidelity and gene loss through repeat induced recombination events. Moreover, 
this system could be used to assess the stability of a given integration site with the aim 
of identifying sites for targeted integration efforts. As well as microsatellites, this 
probing plasmid could be littered with other types of repetitive sequences that might 
better imitate the repetitive nature of a plasmid that is used commercially, such as with 
the GS vector system, to assess whether repetitive sequences are responsible for 
recombinant gene loss. 
 
Another avenue of research could be to sequence cell lines, such as B1-B10, which 
show production instability to ascertain whether there is evidence of recombination-
based gene loss around repetitive elements in recombinant plasmid DNA. Also, 
sequencing may identify point mutations in the recombinant plasmid sequence in 
elements that could affect gene expression (promoters and enhancers) or elements that 
may affect processing downstream, such as translation or protein folding. Chapter 5 
provides an in depth analysis of mutation in recombinant plasmid DNA. 
 
This study also showed that the CHO cell karyotype is extremely unstable and 
changeable. As stated in section 3.3.2 it is difficult to draw correlations between a 
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changeable karyotype phenotype and changes in productivity. Each change in karyotype 
may have a unique impact on the productivity phenotype and so to gain a true 
understanding of how a given chromosomal change impacts upon recombinant protein 
expression then a single cell analysis of protein production is required, which could be 
done through techniques such as FACS single cell sorting. Perhaps if the location of 
genomic insertion was ascertained through methods such as fluorescent in-situ 
hybridization (FISH) and compared with the observed chromosomal changes then it 
could be established whether changes in productivity could be attributed to changes in 
genomic location. However, this may be a reductive theory, because changes in 
productivity could be a result of the changes in gene expression of other influential gene 
products, which are spread throughout the genome. Again, a transcriptomic analysis 
could assess globally for changes in gene expression for a correlation analysis with 
changes in productivity and it could be determined whether genes responsible for the 
regulation of chromosomal stability have changed in their gene expression. Indeed, 
sequencing may even uncover mutations in these genes.  
 
If further analysis led to the confirmation of the conclusions in this study, that the CHO 
cell karyotype is unstable and could be responsible for global genetic instability, then 
the implementation of a high-throughput karyotyping system into the bioprocesses 
involved in the production of recombinant proteins may be able to be used as a 
predictive tool for genetic instability of cell lines with the aim of eliminating unstable 
candidate cell lines from the developmental process. Moreover, it may be possible to 
evolve or engineer cell lines towards more karyotypically stable phenotypes. 
 
As mentioned above, chapter 5 provides an in depth analysis of point mutations in 
recombinant plasmid DNA. This study required the generation of stable CHO cells to 
acquire recombinant plasmid DNA. Therefore, it was necessary to optimise an 
electroporation protocol to facilitate the transfection of plasmid DNA. Preliminary 
analysis revealed that industry electroporation conditions could be vastly improved 
upon and so chapter 4 shows the DoE-based electroporation optimization carried out.  
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Chapter 4 
 
Electroporation Optimisation Using 
DoE Methodology 
 
 
4.1. Introduction 
 
4.1.1. Chapter Summary 
 
As mentioned in section 3.3.4, it was necessary to generate a stable CHO cell line in 
order to investigate the fidelity of recombinant plasmid DNA and to assess whether 
there is a substantial level of DNA mutation that could impact upon product quality. 
Preliminary experiments revealed that the standard electroporation conditions used in 
industry were suboptimal. Therefore, it was decided that a comprehensive optimisation 
process would help provide more effective electroporation conditions for the generation 
of stable CHO cells and could also provide a framework for future, product-specific, 
transfection optimisation for CHO bioprocesses.  
 
This chapter demonstrates the effectiveness of DoE methodology for the optimisation of 
bioprocess-related protocols and how it offers a higher level of precision and insight as 
to how different parameters contribute towards the experimental output. The results 
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showed that an increase in the level of electroporation parameters (voltage, pulse length, 
DNA load) increased transfection efficiency and decreased cell viability. This inverse 
relationship of transfection efficiency and cell viability was found to be somewhat 
predictive and was utilized in the optimisation process. The DoE strategy was to start 
with a wide range in electroporation parameters and to gradually narrow towards an 
optimal region of the design space. This narrow region was then experimentally tested 
to yield the final, optimal set of electroporation conditions. These conditions (320-26) 
increased transfection efficiency by ~17% compared to standard industrial conditions, 
without a substantial detriment to cell health. The optimal conditions could then be 
taken forward to generate a stable CHO cell pool. It was concluded that DoE, or other 
modelling methodologies, could be used in the same manner demonstrated here to 
quickly optimise electroporation for the generation of producing stable cell lines in a 
product-specific manner. 
 
4.1.2. DoE for Electroporation Optimisation  
 
All the variables discussed in section 1.3.6 should be considered when optimising an 
electroporation protocol. Different cell types and applications will have different 
optimal conditions for electroporation (Jordan et al., 2008). Typically, two output 
factors need to be maximised when optimising electroporation: Transfection efficiency, 
a marker of protein expression, and cell viability (Pucihar et al., 2011), which is 
decreased by DNA electroporation-mediated apoptosis (Shimokawa et al., 2000).  There 
is an inverse correlation between the two, because stronger conditions will facilitate 
greater membrane permeabilisation (i.e. DNA entering the cell), but at a greater cost to 
the health and recovery of a population of cells. Therefore an optimal trade-off needs to 
be made to ensure the maximum transfection efficiency without compromising cell 
viability (Andreason and Evans, 1989). For each new biopharmaceutical product being 
developed, the cellular reaction to electroporation may change in terms of transfection 
efficiency or cell viability. For example cell types will differ in their tolerance to 
electroporation parameters (Jordan et al., 2008), the metabolic burden on the cell may 
vary from product to product (Kim et al., 2011), or vector types and sizes can be 
interchangeable each having a different effect on an electroporation process and gene 
expression (Jordan et al., 2007, Wurm, 2004). Each of these factors will impact on cell 
viability and transfection efficiency and so electroporation parameters could be adapted 
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to cater for the different features of each new product – cell – vector combination. 
Median fluorescence will be used as a secondary measurement of gene expression in 
this study, which is a measure of expression intensity rather than expression by cell 
number. It has a more variable output than transfection efficiency and so is less reliable 
for comparing parameter settings. Median fluorescence is more valuable when 
considering transient expression systems, in which immediate high levels of expression 
are required. Average cell diameter (ACD) will be used as a secondary assessment of 
cell health, because electroporation causes cells to shrink through loss of cellular 
content, which is likely to be a stressor (Chang and Reese, 1990). 
 
Typically, an optimisation procedure like this would be carried out using a one factor at 
a time (OFAT) approach in which one factor is varied while the others are kept constant 
to measure its effect on the system. All factors are independently measured in this 
manner. Alternatively, DoE methodology mathematically models the response in a 
multifactorial manner and statistically analyses the model for significance. It offers a 
better estimate at optimal conditions with fewer experimental runs and all factors can be 
tested simultaneously. Furthermore, DoE offers insight into how different factors 
interact within a system, which OFAT fails to do. DoE methodology is a proven tool for 
the optimisation of transfection methods. Two examples of which are the optimisation 
of PEI-mediated transfection for transient production by (Thompson et al., 2012) and 
the optimisation of microporation by (Madeira et al., 2010). Design Expert 9.0.4 
software was used to facilitate DoE experimental design and analysis. 
 
As described above there are many variables that contribute to the efficiency of an 
electroporation protocol, both within the sample itself and by the electroporation device 
parameters that are set. A complete DoE analysis would first assess all of these 
variables in a factorial design, whereby all factors would be varied simultaneously at 
high and low levels to determine whether they have a significant impact on the 
response. Subsequently, these high-impact variables would be taken forward using 
response surface methods (RSM) to give a three-dimensional map response in which the 
output can be visualised in detail. However, the number of variables that would need to 
be analysed by an initial factorial design is extensive. The literature (section 1.3.6) has 
already defined how these factors interact in a typical electroporation system and can 
indicate which factors have the greatest effect on transfection efficiency and cell 
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viability (equations above). Moreover, the interactive nature of these factors means that 
a balance of factor levels is needed, which could be in the form of a number of optimal 
sets of parameters. For example, a sample with a low resistance would require a 
different voltage and pulse length to a sample with a high resistance. Varying sample 
resistance or parameter settings to calculated extents could achieve the same balance 
and subsequently the same transfection efficiency and cell viability. Therefore, it is 
unnecessary to vary all influential factors to discover an optimal output. Furthermore, in 
reality, the factors affecting the samples response to electroporation, including DNA 
vector, cell type, media and recombinant protein, will have already been carefully 
designed for each product. So, to apply DoE optimisation to electroporation universally, 
it would be more practical to optimise with electroporator parameter settings (voltage, 
pulse length, waveform) to achieve this balance, rather than to factor electroporation 
into design of sample components. Therefore, because of this logistical practicality and 
the level of definition electroporation already has, it was decided to proceed directly to 
RSM based methods of analysis with only a subset of factors. 
 
The electroporation factors investigated in this work were voltage, pulse length, 
waveform and to a lesser extent, DNA load. Other factors were kept constant 
throughout the study. The work demonstrated in this chapter uses Central Composite 
Designs (CCDs) (Figure 4.1.) to model electroporation responses. In a CCD each factor 
is measured at two initial levels, the low factorial and high factorial, which determine 
the boundaries of the design space being investigated. Center points are measured 
repeatedly to estimate the pure error of the model, and to estimate the curvature of the 
responses. Two levels outside of the design space are measured for each factor to enable 
the model to fully estimate the quadratic nature of the system in terms of each factor 
individually. These are called the low and high axial factors. CCDs can only adequately 
model up to and including quadratic terms, because the number of experimental runs is 
not enough for anything higher and so leaves cubic and quartic terms aliased. The 
procedure for analyzing these statistical models is clearly outlined by the design expert 
software. Firstly, diagnostics are carried out regarding normality and suggestions are 
made for data transformation and data point elimination, which might lead to a more 
accurate interpretation of the data. A fit summary is then provided, using sequential 
model sum of squares (SMSS) and model summary statistics (MSS), which suggests the 
order of model to be used. A model is then fit and is subsequently analysed using an 
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ANOVA to identify the experimental factors which have a significant impact on the 
response variable. It also provides statistics such as: Lack of fit, which informs the user 
if the model fits the data to an acceptable level of statistical significance; R-squared, 
which informs the user of the proportion of variance in the response that can be 
explained by the model; The predicted R-squared, which informs the user on the 
accuracy of the model in terms of its predictive capacity; ‘Adeq Precision’, which 
informs the user as to whether the signal to noise ratio of the response is strong enough 
for the model to adequately model the design space (>4). The model response to the 
independent variables can then be visualized using a response surface plot. The model 
terms and the response plot give the user a clear idea of the type and intensity of the 
relationship of the independent variables and the response, and indeed whether any of 
the independent variables interact in terms of their relationship with the response. 
Lastly, the optimisation function, which uses an inbuilt desirability function within the 
software, can then be used to combine response models to provide the user with a final 
set of optimal independent variable levels to use for future use, according to the 
priorities and thresholds set regarding the importance of each of the independent 
variables. So, for example, transfection efficiency might be given a higher priority than 
median fluorescence and cell viability can be set at a minimum value of 65% when 
determining optimal conditions. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Central Composite Design 
This figure illustrates a 3-factor CCD. Each dimension of the cube represents a different 
factor in terms of factorials (black dots), center points (grey dot) and axial points (stars). 
Figure adapted from Anderson and Whitcomb (2005). 
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4.1.3 Chapter Aims and Hypothesis 
 
The hypotheses of the investigation were that: 
•    A balance would need to be met between applied voltage and pulse length to 
give maximal transfection efficiency whilst maintaining high cell viabilities and 
that these optimal parameters would vary with waveform. 
•    DoE methods would be able to identify a number of parameters that met this 
balance and, ideally, would identify those that were more optimal than others. 
•    DNA load would also need to be balanced in the same manner, with increased 
loads enabling higher transfection efficiencies with a cost to cell viability. 
•    The optimal parameters determined by DoE methodology would achieve higher 
transfection efficiencies than industrial parameter settings (Pfizer conditions). 
•    The optimal parameters generate would be used to generate stable CHO cell 
pools in future work. 
 
4.2. Results 
 
It was decided that the investigation would involve a succession of RSM-based 
experiments in which the factor level ranges would progressively narrow towards 
narrow optimal range. This optimal range would then be tested to ascertain the most 
optimal parameter settings. The phCMV-CGFP plasmid (Figure 4.2.) was linearised 
using restriction enzyme AflII. Gene expression responses were analysed via GFP 
fluorescence detection by flow cytometry in terms of transfection efficiency (percentage 
cells expressing GFP) and median fluorescence (level of GFP expression). Cell health 
measurements were taken in the form of cell viability (%) and average cell diameter 
(ACD) (um), which were assessed using a ViCell. All assessments were carried out 24 
hours after electroporation. 
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Figure 4.2. phCMV C-GFP Vector 
The vector contains a GPF ORF surrounded by the plasmid multiple cloning site 
(MCS). The GFP ORF is flanked by a CMV promoter and an SV40 polyA tail. Genes 
coding for Kanamycin and Neomycin (Kan/Neo) are included for bacterial and 
mammalian selection respectively. The Kan/Neo open reading frame is under the AmpP 
and SV40p promoters and followed by the HSV PolyA tail. pUC ori is included for 
bacterial replication. 
 
The factors tested were field strength, pulse length / time constant, DNA load (initial 
RSM only), waveform and pulse number (square wave only). Field strength is typically 
measured in V/cm, but will hereafter be referred to in terms of its voltage unless 
specifically stated (Equation 1.1. can be used to calculate actual field strength), because 
this is the measurement set on the electroporation device. Other electroporation 
variables described in section 1.3.6 were kept constant: The distance between electrodes 
was kept at 0.4 cm; The media and cell type were used in line with Pfizer standard 
protocols as described in chapter 2; DNA was suspended in TE buffer and consistently 
administered in 40 ul; All experiments were carried out at room temperature. 
 
This optimisation is directed towards application in stable cell generation processes and 
so the responses are analysed differently to how they would be for transient expression 
optimisation. Clearly, for both TGE and SGE a high transfection efficiency is desirable, 
but it is more crucial in a TGE setting that cell recovery is fast, because of the short 
window for production. Whereas, with SGE a fast recovery is less crucial, because 
inevitably only one cell is used as a source to generate a new cell line. Therefore a 
greater compromise on post-electroporation cell viability was accepted here, because it 
would mean more vector copies have the chance to integrate with the CHO genome. In 
this study a cell viability lower than 50% was used as a cut off for conditions that were 
deemed to be too harsh (Canatella and Prausnitz, 2001). 
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4.2.1. Cell Number Optimisation 
 
Cell number is another factor that affects sample resistance. A standard Pfizer 
electroporation protocol for generating stable cell lines involves the electroporation of 1 
x 107 cells, whereas other protocols and instruction manuals (Terefe et al., 2008, Lonza, 
2009, Bio-Rad, n.d.) describe processes using 1-2 x 106 cells. Clearly, this optimisation 
procedure needs to be catered towards bettering existing protocols for stable cell line 
generation in an industrial setting, but lower cell densities are more practical for 
enabling a high-throughput optimisation process. Therefore a preliminary experiment 
was carried out to test the effect of cell number, using Pfizer standard pulse settings, on 
transfection efficiency, median fluorescence and cell viability (Figure 4.3A, 4.3B and 
4.3C respectively). One-way ANOVAs followed by Tukey’s multicomparisons tests 
were used to call significant variation between means and pairwise variation between 
conditions respectively. ANOVAs showed significant variation between means for all 
three responses (p < 0.0001). There was no significant difference in transfection 
efficiency or median fluorescence when using 1 x 106 cells or 1 x 107 cells for 
electroporation. However, there was a small, but significant increase in viability when 
using 1 x 107 cells (74%) compared to 1 x 106 cells (69.5%) (p < 0.05). The cell number 
taken forward for subsequent experiments was 1 x 106 cells to enable a more high-
throughput approach with the caveat that cell viability would be a slight underestimate 
of standard conditions. When cell number was changed to 1 x 106 cells, but the cell-to-
DNA ratio was kept the same as Pfizer conditions by changing DNA load to 5 ug, 
transfection efficiency and median fluorescence were significantly (p < 0.05) lower (by 
46.7% and ~12.8-fold respectively) and cell viability was significantly (p < 0.05) higher 
(by 10.4%) than Pfizer standard conditions. This indicates that a consistent cell to DNA 
ratio is not necessarily an important factor to balance, but rather that DNA 
concentration in a given volume is more influential. Therefore, despite the 10-fold 
change to cell number compared to Pfizer standard conditions, the DNA load in 
optimisation would be held at standard levels (50 ug). 
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Figure 4.3. Cell Number Optimisation 
Cell number (1 x 106 or 1 x 107) and DNA load (5 ug or 50 ug) were varied and 
responses were measured for A) Transfection efficiency, B) Median Fluorescence and 
C) Cell Viability. * relates to the significant differences referred to the in the text. 
 
4.2.2. Sample volume Optimisation 
 
Sample volume is another factor effecting sample resistance. In standard Pfizer 
conditions 700 ul of sample is used for electroporation, whereas the Bio-Rad gene 
pulser Xcell standard conditions for mammalian cell electroporation uses 400 ul (Bio-
Rad, n.d.). A one-factor RSM experiment was carried out to determine the sample 
volume to be used in this study, in which the design space to be tested spanned between 
400-800 ul (factor A). The electroporation parameters set were in line with Pfizer 
standard conditions. The Design Expert software analysis interface guides the user 
through analysis. 
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 Response Model Summary 
Response Transform (l) 
Model 
Order 
Model 
Terms 
Lack of 
Fit (p) 
Adjusted
R2 
Predicted 
R2 
Adeq 
Precision 
Transfection 
Efficiency -- Cubic A
2 A3 0.7171 0.9458 0.8786 12.686 
Cell 
Viability -- Quadratic A A
2 0.5227 0.7749 0.5513 7.101 
Table 4.1: Sample Volume – Response Model Outputs 
The table contains the lambda value for data transformation, the order of the model, the 
significant terms of the model, the lack of fit p-value of the model, the adjusted R-
Squared, the predicted R-squared and the “Adec Precision”.  
 
 
 
Models were generated for the transfection efficiency and cell viability response to 
changes in sample volume:  
 
Transfection Efficiency = + 65.81 + 4.23*A – 5.91*A2 – 12.24A3  (Coded Factors) 
 
Cell Viability = + 82.33 + 2.51*A – 4.14*A2                                    (Coded Factors) 
 
 
The models were deemed to fit the data and describe an acceptable proportion of the 
response variance. Data residuals were normally distributed. The models and their 
response surfaces show (Figure 4.4 and 4.5) that an increase in sample volume results in 
very little change in transfection efficiency (approximately constant at 65%) until 
volumes exceed 650 ul, at which point transfection efficiency starts to decline. Cell 
viability increases with sample volume from 400 ul to 650 ul, at which point cell 
viability starts to decrease. Cubic and quadratic terms were the most influential for 
transfection efficiency and cell viability respectively. Transfection efficiency and cell 
viability were maximized with equal priority using the optimisation function, which 
recommended an optimal sample volume of 649.97 ul. Therefore, it was decided to 
proceed using 650 ul sample volume in future experiments. A summary of important 
model statistical outputs are shown in table 4.1 and further information is provided in 
tables A1-A4 and figures A1 and A2. 
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Figure 4.4. Sample Volume: Transfection Efficiency: 
The graph shows transfection efficiency change with sample volume. The black line 
represents the data trend, red dots represent the actual data points and the blue dotted 
lines represent the 95% confidence range for each point. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Sample volume: Cell Viability 
The graph shows the cell viability response to changing sample volume. The black line 
represents the data trend, red dots represent the actual data points and the blue dotted 
lines represent the 95% confidence range for each point. 
 
 
 
Due to the optimisation of cell number and sample volume and other factors influencing 
sample resistance being kept constant, we could assume that sample resistance was 
relatively consistent throughout the investigation. The approximate resistance for each 
sample was 30 ohms. 
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4.2.3. Electroporation Optimisation: Wide Parameters 
 
A review of Bio-Rad protocol optimisations (Terefe et al., 2008), other literature and 
Pfizer standard conditions (see section 2.5.) was carried out to determine the initial 
electroporation parameter ranges to be investigated with the idea of starting with wide 
ranges in order to completely characterise how these parameters effect the CHO cell 
response at their extreme levels. The aim was to discover areas of the design space that 
yield high transfection efficiencies and gene expression, whilst maintaining a high cell 
viability. Voltage, pulse length and DNA load are numerical factors, whereas waveform 
is a categorical factor. It was decided that experiments for exponential decay and square 
wave electroporation would be conducted side-by-side rather than integrated into the 
same CCD. 
 
4.2.3.1. Exponential Decay Wide 
 
A three-factor (Voltage, pulse length, DNA concentration), two level, rotatable CCD 
was set up with the Design Expert software, inputting the axial values instead of 
factorial values for practicality (keeping factors above 0). This generated a 20-run 
experiment including 8 factorial points, 6 center points and 6 axial points. The levels for 
each factor are laid out in Table 4.2. The four responses modeled were transfection 
efficiency, median fluorescence, cell viability and ACD. 
 
Table 4.2. Initial Exponential Decay Parameter Ranges 
The table shows the parameters and their unit ranges used in the experiment, including 
the factorial, center and axial (a) points. ‘+’ and ‘-‘ refer to upper and lower 
respectively. 
 
 The following models for the responses analysed had a significant lack of fit:  
• Transfection Efficiency – F value = 28.31, p = 0.0009. 
• Average Cell Diameter – F value = 19.79, p = 0.0026 
 
Factor Name Units -1 Factorial +1 Factorial Center - a + a 
A Field Strength V 89.05 320.95 205 10 400 
B Pulse Length ms 8.91 32.09 20.5 1 40 
C DNA Load ug/mL 41.34 159 100.5 1 200 
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This means that the model could not sufficiently describe the relationship between the 
experimental factors and the responses with any statistical significance. This is likely to 
be a result of the large range in experimental parameters investigated. In large design 
spaces such as this, different areas of the design space could have vastly different 
responses, causing the response variation to be large. With so few values within a large 
design space being experimentally tested this is problematic, because the experimental 
design does not have the resolution to model the response adequately. Moreover, only a 
small area of this large design space will be ‘useful’ for transfection, which means that 
responses will drastically change within this area. This means the variance is different 
for different areas of the design space. The center points of a CCD are used to infer the 
pure error of a model, but cannot do so adequately here because pure error will not be 
consistent (Figure 4.6.). However, these models report detection signals above a 
threshold that would be expected from noise alone (‘Adeq Precision’ statistic > 4), and 
still seem to explain some of the design space variance. Therefore, the models can still 
be used, with caution, to spot associations and indications as to how these factors 
impact responses. This was done through ANOVA “significance” values that were 
instead called as indicative or associative. Furthermore, the models were still used to 
derive a set of narrower parameter ranges for future experiments. A narrower parameter 
range, closer to the optimal range for transfection, is much more likely to be modeled 
effectively. This is because the center point-based estimation of pure error is more 
likely to be reflective of design space variance as a whole. Even though significantly 
fitted models were generated for median fluorescence and cell viability, it is still true 
that a large design space provides a low resolution analysis. It might be that these two 
responses are more straightforward in their relationship with the experimental factors, 
or that the experimentally tested values may have been positioned more optimally for 
these responses by chance. Due to the significant lack of fit and low resolution of these 
wide range CCDs, only general trends will be commented upon and model details, such 
as adjusted R-squared and predicted R-squared, will not be used in these analyses.  
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Figure 4.6. Variance Inconsistency in a Large Design Space 
The schematic illustrates the inconsistency in variance over the large design space, in 
which intense colour represents greater variance. The smaller cube illustrates the 
narrower design space designed using conclusions based upon the larger design space 
output. This smaller design space is more likely to be consistent in response variance. 
 
 
 
Although the accuracy is compromised by the large design space, as reflected by the 
lack of fit in two of the responses, there are still clear trends to be seen in the data from 
this CCD. Table 4.3 contains the transformation and model information for the four 
responses in this experiment. Transfection efficiency, median fluorescence and cell 
viability data were transformed according to the lambda values in table 4.3 and outliers 
were removed from the median fluorescence response according to advisory software 
diagnostics (Figure A5). The following models were generated: 
 
(Transfection Efficiency) 0.69 =  + 8.09 + 5.86*A + 2.48*B + 1.75*C + 2.01*AB + 
1.08*AC – 0.77*BC 
                     (Coded Factors) 
 
(Median Fluorescence)-0.02 = + 1.08 + 0.019*A + 7.690E-003*B + 5.688E-003*C + 
7.655E-003*AB + 4.596E-003*AC + 4.308E-004*BC + 3.904E-003*A2 – 2.695E-
003*B2 – 3.225E-003*C2 
         (Coded factors) 
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(Cell Viability) 2.86 =  + 4.379E+005 – 1.494E+005*A – 68511.94*B – 34325.26*C – 
76478.43*AB – 35674.56*AC + 23039.14*BC – 65982.96*A2 – 8770.35*B2 – 
5173.46*C2  
         (Coded Factors) 
 
Average Cell Diameter =  + 15.14 – 1.16*A – 0.55*B – 0.18*C – 0.86*AB – 0.22*AC 
+ 0.11*BC – 0.73*A2 – 0.065*B2 – 0.026*C2 
        (Coded factors) 
 
 
 Response Model Summary 
Response Transform (l) 
Model 
Order 
Model 
Terms 
Lack of 
Fit (p) 
Adjusted
R2 
Predicted 
R2 
Adeq 
Precision 
Transfection 
Efficiency 0.69 2FI A B C AB 0.0009 0.8605 0.6307 16.498 
Median 
Fluorescence -0.02 Quadratic 
A B C AB 
AC A2 B2 
C2 
0.0732 0.9885 0.9524 43.225 
Cell 
Viability 2.86 Quadratic 
A B C AB 
AC A2 0.1008 0.9685 0.8843 26.035 
ACD -- Quadratic A B AB A2 0.0026 0.8505 0.4142 12.103 
Table 4.3 Exponential Decay: Wide – Response Model Outputs 
The table contains the lambda value for data transformation, the order of the model, the 
significant terms of the model, the lack of fit p-value of the model, the adjusted R-
Squared, the predicted R-squared and the “Adec Precision”.  
 
 
Despite model inaccuracies, there are clear trends within the dataset. An increase in all 
independent variables leads to an increase in the gene expression responses and a 
decrease in cell health responses. Field strength appears to have the largest impact on 
the response, followed by pulse length and then DNA load. There appears to be 
interaction between field strength and pulse length and between field strength and DNA 
load. This design space yields transfection efficiencies between 1% and 80% and cell 
viabilities ranging from 1% to 100%. Gene expression appears to peak sharply at a 
specific point within the design space, with very little activity being detected below 
~260 V for a duration of ~17 ms. ACD ranges from 10 um to 16 um. Because these 
models are not completely informative response surfaces are only included in the 
appendix, along with fit summary statistics, the ANOVA statistics and normal 
distribution plots (Tables A5-A12 and Figures A3-A10). 
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The numerical optimisation function of the design expert software was used as a guide 
to generate a narrower set of electroporation parameters to be tested. In doing this 
criteria can be set for each factor and response and the model will provide predictions 
based upon these desired criteria inputs. DNA load was kept constant at 76.92 ug/ml (50 
ug – Pfizer conditions) and transfection efficiency and cell viability were both 
maximised with a minimum cut off of ~60%. The suggestion given was to use 
electroporation parameters of 309.09 V and 32.09 ms. To further analyse the cell 
response to a design space centering around these suggested conditions, cell viability 
was investigated in more detail. Voltages in a range of 260 – 400 V and pulse lengths of 
27 ms, 32 ms and 37 ms were tested and viability was measured 24 hours post-
electroporation (Figure 4.7). 
 
 
 
 
 
 
 
 
 
Figure 4.7. Exponential Decay: Cell Viability Optimisation 
Cell viability was assessed in response to incremental changes in voltage (260-400 V) at 
three different pulse lengths (27, 32 and 37 ms). 
 
So far this study has agreed with others of its kind in that transfection efficiency and 
cell viability have inverse responses electroporation. Therefore, it is logical to postulate 
that transfection efficiency and cell viability could have a direct inverse correlation, 
such that changes in either could predict the electroporation response of the other. For 
this reason it was decided that the parameter settings resulting in cell viability changes 
here could be used to guide new experimental parameter ranges for subsequent CCD 
designs. Taking the software optimisation and viability study into account, centering the 
next response surface model parameter around 310 V was deemed appropriate. The 
upper limit was set to 360 V, because this is where viabilities were below 50% at each 
pulse length in the viability study. Therefore the next CCD design ranged between 260-
360 V in its axial points, centering around 310 V. The initial indication from the 
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software optimisation function was to use a pulse length of ~32 ms. However, the 
viability plot shows that the viability around the 310 V center is lower (~55%) than 
model prediction at this pulse length. Therefore, the lower pulse length of 27 ms was 
used as the center point, spanning a range of 24-30 ms (axial points). 
 
4.2.3.2. Square Wave Wide 
 
Due to the issues encountered using a large design space, the wide square wave 
parameters were only analysed for transfection efficiency and cell viability to help 
derive a narrow parameter range for further analysis. Square wave electroporation offers 
the option to use more than one pulse and so this analysis will compare electroporation 
with one or two square wave pulses. All other factors had the same ranges as with the 
exponential decay analysis and were repeated for one and two pulses. Table 4.4 shows  
 the levels used for each factor. 
 
 
 
Table 4.4. Initial Square Wave Parameter Ranges 
The table states the parameters and their unit ranges used in the experiment, including 
the factorial, center and axial (a) points. ‘+’ and ‘-‘ refer to upper and lower 
respectively. 
 
 
Both the models for the transfection efficiency and cell viability responses had 
significant lack of fit: 
• Transfection Efficiency – F value = 36.5, p < 0.0001 
• Cell Viability – F value = 3.01, p = 0.0418 
Therefore, as explained in the previous section, statistical significance cannot be derived 
from these models, but instead just associative inference. 
 
Factor Name Units -1 Factorial +1 Factorial Center - a + a 
A Field Strength V 89.05 320.95 205 10 400 
B Pulse Length ms 8.91 32.09 20.5 1 40 
C DNA Load ug / mL 41.34 159 100.5 1 200 
D Pulses Numerical  One or two pulses used 
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 Response Model Summary 
Response Transform (l) 
Model 
Order 
Model 
Terms 
Lack of 
Fit (p) 
Adjusted
R2 
Predicted 
R2 
Adeq 
Precision 
Transfection 
Efficiency 0.19 Quadratic 
A C A2 B2 
C2 <0.0001 0.7350 0.4291 10.242 
Cell 
Viability 2.49 Quadratic 
A B C D, 
AB BC 
A2 
0.0418 0.9425 0.8795 25.974 
Table 4.5 Square Wave: Wide – Response Model Outputs 
The table contains the lambda value for data transformation, the order of the model, the 
significant terms of the model, the lack of fit p-value of the model, the adjusted R-
Squared, the predicted R-squared and the “Adec Precision”.  
 
 
Although the accuracy is compromised by the large design space, as reflected by the 
lack of fit in the two responses, there are still clear trends to be seen in the data from 
this CCD. Table 4.5 contains the transformation and model information for the two 
responses in this experiment. Transfection efficiency and cell viability data were 
transformed according to the lambda values in table 4.5 and outliers were removed from 
the cell viability response according to advisory software diagnostics (Figure A13). The 
following models were generated: 
 
 
(Transfection Efficiency) 0.19 = + 2.1 + 0.43*A + 0.086*B + 0.15*C + 0.036*D – 
0.075*AB + 0.039*AC +2.128E-003*AD + 0.019*BC – 0.011*BD + 5.846E-003*CD 
– 0.15*A2 – 0.16*B2 – 0.14*C2 
          (Coded Factors) 
 
 
(Cell Viability) 2.49 = + 67716.96 – 28638.97*A – 12326.14*B – 4854.42*C – 
3331.83*D – 13377.86*AB – 2575.12*AC – 641.53*AD + 3920.6*BC + 1199.41*BD 
– 895.35*CD – 8409.94*A2 + 1347.79*B2 – 691.88*C2 
          (Coded Factors) 
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As with the exponential decay CCD, transfection efficiency increases with an increase 
inthe electroporation parameters field strength, DNA load, and additionally, pulse 
number. However, transfection efficiency peaks around the midrange of pulse length 
delivery, which would indicate that the optimum pulse length was in the region of 20 
ms. Cell viability, again, decreases with an increase in all independent variables, which 
is the inverse response to transfection efficiency. Within this design space, modeled 
transfection efficiency ranged from ~10% to 120%, which illustrates the model lack of 
fit, because transfection efficiency cannot exceed 100%. However, one conclusion that 
could be made was that 80% of the tested points in the design space that yielded high 
transfection efficiencies were those in which 2 pulses were administered. Therefore, 
square wave protocols from this point onwards would be carried out with 2 pulses only. 
Cell viability ranged from ~10% to 100%. The independent variables appeared to have 
the following order of influence: Field strength > pulse length > DNA load > pulse 
number. Again, because of the lack of fit if these models, the response surfaces are only 
included in the appendix, along with the fit summary statistics, the ANOVA statistics 
and normal distribution plots (Tables A13-A16 and Figures A11-A14). 
 
The software optimisation function was used to guide the next set of experimental 
parameters. DNA was kept constant at 75.92 ug/mL (50ug). Transfection efficiency and 
cell viability were maximised with minimum threshold values of 60%. The software 
predicted that 302.98 V, 15.44 ms with two pulses were optimal conditions for the 
criteria given. As with exponential decay, a viability response study (Figure 4.8) was 
undertaken to probe further into these conditions. Two square wave pulses were used 
with field strength and pulse length ranging 260-400 V and 10-20 ms respectively. The 
response study was in agreement with the software in terms of voltage (~300 V for the 
center), but for pulse length 15 ms caused too much cell death, so an additional 
experimental run using 12.5 ms was used to determine a more optimal center. It was 
decided that a pulse length center point of 11.5 ms would be used with the prediction 
that its response would fall between the 10 ms and 12.5 ms responses. The axial ranges 
of field strength and pulse length were to be set at 271.7-328.3 V and 8-15 ms 
respectively. 
Chapter 4: Electroporation Optimisation Using DoE Methodology 
	 106	
 
 
 
 
 
 
 
 
Figure 4.8. Square Wave: Cell Viability Optimisation 
Cell viability was assessed in response to incremental changes in voltage (260-400 V) at 
four different pulse lengths (10, 12.5, 15 and 20 ms). 
 
4.2.4. Electroporation Optimisation: Narrow Parameters 
 
4.2.4.1. Exponential Decay Narrow - 1: 
 
A two-factor (field strength and pulse length), two-level, rotatable CCD was devised 
using the parameter ranges determined in the section 4.2.3.1. DNA load was kept 
constant at 50 ug. The factors and their ranges are laid out in Table 4.6 This generated a 
13-run experiment, measuring the four responses: transfection efficiency, median 
fluorescence, cell viability and ACD. The aim of this CCD was to provide insight into 
the electroporation parameters that yield optimal transfection responses. The hypothesis 
was that this parameter range would provide a higher resolution analysis around the 
dynamic range of optimal responses and that this set of models would better fit the data 
than with the previous wide range analysis. 
 
Factor Name Units -1 Factorial +1 Factorial Center - a + a 
A Field Strength V 274.6 345.4 310 260 360 
B Pulse Length ms 24.88 29.12 27 24 30 
Table 4.6. Exponential Decay: Narrow Parameter Ranges - 1 
The table states the parameters and their unit ranges used in the experiment, including 
the factorial, center and axial (a) points. ‘+’ and ‘-‘ refer to upper and lower 
respectively. 
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 Response Model Summary 
Response Transform (l) 
Model 
Order 
Model 
Terms 
Lack of 
Fit (p) 
Adjusted
R2 
Predicted 
R2 
Adeq 
Precision 
Transfection 
Efficiency 3 Quadratic 
A AB A2 
B2 0.4359 0.9536 0.8887 19.046 
Median 
Fluorescence 0.84 Quadratic AB A
2 B2 0.5121 0.9465 0.8717 15.38 
Cell 
Viability -- Quadratic A B A
2 0.2363 0.9681 0.9071 26.43 
ACD -- Linear A 0.8799 0.8724 0.8375 19.066 
Table 4.7 Exponential Decay Narrow – 1: Response Model Outputs 
The table contains the lambda value for data transformation, the order of the model, the 
significant terms of the model, the lack of fit p-value of the model, the adjusted R-
Squared, the predicted R-squared and the “Adec Precision”.  
 
 
Table 4.7 contains the transformation and model information for the two responses in 
this experiment. Transfection efficiency and median fluorescence data were transformed 
according to the lambda values in table 4.7 and outliers were removed from the median 
fluorescence response according to advisory software diagnostics (Figure A16). The 
following models were generated: 
 
(Transfection Efficiency) 3 = + 6.636E+005 -35018.98*A + 17119.18*B – 
53342.77*AB – 2.168E+005*A2 – 35059.3*B2 
          (Coded factors) 
 
(Median Fluorescence) 0.84 = +24951.96 – 1628.93*A + 66.79*B – 6115.63*AB – 
10220.63*A2 – 4262.72*B2     (Coded Factors) 
 
Cell Viability = + 63.29 – 24.19*A – 4.73*B – 1.72*AB – 8.23*A2 – 2.47*B2 
         (Coded Factors) 
 
Average Cell Diameter = +12.83 – 1.32*A + 0.055*B 
 
The statistics displayed in table 4.7, along with supplementary information in Tables 
A17-A24 and Figures A15-A18 , were used to assess the models. The models predicting 
the four responses are all deemed to significantly fit the data (lack of fit) and explain a 
large proportion of variance (R2) in the response. Statistically, the predictive capacity of 
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these models is deemed to be high (Predicted-R2), which validates the accuracy of the 
model and its usefulness in describing the response in the given design space. 
Transfection efficiency (Figure 4.9a) appears to increase with field strength up until ~ 
305 V, at which point it starts to decrease. Field strength and pulse length interact in 
their effect on transfection efficiency, which is can be seen by a positive correlation of 
pulse length with transfection efficiency at low voltages, but a negative correlation at 
high voltages. Transfection efficiency ranges from ~70% to ~85% in this CCD. The 
same result is seen in the median fluorescence response (Figure 4.9b), which shows a 
peak in expression around the middle of the design space (305 V, 27 ms). The cell 
health responses, cell viability and ACD are both negatively correlated with field 
strength and cell viability is also negatively correlated with pulse length (Figures 4.9c 
and 4.9d) and their predicted range is from ~20% to ~80% and ~11 um to -14 um 
respectively according to the response surface plots. This could perhaps be the reason 
for the change in response-factor associations in transfection efficiency and median 
fluorescence responses, such that with harsher electroporation conditions the health of 
the cell is diminished to the point that its capacity for protein production is lessened. 
Again, these models indicate that field strength has a larger impact than pulse length on 
the electroporation response. 
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Figure 4.9. Exponential Decay: Narrow 1 –Response Surfaces 
The response surface depicts the relationship between the transfection efficiency (A), 
median fluorescence (B), cell viability (C) and ACD (D) with both experimental factors; 
field strength and pulse length. 
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4.2.4.2. Square wave Narrow 
 
A two-factor (field strength and pulse length), two-level, rotatable CCD was devised 
using the parameter ranges determined in the previous section. DNA load was kept 
constant at 50 ug and pulse number was kept constant at 2. The factors and their ranges 
are laid out in Table 4.8 This generated a 13-run experiment, measuring the four 
responses: transfection efficiency, median fluorescence, cell viability and ACD. The 
aim of this CCD was to provide insight into the electroporation parameters that yield 
optimal transfection. The hypothesis was that this parameter range would provide a 
higher resolution analysis around the dynamic range of optimal responses and that this 
set of models would better fit the data than with the previous wide range analysis. 
 
 
 
Table 4.8. Square Wave: Narrow Parameter Ranges 
The table states the parameters and their unit ranges used in the experiment, including 
the factorial, center and axial (a) points. ‘+’ and ‘-‘ refer to upper and lower 
respectively. 
 
 
Table 4.9 contains the transformation and model information for the two responses in 
this experiment. Transfection efficiency and median fluorescence data were transformed 
according to the lambda values in table 4.9. The following models were generated: 
 
(Transfection Efficiency) -2.55 = + 64747.49 + 15441.15*A + 11525.43*B 
         (Coded Factors) 
 
(Median Fluorescence) 0.17 = + 6.78 + 0.78*A + 0.46*B – 0.051*AB – 0.16*A2 – 
0.15*B2 
         (Coded Factors) 
 
Cell Viability = + 77.93 – 12.03*A – 12.36*B – 7.36*AB – 4.5*A2 – 6.08*B2 
         (Coded Factors) 
Factor Name Units -1 Factorial +1 Factorial Center - a + a 
A Field Strength V 280 320 300 271.7 328.3 
B Pulse Length ms 11.5 9.03 11.5 8 15 
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(ACD) -3 = + 3.943E-004 + 6.706E-005*A + 1.061E-004*B + 8.037E-005*AB 
+2.971E-005*A2 + 1.424E-005*B2 
         (Coded Factors) 
 
 
 Response Model Summary 
Response Transform (l) 
Model 
Order 
Model 
Terms 
Lack of 
Fit (p) 
Adjusted
R2 
Predicted 
R2 
Adeq 
Precision 
Transfection 
Efficiency 2.55 Linear A B 0.2934 0.8484 0.7765 17.132 
Median 
Fluorescence 0.17 Quadratic A B A
2 B2 0.4934 0.9586 0.9062 23.426 
Cell 
Viability -- Quadratic 
A B AB 
A2 B2 0.1259 0.9565 0.8578 22.359 
ACD -3 Quadratic A B AB A2 0.3659 0.9678 0.9173 29.605 
Table 4.9. Square Wave Narrow: Response Model Outputs 
The table contains the lambda value for data transformation, the order of the model, the 
significant terms of the model, the lack of fit p-value of the model, the adjusted R-
Squared, the predicted R-squared and the “Adec Precision”.  
 
 
The statistics displayed in table 4.9, along with supplementary information in tables 
A25-A32 and figures A19-A22, were used to assess the models. The models predicting 
the four responses are all deemed to significantly fit the data (lack of fit) and explain a 
large proportion of variance (R2) in the response. Statistically, the predictive capacity of 
these models is deemed to be high (Predicted-R2), which validates the accuracy of the 
model and its usefulness in describing the response in the given design space. Increases 
in field strength and pulse length result in higher transfection efficiency and median 
fluorescence, but lower cell viabilities and ACD (Figure 4.10a-d). Predicted transfection 
efficiency,  ranged from ~65% to ~90%, cell viability ranged from ~30% to ~85%, and 
ACD ranged from ~11 um to ~15 um according to the response surface plots. Again 
field strength had larger impact upon the response than did pulse length and there was 
significant interaction between the two independent variables. 
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Figure 4.10. Square Wave: Narrow –Response Surfaces 
The response surface depicts the relationship between the transfection efficiency (A), 
median fluorescence (B), cell viability (C) and ACD (D) with both experimental factors; 
field strength and pulse length. 
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4.2.4.3. Optimisation - 1 
 
After using the optimisation function for the exponential decay narrow dataset, in which 
transfection efficiency and cell viability were maximised with minimum threshold 
values of 80% and 60% respectively, the suggested voltage for optimal responses was ~ 
300 V. Given this output it was decided to run another RSM model-based experiment 
for exponential decay electroporation using the same voltage range as the narrow square 
wave experiment, because it would allow for a better comparison between the two 
waveforms in terms of actual voltages and data range resolution. Therefore, as well as 
the above criteria for transfection efficiency and cell viability, using the optimisation 
function, voltage was set at 300 V for optimisation to generate a new center point for 
pulse length. The suggested pulse length was 26-27 ms, so it was decided to center the 
new experiment around 300 V and 26 ms. The factors and their ranges are laid out in 
table 4.10. 
 
 
4.2.4.4. Exponential Decay Narrow – 2 
Table 4.10. Exponential Decay: Narrow Parameter Ranges - 2 
The table states the parameters and their unit ranges used in the experiment, including 
the factorial, center and axial (a) points. ‘+’ and ‘-‘ refer to upper and lower 
respectively. 
 
 
Table 4.11 contains the transformation and model information for the two responses in 
this experiment. Transfection efficiency and median fluorescence data were transformed 
according to the lambda values in table 4.9. The following models were generated: 
 
(Transfection Efficiency) 3 = + 6.016E+005 + 1.590E+005*A + 63563.37*B + 
27385.12*AB – 30514.23*A2 – 19458.31*B2 
         (Coded Factors) 
 
Factor Name Units -1 Factorial +1 Factorial Center - a + a 
A Field Strength V 280 320 300 271.7 328.3 
B Pulse Length ms 24 28 26 23.17 28.83 
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(Median Fluorescence) 2.53 = + 2.637E+012 + 8.610E+011*A + 4.782E+011*B – 
4.477E+010*AB – 4.688E+011*A2 – 6.313E+011*B2 
         (Coded Factors) 
 
(Cell Viability) 1.5 = + 583.94 – 95.73*A – 81.07*B – 11.92*AB – 39.00*A2 + 3.29*B2 
         (Coded Factors) 
 
(ACD) 1.75 = + 102.08 – 8.15*A – 8.64*B – 2.89*AB – 5.29*A2 +0.13*B2 
         (Coded Factors) 
 
 
 Response Model Summary 
Response Transform (l) 
Model 
Order 
Model 
Terms 
Lack of 
Fit (p) 
Adjusted
R2 
Predicted 
R2 
Adeq 
Precision 
Transfection 
Efficiency 3 Quadratic A B A
2 0.1143 0.9665 0.8891 27.035 
Median 
Fluorescence 2.53 Quadratic A B A
2 B2 0.1931 0.8323 0.4902 9.598 
Cell 
Viability 1.5 Quadratic A B A
2 0.4198 0.9281 0.8248 17.748 
ACD 1.75 Quadratic A B A2 0.4027 0.8838 0.7120 14.608 
Table 4.11. Exponential Decay Narrow 2: Response Model Outputs 
The table contains the lambda value for data transformation, the order of the model, the 
significant terms of the model, the lack of fit p-value of the model, the adjusted R-
Squared, the predicted R-squared and the “Adec Precision”.  
 
 
The statistics displayed in table 4.11, along with supplementary information in tables 
A33-A40 and figures A23-A26 , were used to assess the models. The models predicting 
the four responses are all deemed to significantly fit the data (lack of fit) and explain a 
large proportion of variance (R2) in the response. Statistically, the predictive capacity of 
these models is deemed to be high (Predicted-R2), which validates the accuracy of the 
model and its usefulness in describing the response in the given design space. However, 
this was not true for median fluorescence, whereby the model had a diminished 
predicted R-squared (0.4902) compared to the other responses. Increases in field 
strength and pulse length result in higher transfection efficiency and median 
fluorescence, but lower cell viabilities and ACD (Figure 4.11a-d). Predicted transfection 
efficiency, ranged from ~70% to ~92%, cell viability ranged from ~55% to ~80%, and 
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ACD ranged from ~12 um to ~15 um according to the response surface plots. Again 
field strength had larger impact upon the response than did pulse length and there was 
significant interaction between the two independent variables. This lack of interaction 
could potentially be explained by the increase in the lower ends of the cell viability 
response. In previous CCDs, in which harsher conditions led to extreme lows in cell 
viability, the interaction between field strength and pulse length was more substantial. 
One explanation for this could be that low cell viabilities prohibit protein production 
and that the combination of high voltages and longer pulse lengths diminish cell 
viability to such an extent that the correlations between higher levels of electroporation 
and gene expression is reversed. 
 
 
 
 
Figure 4.11. Exponential Decay: Narrow 2 –Response Surfaces 
The response surface depicts the relationship between the transfection efficiency (A), 
median fluorescence (B), cell viability (C) and ACD (D) with both experimental factors; 
field strength and pulse length. 
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4.2.4.5. Optimisation – 2 
 
The design expert software optimisation function was used to determine the optimal 
electroporation conditions for exponential decay and square wave waveforms. 
Transfection efficiency was maximised, with a minimum threshold value of 80% and 
viability was targeted towards 65% with a minimum threshold value of 60%. For the 
exponential decay waveform the optimisation function suggested using 310.8 V and 
25.9 ms for field strength and pulse length respectively. The software predicted a 
transfection efficiency of 87.7% and cell viability of 65% using these conditions. For 
the square wave waveform the optimisation function suggested using 320 V and 11 ms 
for field strength and pulse length respectively. The software predicted a transfection 
efficiency of 82.8% and a cell viability of 65% using these conditions. A second set of 
criteria, in which cell viability was sacrificed for higher transfection efficiency, was 
then tested. Transfection efficiency was maximised with a minimum threshold value of 
90% and cell viability targeted towards 55% with a minimum threshold value of 50%. 
For the exponential decay waveform the software suggested using 317.8 V and 27.3 ms 
for field strength and pulse length respectively. A prediction of 91.6% transfection 
efficiency and 55% cell viability was given for these criteria. For the square wave 
waveform no solutions were offered when using these criteria. The highest achievable 
predicted transfection efficiency with this viability setting was 86%, when using 320 V 
and 12.73 ms for field strength and pulse length respectively. Therefore, it was 
concluded that the exponential decay waveform was better suited for this platform and 
would be taken forward for use in future experiments. 
 
4.2.5. Optimal Electroporation Conditions Testing 
 
Design of Experiments software allowed for a complete dissection of the 
electroporation response across a wide range of parameter settings and led to the 
elucidation of parameter settings, which were predicted to result in highly efficient 
transfection. However, model predictions are not sufficient and outputs need to be 
tested. The software optimisation function was used to predict transfection responses 
using two sets of criteria for exponential decay electroporation: 
1. > 80% transfection efficiency and 65% cell viability = ~310 V and ~26 ms. 
2. > 90% transfection efficiency and 55% cell viability = ~318 V and ~27.5 ms. 
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In order to test the model and decide upon optimal conditions to take forward a more 
traditional OFAT approach was used to investigate this small range of parameter 
settings. Field strengths of 310 V, 315 V and 320 V with pulse lengths of 25 ms, 26 ms, 
27 ms and 28 ms were tested. It was also important to experimentally test this range of 
settings, because the resolution of the electroporation device is such that it cannot 
precisely achieve input settings and exact conditions can vary from sample to sample. 
Therefore the predicted optimum settings may differ from the actual optimum settings. 
In terms of the fluorescence characteristics, transfection efficiency (Figure 4.12a) and 
median fluorescence (Figure 4.12b), there appears to be a general upward trend with 
increased electroporation strength, with the 320 V – 26 ms setting (hereafter referred to 
as 320-26) transfecting the most cells and having the highest gene expression. 
Fluorescence characteristics decrease with harsher settings than 320-26. A one-way 
ANOVA showed the differences among the means were statistically significant for both 
transfection efficiency and median fluorescence (both < 0.0001) and a Tukey’s multiple 
comparisons test showed that 320-26 was significantly superior to all other conditions 
(all p < 0.05). In terms of cell health measurements, cell viability and average cell 
diameter, there does not appear to be a significant trend in the results. A one-way 
ANOVA showed the differences among the means were statistically significant for both 
cell viability and ACD (both p < 0.0001), but a Tukey’s multiple comparisons test 
showed that there is no significant difference between the 320-26 and any other 
condition (all p > 0.05). Therefore, there is no cell health disadvantage to using these 
superior transfection conditions, which had an average transfection efficiency of 93.7% 
and average cell viability of 56.3%. Interestingly, cell viability only decreases by ~10% 
for mock transfection compared to the negative control, which means that DNA is the 
main contributor to low cell viability rather than electroporation intensity itself. 
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Figure 4.12. Electroporation Optimal Range OFAT 
The figure shows the electroporation responses in terms of A) Transfection Efficiency 
(Y-axis altered for clarity between bars), B) Median Fluorescence, C) Cell Viability, 
and D) Average Cell Diameter. The field strengths tested were 310 V, 315 V and 320 V. 
The pulse lengths tested were 25 ms, 26 ms, 27 ms and 28 ms. Mock transfections were 
run at the harshest condition (320 V, 28 ms). * relates to a significant difference of the 
320-26 condition. 
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320-26 was then compared to Pfizer conditions and to conditions used for transfection 
in the generation of stable cell lines, using 1 x 107 cells instead of 1 x 106 cells (referred 
to as ‘320-26 scaled-up’ conditions). Each response was analysed by an ANOVA 
followed by a Tukey’s multiple comparisons test (significant when p < 0.05). All 
responses had a significant difference between sample means (p < 0.0001 for 
transfection efficiency, cell viability and ACD, p = 0.0001 for median fluorescence). 
There was no significant difference in transfection efficiency (Figure 4.13a) between 
320-26 and 320-26 scaled-up conditions and both 320-26 conditions were significantly 
higher than Pfizer conditions (~75%) by ~17%. There was a significant decrease in 
median fluorescence (Figure 4.13b) between 320-26 and 320-26 scaled-up conditions 
(0.7-fold), but both were significantly higher than with Pfizer conditions (3.6-fold and 
2.5-fold respectively). Cell viability (Figure 4.13c) for 320-26 scaled-up conditions 
(75.8%) and Pfizer conditions (82.3) are both significantly higher than 320-26 (64%), 
but are not significantly different from one another, meaning the increase in transfection 
efficiency does not come at the cost of decreased cell viability compared to Pfizer 
conditions. ACD (Figure 4.13d) is significantly increased in 320-26 scaled-up 
conditions (14.4 um) compared to 320-26 (13.3 um) and significantly lower than with 
Pfizer conditions (15.1 um). Therefore, despite not having a significant difference in 
cell viability from Pfizer conditions, using scaled-up 320-26 does appear to have a 
significant physiological impact on the cell, which may indicate a slight decrease in cell 
health compared to Pfizer conditions. 
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Figure 4.13. 320-26 Scale-up and Pfizer Conditions Comparison 
This figure illustrates the differences in electroporation responses for 320-26 scale up to 
the stable cell line-generating cell number (1 x 107) and compares these optimised 
conditions to Pfizer conditions. The responses analysed are A) transfection efficiency, 
B) median fluorescence, C) cell viability, and D) ACD. Mock transfections were 
electroporated using 320-26. 
  
4.3. Discussion 
 
The aim of this chapter was to investigate an industrial cell line response to varying 
electroporation conditions in order to improve industrial standard electroporation 
conditions. Field strength, pulse length, waveform and initially DNA load and pulse 
number (square wave only) were the variable factors tested. The response was analysed 
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in the form of transfection efficiency (percentage of cells producing GFP), median 
fluorescence (intensity of GFP expression), cell viability (percentage of live cells), and 
ACD (a marker of physiological stress). The hypothesis was that DoE methodologies 
would provide a more complete analysis of electroporation and as a result would be 
more able to identify the optimal dynamic range of activity for the generation of optimal 
electroporation protocols. Firstly, the results will be discussed in terms of the success of 
using DoE methodologies for optimisation purposes and then, in terms of the effects of 
the experimental factors on the cell response. 
 
4.3.1. DoE in Process Optimisation 
 
The Design Expert 9.0.4 software package offers an easy to use interface for 
mathematical modeling of a predefined design space, in which a response is measured 
against all experimental factors simultaneously (Anderson and Whitcomb, 2005, 
Anderson, 2007). This study utilised CCDs whereby two levels for each factor were 
tested, which defines the limits of the design space. A central point is repeated multiple 
times in order to estimate the pure error of the output and provides information on 
response curvature. Axial points (values outside of the design space) are also tested to 
provide more information on the response within the design space, which provides 
factor-specific information on response curvature. The output provides information on 
factor interaction as well as individual factor effects in the form of a response surface 
that can be visualised in 3D and statistically validated. This utilises the information 
provided by experimental runs and the subsequent model to provide a prediction for 
individual responses throughout the whole design space. The software optimisation 
function can then be used to integrate the response models and suggest optimal 
parameter settings based on criteria of the users choosing (Anderson and Whitcomb, 
2005, Anderson, 2007). 
 
As was seen in this work with the initial wide parameter setting experiments, DoE 
methodologies are not completely accurate when faced with a large design space. This 
is likely to be due to two reasons. Firstly, a relatively small proportion of the design 
space showed high levels of activity in terms of transfection responses. A large design 
space means it is likely that this activity will not be described accurately, because 
experimentally tested values are too far apart to provide a high-resolution analysis. 
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Secondly, the center points are used to estimate the pure error of the whole design 
space. If there are pockets of the design space that show more activity than other areas, 
then pure error will not be consistent throughout and thus cannot be estimated 
accurately from testing only one point (Box and Draper, 1959). These traits of a large 
design space clearly had a large impact on the model lack of fit in this study. Despite 
the fact that such models were defined statistically as being ineffective predictive tools, 
the outputs were still able to sufficiently guide the next set of experiments in the form of 
narrow range CCDs. This guidance was tweaked via assistance from viability response 
experiments. It was found that the optimisation function suggested settings that were 
too strong, causing more cell death than the models had predicted, and so suggested 
pulse lengths were altered accordingly for subsequent narrow CCD experiments. The 
error estimation and resolution problems faced in the initial experiments were 
apparently minimised in these narrow range design spaces, such that all subsequent 
models were deemed to fit the data well, statistically. For square wave electroporation 
the wide CCD output and cell viability responses study generated narrow parameter 
ranges that seemed to describe the dynamic range of activity for electroporation with 
reasonable resolution. For exponential decay electroporation, two narrow range CCDs 
were needed. The CCD output from wide parameter settings and the cell viability 
response study provided slightly wider parameter settings than with square wave 
electroporation. Therefore, the initial attempt at a narrow parameter range was used as a 
guide to generate a second narrow range CCD, which had a similar resolution to the 
square wave experiment. Investigating each waveform using similar parameter range 
settings enabled better comparison between the two. Two sets of criteria, in which cell 
viability was sacrificed to varying degrees for increased transfection efficiency, were 
then used to generate a final set of parameter settings to be tested using a OFAT 
approach. These final settings were all capable of higher transfection efficiencies than 
with Pfizer standard conditions and one setting was identified as being significantly 
better than the others (320-26). 
 
Clearly, this study shows the benefits of using DoE-based modeling for process 
optimisation. It provides information on factor-response relationships in the form of 
relationship order and factor interaction and it does this with fewer experimental runs 
than would be needed with a OFAT approach. Moreover, the study delivered a new 
parameter setting, which was a significant (~17%) improvement on Pfizer industrial 
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standard settings, which arguably could not have been done using OFAT methodology, 
especially in this timeframe. However, as stated previously, this approach is not without 
its limitations. Pure error must be consistent throughout the design space and the sparse 
distribution of experimentally tested points in large design spaces could mean useful 
information is missed. Moreover, the strategy used in this study involved the generation 
of CCDs, in which ranges became progressively narrower. Whilst, this resulted in 
successful optimisation, a strategy in which all of this data could be included in a single 
model might be more informative. Furthermore, using an iterative model that could be 
built upon and fine tuned with further data might increase its predictive capacity and 
would mean the model could be more applicable to optimisation processes involving 
different components. This will be discussed further in section 4.3.3. 
 
4.3.2. The Electroporation Response 
 
Before starting the optimisation process it was important to ensure that all factors that 
could impact on electroporation responses were kept constant at appropriate levels. 
These were factors that could impact on sample resistance. For the most part conditions 
for these variables were ascertained from Bio-rad protocols (Bio-Rad, n.d.) and Pfizer 
standard conditions. However, these sources gave contradictory information on cell 
number and sample volume and so it was necessary for them to be optimised before 
proceeding. It was found that a ten-fold decrease cell density did not have a significant 
impact on electroporation responses besides causing a slight decrease in cell viability 
and so it was decided to proceed using 1 x 106 cells to enable more high-throughput 
experiments to be a carried out. This cell number was then tested with a ten-fold 
decrease in DNA load, causing transfection efficiency and cell viability to have a 
significant decrease and increase respectively. This shows that the cell-to-DNA ratio is 
not an important factor to keep constant for electroporation, but rather the concentration 
of DNA in a given sample volume. However, as stated in section 1.3.6, the cell 
membrane interacts with DNA and DNA then actively enters the cell by electrophoresis. 
Therefore, fewer cells provide less membrane surface for DNA to interact with and may 
result in a greater number of DNA molecules interacting with each cell. This is 
supported by figure 4.13B, in which median fluorescence is higher at a lower cell 
density. A greater number of DNA molecules per cell could lead to a greater number of 
integration events per cell, which would be advantageous in electroporation procedures 
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for the generation of high-producing stable cell lines. So perhaps the use of lower cell 
numbers would better suit the needs of industrial bioprocesses. It was also found that a 
lower sample volume decreased cell viability and did not affect transfection efficiency 
until sample volume exceeded ~ 700 ul, with slight peaks at ~ 400 ul and ~ 550 ul. So it 
was decided to proceed with a sample volume of 650 ul.  
 
The DoE results throughout generally agreed with the hypothesis that stronger 
electroporation conditions and higher DNA loads are positively correlated with 
transfection efficiency and high gene expression, but negatively correlated with cell 
viability and average cell diameter. As expected, for optimisation of electroporation, a 
tradeoff was needed between DNA entry to the cell and cell health (Andreason and 
Evans, 1989). Field strength and pulse length are the experimental factors that control 
the intensity of electric charge delivered to the sample and they do this in different 
ways. Field strength controls the membrane surface area that becomes permeabilised 
and pulse length and pulse number control the extent of permeabilisation within this 
area (Gehl, 2003, Escoffre et al., 2009). Clearly, both an increased permeabilised area 
and extent of permeabilisation will be influential in transfection. A combination of these 
two factors is needed to facilitate successful transfection of DNA. Both of these factors 
impact on the transfection response by altering the plasma membrane, which means 
they are linked. Therefore a balance needs to be found to ensure their additive effect is 
not too harsh. Indeed, this study confirmed their interaction through modeling. 
Generally, field strength had a larger effect on the responses than pulse length, meaning 
that the surface area of permeabilisation is more influential in transfection than 
permeabilisation intensity. However, permeabilisation intensity, or more specifically 
pore diameter, must reach a certain level to facilitate the transfection of DNA molecules 
of a particular size, so pulse length must remain high enough for transfection to occur. 
For these reasons field strength was considered a higher priority and pulse length was 
optimised around it. Transfection for the purposes of stable gene expression is less 
concerned with immediate cell viability, because the cell population is given time to 
recover. Subsequently, desirable cells are selected for clonal cell line generation. 
Perhaps with transient gene expression, in which cells are needed to be actively 
producing recombinant protein sooner, a higher priority would be given to pulse length 
and pulse number to ensure higher immediate cell viabilities. However, transient 
electroporation would be with circular DNA, which is not as difficult to transfect 
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(Schmidt et al., 2004), and so conditions are not required to be as strong to reach high 
transfection efficiencies.  
 
As expected, DNA load was positively correlated with gene expression and showed 
toxicity to CHO cells (Winterbourne et al., 1988). Moreover, it was shown to interact 
with field strength (area of cell permeabilisation), which supports the idea that reducing 
cell number may increase the number of DNA molecules entering the cell and, 
subsequently, integration events. However, it is difficult to draw firm conclusions for 
the effect of DNA load, because it was only investigated in a wide design space, in 
which models were not fit with significance. Analysis of the effect of pulse number on 
square wave electroporation showed no significant relationship with transfection 
efficiency. However, the response surface and individual data points indicated that two 
pulses led to cells having a higher transfection efficiency than with one pulse. Pulse 
number was negatively correlated with cell viability. Again, it is difficult to draw firm 
conclusions on pulse number from this study, because it was only investigated in the 
large design space.  
 
The final CCDs for exponential decay and square wave electroporation allowed for a 
direct comparison of the two waveforms through the use of models that significantly fit 
the data. Two criteria were used for optimisation: maximising transfection efficiency 
with a minimum threshold value of 80%, whilst targeting cell viability to 65% with a 
minimum threshold value of 60%, and; maximising transfection efficiency with a 
minimum threshold value of 90%, whilst targeting cell viability to 55% with a 
minimum threshold value of 50%. The results showed that exponential decay was the 
superior waveform in this study, predicting a peak transfection efficiency of 91.6% 
using 317.8 V and 27.3 ms. A narrow range of values derived from this final 
exponential decay CCD were experimentally tested to ascertain which electroporation 
parameter setting was optimal. All of these parameter settings achieved transfection 
efficiencies > 84%. The 320-26 condition achieved 93.7% transfection efficiency, only 
2.1% higher than model prediction, which indicates that model prediction was accurate. 
Median fluorescence was also significantly higher than other parameter settings when 
using this condition. There appeared to be no significant differences in cell health 
responses when testing these settings, which indicates that there is no health 
disadvantage in using this condition. When the 320-26 parameter settings were applied 
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to 1 x 107 cells (as used in stable transfection), there was no significant change in 
transfection efficiency and cell health characteristics were marginally improved. The 
optimised conditions were superior to Pfizer conditions. 
 
This study agrees with the literature in terms of the inverse correlation between 
transfection efficiency and cell viability (Andreason and Evans, 1989). It was shown 
that the transfection response shows a dramatic increase in activity when experimental 
factors reached a certain threshold level. These thresholds were approximately the same 
for both transfection efficiency and cell viability (260 V, 17 ms for exponential decay 
electroporation). Therefore, it could be likely that transfection efficiency and cell 
viability are extremely linked and that their inverse relationship could be used as a 
predictive tool. This was the case in the first round of optimisations, whereby a cell 
viability response study helped provide a set of electroporation parameters for the next 
set of experiments. The resulting design spaces covered the dynamic range of optimal 
transfection efficiency well. Therefore, in this case, cell viability was an accurate 
predictor of optimal transfection efficiency. If the relationship between transfection 
efficiency and cell viability were to be more thoroughly defined then cell viability may 
be able to be used as a predictor of transfection efficiency in the optimisation of 
electroporation for new expression systems. This would be advantageous, because it 
would greatly reduce the workload in an electroporation optimisation procedure by 
minimising the need for protein expression assays. If electroporation optimisation 
procedures were to be implemented into the development of new biopharmaceuticals it 
would increase the number of plasmid copies entering the host cell. In the case of stable 
cell line generation this is advantageous, because it could increase the number of 
integration events and subsequently the number of high producing clones detected in 
screening. Therefore, optimised electroporation might lead to integration of more 
plasmid copies in to desirable genomic locations. In the case of transient gene 
expression, conditions could be discovered that may increase gene expression without 
having a diminishing effect on cell viability. 
  
4.3.3. Future Work 
 
This study provides evidence that industrial standard conditions for electroporation can 
be vastly improved by using modeling approaches. Moreover, these approaches allow 
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for a more global explanation as to how electroporation factors interact in their impact 
on the cell response. However, the optimised conditions derived here are likely to be 
unique to this system. So for these optimisation strategies to find commercial 
application, the conclusions found here need to be consistent across all potential 
permutations of the bioprocesses. For example, a change in vector size would impact on 
plasmid DNA entry into the cell via electrophoresis. Larger vectors may need stronger 
electroporation conditions to enter the cell, which may come at the cost of decreased 
cell viability. Also, different vector designs will be capable of variable levels of gene 
expression, which would impact upon transfection efficiency and the level of gene 
expression per cell. The recombinant product will also impact on the optimisation 
process. Some products will be more of a metabolic burden than others, which will 
impact on cell viability and growth. Whereas, other proteins are more difficult to 
express, which will impact on gene expression capabilities of a given system. In 
addition, different cell lines are likely to have different reactions to electroporation, in 
terms of gene expression and health characteristics and so may need to be uniquely 
optimised. 
 
For further investigation of electroporation parameter settings, analyses similar to those 
carried out in this study should be conducted, but with more experimentally tested 
points to provide a higher resolution analysis. Indeed, higher levels of experimental 
repetition and an increase in the number of experimentally tested points would increase 
experimental accuracy and the estimation of systematic error. In particular, square wave 
electroporation and DNA load in this study were not tested fully and a more detailed 
study may reveal that altering their input values would have a positive impact on 
transfection. Indeed, it could be the case that different bioprocess conditions (as 
mentioned above) might be more suited to electroporation settings that are different to 
what would be predicted by this study.  
 
As mentioned in section 4.2.1, the DoE methodology used with the design expert 
software may not be the most efficient and informative modeling method to do this, 
because a model which cannot be integrated or built upon is limited. Moreover, as 
described in section 4.1.2 and shown in these results, the factors influencing transfection 
are interactive and so a single model that fully integrates all variable aspects of 
electroporation and bioprocess variations would be more informative and have a higher 
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accuracy in predicting optimal parameters across the complete range of bioprocess 
needs. By utilising a modeling strategy that is open ended, the predicted response across 
the entire design space could be experimentally tested and the results fed back into the 
model to improve it. This data-rich and iterative process would lead to a more accurate, 
experimentally tested and predictive model. This is something the design expert 
software is unable to do. 
 
All of these variations would paint a detailed picture as to how each factor in a new 
biopharmaceutical system might affect the electroporation response. When a new 
product is being developed a new combination of cell line, vector and product type will 
need to be tested. The model would use this information to provide predicted optimal 
electroporation conditions and responses to them. Then an experimental test, centered 
around this prediction, would be carried out to ascertain the actual optimal set of 
electroporation parameters. Each new product that was tested would provide more data 
for the model to improve is accuracy. Eventually, a database of information could be 
generated, containing electroporation responses to all previous permutations of the 
bioprocess, which could serve as a useful repository for future optimisations. 
 
A fully integrative model such as this would provide a complete analysis into how 
bioprocess factors and electroporation parameters interact, providing useful insight into 
their relationships. Arguably, the most useful definition generated by the model could 
be the relationship between transfection efficiency and cell viability. If this relationship 
were to be accurately defined then only cell viability may need to be measured in an 
optimisation process. An end product for this modeling system could be in the form of 
an electroporation 96-well plate, in which cells are tested with new vectors and products 
against many electroporation conditions for a high resolution assessment. The viability 
response to these conditions could then be used to predict the relative gene expression 
response and provide optimal parameter settings.  
 
As mentioned at the start of the chapter, the primary purpose of this chapter was to 
optimise an in-house electroporation protocol in order to generate a stable GFP CHO 
cell pool and so the immediate future work to be carried out is to generate these stable 
pools and carry out mutational analysis on recombinant plasmid DNA. 	
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Chapter 5 
 
Plasmid DNA Mutation Analysis 
 
5.1. Introduction 
 
5.1.1 Chapter Summary 
 
This chapter takes a different approach to investigating the genetic instability 
phenomenon described in CHO cells. In chapter 3, two whole-genome methods were 
used to analyse CHO cell genomic instability at the base pair, gene copy and 
chromosomal level. The work carried out was not able to validate microsatellite analysis 
as a potential marker for instability detection at the base pair level. Even though further 
work with microsatellites might have yielded more informative results it was decided to 
use DNA sequencing as a tool to measure base pair change directly. Despite the 
importance of CHO cell whole-genome stability this chapter focuses on the fidelity of 
recombinant DNA specifically and the potential threat of sequence variants to product 
quality, as well as providing a commentary on base pair change as a whole. 
 
As will be described in detail in the next section sequence variants, resulting from non-
synonymous DNA mutations are a threat to product quality and, in some cases, are 
estimated to be present in approximately a quarter of protein-producing clones. The aim 
of this chapter was to develop a secondary analysis tool for PacBio SMRT sequencing, 
which would enable a higher sensitivity in mutation calling compared to the sensitivity 
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being reported in the literature. This DNA sequencing platform would then be used to 
sequence plasmid DNA at various points in the process for generating stable GFP pools, 
which previously has only been carried out on clonal or nearly clonal cell populations. 
This would enable a more comprehensive characterization and of the frequency, type 
and biases of the mutation that is seen in recombinant DNA. 
 
Development of the secondary analysis platform for SMRT sequencing allowed 
mutations to be called from single DNA molecules at coverages reaching 10,000X, 
meaning that mutation detection was carried out to a 0.01% level. Apart from one 
mutation originating from the manufacturer, no or very little mutation was detected in 
plasmid stocks or DNA that had been transfected into CHO cells, but not integrated into 
the genome. A high level of low frequency mutation was detected in recombinant DNA, 
such that approximately a quarter of all plasmid copies contained at least one mutation. 
The mutations detected were predominantly in C and G base pairs (85%), but there were 
no positional biases, with an even distribution of mutation being detected across the 
length of the plasmid. Mutation was deemed to be unaffected by natural selecetion.  
 
5.1.2. Sequence Variants 
 
This study is focused on sequence variants as a product quality attribute and their 
identification in heterogeneous cell lines, in which sequence variants are likely to be 
present at low frequencies. Many studies have identified sequence variants in 
recombinant products through peptide mapping, mass spectrometry, capillary isoelectric 
focusing and other protein analytical techniques. These variants have been shown to 
derive from DNA level mutations (Harris et al., 1993, Ren et al., 2011, Zhang et al., 
2015) and amino acid misincorporation during protein synthesis (Wen et al., 2009, Yu 
et al., 2009). Mostly, these sequence variants have been identified through first 
establishing the mutation at the protein level, which can then be used to target the 
culpable DNA mutation at the corresponding locus. Cell line Transcripts are routinely 
reverse-transcribed to cDNAs for sanger sequencing analysis, but this is a relatively low 
resolution sequencing technology and is not likely to detect low level sequence variants 
(Zhang et al., 2015). Next-generation sequencing (NGS) has been used to identify 
sequence variants at the DNA level, but again these studies were targeted towards 
regions corresponding protein sequences that are known to be polymorphic (Zeck et al., 
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2012, Victoria et al., 2010). To our knowledge, Zhang et al. (2015) carried out the first 
NGS-based analysis for novel sequence variant identification in recombinant protein-
producing CHO cells. Using RNA-seq this group were able to successfully identify low 
level sequence variants, some of which were confirmed as being generated during long 
term cell culture. More than 25% of cell lines were shown to carry sequence variants. 
Vector stock sequencing, also using NGS (usually carried out by low resolution sanger 
sequencing), confirmed that these mutations did not originate from plasmid stocks. 
Zhang et al. (2015) were able to establish that at least one of the detected mutations was 
derived from a replication error during long-term cell culture. This means that the 
mutation event occurred after plasmid integration into the CHO genome. This supports 
the ideas discussed in chapter 3 regarding CHO cells having a mutator phenotype, 
which was shown here to extend to changes at the base pair level. Indeed, it has been 
shown previously that CHO cells are extremely prone to mutation at the base pair level. 
In one study it was shown that over 300,000 new SNPs were detected in the generation 
of the C0101 mAb-producing cell line from its CHO-S parent (Lewis et al., 2013).  The 
Zhang et al. (2015) study was unable to determine whether some of the observed 
sequence variants derived from changes before genome integration. Various studies 
have shown that plasmid DNA sequences being transfected into mammalian cells 
undergo variety of changes such as deletions, insertions and point mutations prior to 
genome integration. This has been observed in monkey, mouse and human cells (Hauser 
et al., 1987, Lebkowski et al., 1984). Studies have indicated that the cause of this 
plasmid DNA instability results from damaging agents both in the cytosol (Lechardeur 
et al., 1999) and in the nucleus (Lebkowski et al., 1984). It is noteworthy that point 
mutations predominantly occur at G:C base pairs, which could indicate towards their 
source of origin (Miller et al., 1984, Hauser et al., 1987). To our knowledge there have 
been no studies to investigate the potential mutation of transfected DNA before genome 
integration. 
 
5.1.3. Single Molecule Sequencing 
 
This study uses PacBio RS II Single-Molecule Real-Time (SMRT) sequencing to 
further study sequence variants in recombinant CHO cells at the DNA level. This 
technology utilises zero-mode waveguides (ZMWs), which are nanoholes 70 nm in 
diameter (McCarthy, 2010, Levene et al., 2003). The small size prohibits light waves 
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from traversing the ZMW, which leads to only the bottom of the ZMW (20-30 nm) 
being illuminated. A DNA polymerase molecule is fixed to the bottom of the ZMW and 
a single DNA molecule is used as a sequencing template (McCarthy, 2010, Gupta, 
2008, Levene et al., 2003). Nucleotides labeled with different fluorophores are 
incorporated into the synthesised DNA strand which, because incorporation occurs at 
the bottom of the ZMW, is detected by laser illumination. The incorporated nucleotide 
is bound for the time (milliseconds) it takes to create a phosphodiester bond, which is a 
greater amount of time than other, non-bound, nucleotides might diffuse in and out of 
the detection volume (microseconds). This enables the distinct detection of the 
incorporated nucleotide (Gupta, 2008, McCarthy, 2010). The fluorophores are attached 
to the DNA phosphate group as opposed to the base, which is the point of attachment 
for most sequencing technologies. This means that before the next base can be 
incorporated, the fluorophore must be cleaved. Therefore, an efficient system is 
achieved, whereby bases are detected quickly one at a time, allowing for a more 
definitive distinction between bases.  
 
There are tens of thousands of ZMWs per sequencing reaction, allowing for a high 
coverage and single molecule analysis (Gupta, 2008). The PacBio SMRT technology is 
such that a consensus sequence can be called from a single ZMW, which means that a 
consensus sequence is generated from a single DNA molecule. This is made possible by 
circular consensus sequencing (CCS) of a SMRTbell template (Figure 5.1a) (Roberts et 
al., 2013, Travers et al., 2010). The SMRTbell template consists of the linear, double 
stranded target sequence (insert template), which is ligated to looped, single stranded 
hairpin adapters at both ends. Sequencing primers hybridise with the adapter sequence 
and a strand-displacing polymerase facilitates the sequencing of the SMRTbell 
template, whereby the template is sequenced as a single-stranded circle until the 
polymerase detaches naturally (Figure 5.1b) (Travers et al., 2010). The current P6-C4 
chemistry allows a polymerase to sequence for an average of 10-15 kb (so-called read 
length) before strand displacement with some reactions reaching ~ 60 kb, which means 
multiple rounds of this circular sequence can be completed (Rhoads and Au, 2015). The 
resulting sequencing read (Figure 5.1c) is comprised of sense and antisense strand 
sequences, interspersed with adapter sequences. Both sense and antisense sequences are 
then used as individual sequence subreads to generate a consensus sequence (Figure 
5.1d). The utilisation of both sense and antisense information helps eliminate sequence 
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context-based sequencing errors. The number of passes of a given template molecule is 
defined as the number of subreads used to generate the consensus sequence, which is 
determined by template length and read length (Travers et al., 2010). A single pass of 
the SMRT template has a high median error rate of ~11%, but the level of error is 
significantly lowered with each pass (Korlach, 2013, Travers et al., 2010).  
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Figure 5.1. Circular Consensus Sequencing 
The figure illustrates the SMRTbell template (a) and how, by the use of a strand-
displacing DNA polymerase (grey) and a primer (green) complementary to the hairpin 
adapter (red), it is sequenced in a circular fashion as a single-stranded molecule. The 
resulting sequence is comprised of alternating sense (blue) and antisense (orange) 
sequences, interspersed with hairpin adapter sequences (c). A consensus sequence (d) 
(yellow) is generated from these subreads. 
A 
B 
C 
D 
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SMRT sequencing does not require PCR, the technology has been shown not to have 
sequence bias, and there is no signal degradation over time, which means lower error 
rates are achieved and that any errors are randomly distributed along the template 
sequence. This means that CCS can successfully overcome the single pass error rate of 
~11%. Circular consensus accuracy increases with pass number, but this relationship 
starts to reach a plateau around 5 or 6 passes where accuracy starts to level off towards 
QV40 (Phred-type quality value) (99.99%) (Travers et al., 2010).  > 99.999% (> Quality 
Value 60 – QV60) accuracy can be achieved with this technology (Travers et al., 2010, 
Korlach, 2013, Roberts et al., 2013). The top level of accuracy is achieved by forming a 
final consensus sequence from a combination of the CCS consensus outputs. However, 
in order to analyse the sequence output from individual molecules, this study did not 
combine ROIs, so that low-level variants could be detected beyond the 1% frequency 
detection limit reported by Pacific Bioscience (CA, USA) (Dilernia et al., 2015).  
 
5.1.4. Chapter Aims 
• Develop a high resolution SMRT sequencing analysis platform for point 
mutations. 
o Build consensus sequences from individual DNA molecules by using 
only high template pass numbers. 
o Eliminate sequencing and other error to ensure maximum accuracy 
• Investigate the assumption that plasmid stock DNA does not contain sequence 
variants. 
• Determine the extent of mutation in transfected / non-integrated plasmid DNA, 
to establish whether the CHO cell cytoplasmic or nuclear environment is 
mutagenic to plasmid DNA. 
• Assess and characterise the extent and type of mutations that occur in 
recombinant plasmid DNA during the generation and long term cell culture of a 
GFP stable CHO cell line, including: 
o Mutation frequency. 
o Mutation Distribution across the plasmid in terms of nucleotide position 
and potential biases towards coding and non-coding sequences. 
o The type of nucleotide changes. 
o Assessing the level of synonymous and non-synonymous mutations. 
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5.2 Results 
 
This study investigated three potential sources of point mutation: Plasmid DNA stocks, 
the pre-integration cellular environment and the genomic environment (Samples: Low 
and High generation). The phCMV C-GFP plasmid (Genlantis) was used again here to 
assess this genetic instability. Figure 5.2. depicts the process by which stably producing 
CHO cells are generated and highlights (red arrows) the time points within this process 
that DNA samples were taken for SMRT sequencing analysis. The plasmid stock 
analysis aimed to reveal any errors that were present from initial synthesis of the 
plasmid and errors that may have been introduced during cloning in E. coli DH5α cells. 
The general assumption (Zhang et al., 2015) is that plasmid stocks do not carry point 
mutations, so as well as verifying this assumption, this sample will likely serve as a 
negative control for mutation to give an estimate of error levels in this novel analysis 
platform. The investigation into point mutations in DNA prior to integration will reveal 
whether the cytosolic, nuclear or electroporation environment is mutagenic. Any 
mutations present here are likely to be extremely rare, because plasmid DNA is not 
replicated in this environment, as opposed to the other samples, in which DNA had been 
replicated by E. coli or mammalian cell genomic replication. Therefore it was necessary 
to use a method of DNA extraction without the use of PCR, because PCR-based errors 
could present as a false positive for point mutation. Finally, the two genomic samples 
taken at two time points over long-term cell culture aimed to reveal whether the fidelity 
and in vivo error rates of the CHO polymerase and mismatch repair system are 
responsible for introducing point mutations over long-term cell culture. Samples were 
sequenced by GATC biotech (Konstanz, Germany). 
 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Stable Pool Generation 
The illustration shows the process by which stable CHO cells are generated. Firstly, linearised plasmid DNA is transfected into cells. Some of 
this plasmid DNA will be present in the nucleus and an extremely small proportion of plasmid molecules will integrate into the host genome. 
Cells will then be treated with a selection agent to enrich the cell population for cells containing integrated plasmid DNA. This results in the 
generation of a pool of stably producing cells. The red arrows highlight the time points at which DNA samples were taken for SMRT sequencing 
analysis. The two arrows pointing towards the stable pool of cells represent the two cell culture time points that samples were taken. Each arrow 
is labeled with the sample name. 
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5.2.1. Sequencing Analysis Platform Workflow  
 
Figure 5.3 shows the workflow and decision making process for this analysis platform 
and is described in detail in the text below. 
 
 
Figure 5.3: Sequencing Analysis Platform Workflow 
In primary analysis, subreads are used to generate ROIs from single DNA molecules 
and filtered by length, at multiple pass numbers and predicted accuracy. ROIs are then 
aligned to the reference sequence with 95% minimum identity. Error removal is carried 
out assessing the effect of increased pass number, error-prone ROI removal, Phred (Q) 
score, and then positional and base pair biases are removed by only counting mutations 
occurring in more than one ROI. Nucleotide differences compared to the reference 
sequence, which pass these filtering criteria are then called as variants. 
 
 
Primary analysis was carried out by Philip Lobb (Pacific Biosciences, CA, USA). This 
involves the generation of consensus sequences from each ZMW, whereby a so-called 
read of insert (ROI) is generated from the total number of subreads from each well. 
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ROIs that were < 800 bp in length or had a predicted accuracy < 90% were eliminated 
from analysis in order to reduce the abundance of error-prone ROIs. This dataset was 
then provided to us after 0, 5, 10, 15 and 20 – pass filter permutations in FASTA and 
FASTQ formats, so that an in-house assessment of pass number error reduction could 
be conducted. Other important statistics generated at this stage include average ROI 
length, read qualities and average number of passes. 
 
Each dataset was aligned to the reference plasmid sequence using the BLASR sequence 
alignment tool. A ROI was only aligned when it showed a minimum of 95% identity to 
the reference sequence to allow for further error-prone ROI elimination. The BLASR 
output for subsequent sequence processing was in the human readable format, whereas 
the output for the processing of ASCII (American Standard Code for Information 
Interchange) characters relating to a quality score for each given base was in the SAM 
(Sequence Alignment/Map) format. Processing of the aligned sequences and subsequent 
analysis was carried out in R.  
 
SMRT sequencing errors are predominantly indel miscalls (Carneiro et al., 2012), so 
this platform would be likely to show inaccuracies when calling insertions or deletions. 
Therefore, only point mutations were to be assessed. Each ROI was then aligned against 
the reference to enable a total coverage count, mutation count and mutation type to be 
scored at each plasmid position. Upon visual inspection of ROIs containing multiple 
mutations it was found that these mutations were located in small regions of these ROIs, 
which also contained multiple insertions and deletions (Figure A25). These error-prone 
regions were deemed to more likely be a result of individual ZMW error, rather than 
genuine mutation. Therefore, ROIs containing >3 mismatches were removed from 
subsequent analyses. A pass number error filtering step was imposed at this point and is 
explained in section 5.2.2. The ASCII characters were converted to Phred quality (Q) 
scores (Equation 5.1). 
 !ℎ#$%	'()*+,-	./0#$ = 2.344	563	07$#),+89	:-:,$;	8(;<$# − 33	  Equation 5.1 
 
Nucleotides with Phred score of < Q25 (99.7% accuracy) (Fichot and Norman, 2013) 
were eliminated from further analysis to ensure high accuracy in base calling (Q score 
filter). The mutations called here were used to comment upon mutation frequency. 
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However, a further filter that eliminated mutations only present in one ROI (“>1” filter) 
was imposed to comment upon base pair and positional baises of the mutations 
detected, to ensure that errors unque to one ZMW were eliminated.  
 
The data will be presented here in terms of estimations of error, mutation frequency, 
nucleotide change type, plasmid position, sequence bias, and mutational impact on 
protein sequences. The coding for this platform can be found in figure A26. 
  
5.2.2. Estimation of Removed Error 
 
As described previously, SMRT sequencing allows for a consensus sequence to be 
derived from multiple passes of a single DNA molecule. The accuracy of this consensus 
sequence increases with the number of passes used to derive it. However, this effect of 
increased accuracy reaches a plateau after a certain number of passes and so there is a 
tradeoff between increasing accuracy by using a high pass number, and the loss of 
useful data caused by the pass number filter being too strict. This plateau threshold has 
previously been reported at 5 or 6 passes (Travers et al., 2010).  However, because this 
study is not building a consensus between different molecules, a greater importance was 
imposed upon single molecule accuracy. Therefore an analysis of error elimination 
through pass number filtering was carried out in order to determine which pass number 
dataset to use for this analysis (Figure 5.4). Datasets for all 5-pass filters were analysed 
using the secondary analysis platform outlined in the previous section. As stated 
previously, it was assumed that the plasmid stock sample would not contain large 
amounts of mutation, which was confirmed by this analysis. Therefore, it was used as a 
mutation negative control / representation of error to determine the number of passes to 
proceed with in this data analysis. There is a clear decrease in the number of observed 
mutations with increasing pass number. This decline is steep until 10 passes, at which 
point the trend starts to plateau. The sharp change in the gradient of decline indicates 
that this is the point at which the phenomenon of sequencing error elimination by 
increased pass number stops. The more gradual decline seen between 10 and 20 passes  
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Figure 5.4. Pass Number Effect 
The figure shows the number of mutated plasmid positions (out of 4966 bp of the total 
plasmid) that were shown to have at least one mutation across all ROIs for 0, 5, 10, 15 
and 20 passes. 
 
 
 
was assumed to be due to the loss of mutation calls from a decreasing number of ROIs 
that meet the filter criteria (i.e. decline in coverage). The average number of passes for 
this sample was 17.8. Therefore, it is extremely unlikely that the sharp change in 
gradient was due to an abrupt change in sequence coverage. It was decided to proceed 
with the 10 – pass filter for subsequent analysis, because this is the pass number that 
seemed to meet the accuracy – coverage loss tradeoff described above. This pass 
number analysis clearly shows the large amount of error from SMRT sequencing that 
needs to be filtered out by imposing a pass filter. 
 
Removal of further error was facilitated by the Q score and > 1 filters. Figure 5.5 shows 
the number of mutated plasmid positions (normalised by average sample coverage) that 
were called as mutated for the three differently filtered datasets, for all four samples. 
Both filters greatly reduce the number of mutations being called for each sample. These 
filters, especially the >1 filter, are strict and it is likely that genuine mutations will not 
be called as a result. However, this is a necessary precaution to ensure that any trends 
that are found in these data are as genuine and error-free as possible. There is clearly 
more mutation in plasmid DNA that has been integrated into the CHO genome when 
0 5 10 15 20
0
200
400
600
800
Passes
M
ut
at
ed
 P
la
sm
id
 P
os
iti
on
s
Chapter 5: Plasmid DNA Mutation Analysis 
	 142	
compared to the plasmid stock and transfected / non-integrated samples. This will be 
discussed later in the chapter. 
Figure 5.5. Error Filters 
The figure shows the reduction in normalised mutated plasmid positions for the plasmid 
stock, transfected / non-integrated, Low genomic and High genomic samples using a 10 
– pass filter after the imposition of the Q score and >1 filters. 
 
 
 
 
 
Two other filters used to reduce potential error were the 95% minimum percentage 
identity in the BLASR alignment and the elimination of ROIs that contained more than 
3 mismatches. These did not have a large impact on the results. The percentage identity 
filter reduced ROIs from 29775 to 29540, from 15196 to 15063, from 43191 to 41965, 
and from 41902 to 40968 in the plasmid stock, transfected / non-integrated, Low 
genomic and High genomic samples respectively. The >3 mismatch filter reduced ROIs 
from 29540 to 29533, from 15063 to 15060, from 41965 to 41910, and from 40968 to 
40924 in the plasmid stock, transfected / non-integrated, Low genomic and High 
genomic samples respectively.  
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5.2.3. Mutation Analysis of Linearised Plasmid DNA Stocks 
 
The phCMV C-GFP plasmid vector (Genlantis) was amplified using Library Efficiency 
DH5α E. coli cells, purified using a GigaPrep kit (QIAGEN) and linearised using 
restriction enzyme AflII, as described in chapter 2. Plasmid fragmentation and SMRT 
sequencing of linearised plasmid DNA was carried out by GATC biotech. The 
fragmentation step prior to sequencing selected 1 kb fragments for sequencing in order 
to increase the number of sequencing passes per molecule. Primary sequencing analysis 
by Philip Lobb (Pacific Biosciences) generated a 10 – pass – filtered dataset containing 
29705 ROIs, an average ROI length of 1119, a mean ROI quality of 0.9941 and a mean 
of 23.485 passes. BLASR alignment software aligned 29540 ROIs to the reference 
sequence with a minimum percentage identity of 95%. The number of ROIs was 
decreased to 29533 after fragments containing more than 3 mutations were excluded. 
These ROIs were taken forward to secondary sequencing analysis. Figure 5.6 shows the 
sequencing coverage of the plasmid in the linearised plasmid stock sample. The mean 
coverage of this sample was 6600, ranging from 0 to 9041. Aside from two outlier 
bases, covered 1 and 0 times respectively at positions 3434 and 4653, the minimum 
coverage was 3426. Coverage decreases from the start to the end of the plasmid 
sequence and spikes around base pair ~800 and ~4000. 
 
 
Figure 5.7a shows the complete collection of point mutations detected by the secondary 
sequencing analysis platform in terms of plasmid location and frequency. Overall there 
were 92 mutated plasmid positions detected. One of these point mutations, a C à T 
transition in the bacterial origin of replication (position 2539), is present in 6783 of 
6788 fragments (6754 out of 6758 after filtering). We assume here that a mutation 
called at this frequency is genuine. As can be seen, the other detectable mutated plasmid 
positions in this sample have a much lower mutation frequency. Figure 5.7b shows the 
same dataset, but scaled in for examination of the low frequency mutations. After Q 
score filtering (Figure 5.7c) only 48 mutated plasmid positions were detected. With the 
exclusion of the mutation detected at position 2539, there were 47 mutated plasmid 
positions, which had an accumulation of 58 mutation events. 
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Figure 5.6. Plasmid Stock Sample Coverage 
The figure illustrates the coverage of each base pair across the 4966 bp – long GFP 
plasmid in the linearised plasmid stock sample. 
 
 
 
After the data was >1 filtering (Figure 5.7d) only 8 mutated bases were detected. 
Excluding mutation 2539, 7 mutated plasmid positions were detected, which had an 
accumulation of 16 mutation events. The total number of called bases that passed the 
quality score filter was 32,416,625. Therefore, depending on filtering stringency, the 
mutation rates within the low frequency mutation dataset were 1 in 5.6 x 105 and 1 in 
2.0 x 106 for the Q score and >1 filters respectively.  Whilst it is possible that some of 
these point mutations could be genuine, this mutation frequency will be used as an 
estimate of error for this sequencing analysis platform. The overall conclusion was that 
there was genuine mutation found in the plasmid stock sample (position 2539), which 
was present in nearly all ROIs covering this base. Within the low frequency mutations, 
although some of these mutations could be genuine, they are more likely to be 
representative of systematic error in this sequencing platform. 
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Figure 5.7. Plasmid Stock Mutation Frequency 
This figure shows the frequency and locations of detected point mutations in the 
plasmid stock sample. All observed (A), low frequency (B), low frequency quality 
filtered (C) and low frequency quality filtered and >1 filtered (D) point mutations are 
shown. 
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5.2.4. Mutation Analysis of Transfected Non-Integrated Plasmid DNA 
 
Plasmid DNA was used from the same plasmid stock as was used in section 5.2.3 and 
transfected into CHO269M cells using 320-26 electroporation conditions. A modified 
Hirt method protocol (Section 2.2.4) was used to extract linearised plasmid DNA from 
CHO cells 24 hours after transfection as devised by (Arad, 1998). Agarose gel 
electrophoresis was used to confirm the successful extraction of the 5 kb plasmid DNA 
molecules and to assess whether plasmid DNA remains intact in the mammalian cell 
environment (Figure 5.8). The modified Hirt method successfully extracted plasmid 
DNA from CHO cells. However, samples also contained, what appear to be, large 
fragments of genomic contaminant DNA and unidentified smaller DNA fragments. 
Controls demonstrate that these smaller fragments are only present when DNA (linear 
or circular) is transfected into CHO cells and that the electric current alone does not 
cause this phenomenon.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. Transfected DNA Purification 
The figure shows gel images of purified plasmid DNA from CHO cells, containing 
hyperladder I (Lane 1), a mock transfection contol (Lane 2), two purified plasmid 
samples (Lanes 3 and 4), a mock transfection + spiked plasmid DNA control (Lane 5), 
DNA in 320-26 conditions (Lane 6), plasmid DNA (Lane 7), and transfected non-
linearised plasmid DNA (Lane 8).  
				1       2       3       4                    5         6        7                    8          
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Therefore, the electric current alone is not responsible for plasmid or genomic 
fragmentation. These smaller fragments could be the result of plasmid digestion or 
fragmentation in the CHO cell environment or could be a fragmented genomic DNA 
occurs after DNA transfection. This will be discussed further in section 5.3. Clearly it is 
undesirable to sequence DNA samples containing DNA that may not be plasmid DNA, 
because it will lead to reduced sequence coverage. Therefore it was necessary to purify 
the plasmid from this unidentified DNA. SMRT sequencing requires that samples have 
not been in contact with DNA intercalating agents in their preparation, meaning 
common gel extraction techniques cannot be used for purification. Blue Pippin 
technology offers automated gel purification without the need for intercalating agents 
(Sage Science, MA, USA). To validate the use of BluePippin technology for this 
purpose, it was tested in-house. A target purification size of 5.3 kb was used and DNA 
within the maximum range of 4.25 kb and 6.35 kb was collected. This approach was 
successful in removing any visually identifiable (by agarose gel electrophoresis) 
contaminants from the plasmid sample (Figure 5.9). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. BluePippin Purification 
The figure shows the agarose gel image of a Blue Pippin purified CHO plasmid extract 
(Lane 2) with Hyperladder I (Lane 1). 
 
     1           2 
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Therefore, Blue Pippin purification was carried out by GATC Biotech (Konstanz, 
Germany) before sample fragmentation. Unfortunately, GATC Biotech (Konstanz, 
Germany) were unable to use the Blue Pippin instrument at the same resolution as was 
carried out in the validation of the technology. A 5 kb target purification was carried 
out, but with a wider range of 3 kb around this target. SMRT sequencing was carried 
out under the same conditions as with the previous sample. 
 
Primary analysis filtering for ROIs with a minimum of 10 passes, 99% predicted 
accuracy and a minimum length of 800 bp generated 30,824 ROIs, with a mean length 
of 1473 bp, a mean quality of 0.9958 and a mean pass number of 20.012. BLASR 
alignment software aligned 15,063 ROIs to the reference sequence with a minimum 
percentage identity of 95%. This is approximately half of the total number of ROIs 
generated from the primary sequencing analysis. Therefore, it is likely that the Blue 
Pippin purification step was not efficient in removing genomic contaminant DNA. Blue 
Pippin purification with the size range used in the validation study (Figure 5.9) may 
have reduced the amount of non-plasmid DNA in the sample. However, it might be the 
case that there are genomic fragments that are too close in size to plasmid DNA to allow 
for complete purification using this method. The number of ROIs was decreased to 
15,060 after fragments containing more than 3 mutations were excluded. The remaining 
ROIs were taken forward to secondary sequencing analysis. 
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Figure 5.10 shows the sequencing coverage of the plasmid in the non-integrated / 
transfected plasmid DNA sample. The mean coverage of this sample was 4319, ranging 
from 0 to 4919. Two bases with low coverage in the plasmid stock sample, at positions 
3434 and 4653, were covered 0 times in this sample. This could be a result of the 
polymerase having difficulty reading these particular nucleotides within this specific 
sequence. Aside from these outlier bases the minimum coverage was 2975. As opposed 
to the plasmid stock sample, which showed a gradual decrease in coverage across the 
plasmid length, there was no detectable increase or decline in coverage in this sample. 
There are two clear spikes in coverage in line with the coverage spikes seen in the 
linearised plasmid stock sample at ~ 800 bp and 4000 bp respectively. The coverage in 
this sample was less than in the plasmid stock sample, which is presumably due to the 
apparent presence of contaminating DNA that the Blue Pippin instrument failed to 
remove. This would indicate that the unidentified contaminant DNA was not 
fragmented plasmid DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Transfected / Non-Integrated DNA Sample Coverage 
The figure illustrates the coverage of each base pair across the 4966 bp – long GFP 
plasmid in the non-integrated / transfected plasmid DNA sample. 
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Figure 5.11a shows the complete collection of mutated plasmid positions detected by 
the secondary sequencing analysis platform in terms of plasmid location and frequency. 
Overall there were 90 mutated plasmid positions detected. As was seen in the plasmid 
stock sample, a C à T transition in the bacterial origin of replication (position 2539), 
was present in 3986 of 3988 fragments (3974 out of 3974 after filtering). Again, we 
assume here that a mutation called at this frequency is genuine. As can be seen, the 
other detectable mutated plasmid positions in this sample have a much lower frequency. 
Figure 5.11b shows the same dataset, but scaled in for examination of the low frequency 
mutations. After Q score filtering (Figure 5.7c) only 45 mutated plasmid positions were 
detected. With the exclusion of the mutation detected at position 2539, there were 44 
mutated plasmid positions, which had an accumulation of 45 mutation events. After >1 
filtering (Figure 5.7d) only 2 mutated bases were detected. Excluding mutation 2539, 1 
mutated plasmid positions were detected, which was observed twice in total. The total 
number of called bases that passed the Q score filter was 21,246,529. Therefore, 
depending on filtering stringency, the mutation rates within the low frequency mutation 
dataset were 1 in 4.7 x 105 and 1 in 1.1 x 107 for the quality score and >1 filters 
respectively.  As with the plasmid stock sample, it is possible that some of these point 
mutations could be genuine, but it is more likely that this mutation frequency represents 
an estimate of error for this sequencing and analysis platform. It should be noted that 
the coverage for the non-integrated transfected sample was considerably less (65.4%) 
than the coverage for the plasmid stock sample and so low frequency mutations are less 
likely to be detected. Figure 5.5 shows mutation levels after being normalised for 
coverage, in which the mutation frequency in the non-integrated transfected sample was 
marginally higher than for the plasmid stock sample, but not to an extent that indicates 
this is due to anything other than random sampling. Both of these samples are relatively 
low in comparison with the genome-integrated samples. Therefore, the conclusion was 
that there was not convincing evidence that non-genomic cellular environment caused 
mutation of the plasmid DNA.  
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Figure 5.11. Transfected / Non-Integrated Plasmid Mutation Frequency	
This figure shows the frequency and locations of detected point mutations in the 
transfected / non-integrated plasmid sample. All observed (A), low frequency (B), low 
frequency quality filtered (C) and low frequency quality filtered and >1 filtered (D) 
point mutations are shown.	
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5.2.5. Stable GFP Cell Line Generation 
 
In order to investigate the occurrence of point mutation of integrated plasmid DNA, 
GFP stable cell lines were generated. CHO269M cells were transfected using 320-26 
electroporation conditions and cells containing integrated plasmid DNA were selected 
using the neomycin analogue G418 in order to generate a population of plasmid-
containing cells. The Kanamycin / Neomycin resistance gene on the phCMV C-GFP 
vector provides resistance against G418 and thus selects for cells containing integrated 
plasmid DNA, which is detectable through GFP measurements by flow cytometry. 
Some studies have shown that G418 alone is not sufficient to facilitate selection and so 
FACS was used as a supplementary technique to increase the number of recombinants 
in the population (Zhang et al., 2006). FACS was carried out by Kay Hopkinson at the 
University of Sheffield flow cytometry core facility. 
 
Due to the batch – to – batch variation in G418 disulphate stocks, it was necessary to 
carry out a dose response experiment for each batch. Two batches were used during the 
selection process. G418 concentrations 0.1-0.2 mg/mL above the concentration which 
led to complete cell death after 8 days of batch culture were selected for cell line 
selection (Lonza, 2012). Cell viability and VCD were used in making this decision. For 
batch 1 it was decided to proceed using 0.8 mg/mL G418, (Figure 5.12) and for batch 2 
it was decided to proceed using 0.9 mg/mL (Figure 5.13). 
 
A brief summary of transfection, the selection process and cell culture of the stable cell 
line is as follows. 1 x 107 CHO269M cells were transfected with 50 ug of phCMV C-
GFP plasmid using 320-26 electroporation conditions and then immediately transferred 
into T75 flasks containing 40 ml media (detailed in section 2.6). T75 flasks were 
incubated in a humidified static incubator. After 24 hours recovery (Day1) transfection 
efficiency (94%), cell viability (84%) and VCD (0.16 x 106 cells.ml) were in line with 
optimised values presented in chapter 4, and so G418 was added to begin recombinant 
cell selection. Cells were transferred into E125 flasks for shaking incubation on day 7, 
from which time they were passaged on a standard 3-4 day regime. 	
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Figure 5.12. G418 Dose Response: Batch 1 
The figure shows the cell viability (A) and VCD (B) response to a range of G418 
concentrations ranging from 0 – 1 mg/mL over 8 days of batch culture. 
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Figure 5.13. G418 Dose Response: Batch 2	
The figure shows the cell viability (A) and VCD (B) response to a range of G418 
concentrations ranging from 0 – 1.5 mg/mL over 8 days of batch culture. 	
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Cells were sorted for GFP production using a low threshold (top ~90% of GFP positive 
cells) on day 39 and then at a higher threshold (top ~20% of GFP positive cells) on day 
46. A cell bank was made using cryopreservation protocols (section 2.1.2) from stable 
cells on day 59, which was used to generate the “Low” generation sample for DNA 
sequencing. Cells were cultured until day 126, at which point cell banks were made and 
samples taken for the “High” generation sample for DNA sequencing. Figure 5.14 
shows VCD, cell viability and GFP positive cell measurements over the course of stable 
cell line generation and cell culture. As can be seen VCD is slow to increase at the start 
of the selection process, because of the growth inhibition of non-recombinants. Another 
dip in VCD can also be seen around the two FACS events. This is because the FACS 
imposes a strict population bottleneck, which reduces the population of cells and so 
time is needed for VCD to return to normal levels. Cell viability is initially seen to be 
lower, because of electroporation recovery and cell selection. Viability then returns to 
higher levels, but appears to oscillate during each cell subculture. This is due to an 
apparent culture artifact of G418 – containing media, such that viabilities are counted as 
lower towards days 3 and 4 and when cells are replenished with fresh media viabilities 
return to normal levels (~98%) and so were assumed to be healthy. Inspection of Vi-
Cell images reveals artifacts within the culture that are called as dead cells. Initial GFP 
positive cell measurements were high due to transient gene expression, which subsides 
in line with plasmid degradation and dilution. GFP positive measurements then 
remained consistent at ~7% in line with the expectation that G418 may not be a 
sufficient selector (Zhang et al., 2006). The first round of FACS led the GFP positive 
cell measurements ~60% and the second round of FACS led to GFP positive cell 
measurements ~93%. Once this was determined to be stable, the Low generation cell 
bank was generated. GFP positive cell measurements remained fairly consistent, apart 
from a slight decrease around day 85. When high generation samples were taken GFP 
positive cell measurement was ~90%. Generation number for low and high samples was 
~57 and ~133 respectively. 
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Figure 5.14. GFP Stable Cell Line Generation 
The figure shows cell growth (VCD - A) along with cell viability (%) and GFP positive 
cells (%)  (B) over the 126 day selection and culture period of the stable GFP cell line.  
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5.2.6. Genome – Integrated Plasmid: Low Generation  
 
Genomic DNA was extracted from low generation stable GFP cells using a Blood and 
Cell Culture DNA kit (QIAGEN, Manchester, UK). In order to provide a sufficient 
quantity of recombinant plasmid DNA that was free from other CHO genomic DNA, it 
was necessary to carry out PCR. The fragmentation process carried out by GATC 
biotech prior to DNA sequencing could not be carried out on PCR products. Therefore, 
to ensure the sequencing of plasmid templates with sizes allowing for multiple passes it 
was decided to carry out four separate PCR’s, which were designed to amplify four 
overlapping plasmid regions (~1.3 kb) covering the entire plasmid length. PCR was 
carried out using the Phusion High Fidelity DNA polymerase (New England Biolabs, 
UK) and the subsequent samples were quantified using a Nanodrop, so that the four 
PCR products could be pooled together in equal quantities into one sample. SMRT 
sequencing of this sample was carried out by GATC Biotech. Primary analysis filtering 
for ROIs with a minimum of 10 passes, 99% predicted accuracy and a minimum length 
of 800 bp generated 41,500 ROIs, with a mean length of 1338 bp, a mean quality of 
0.9935 and a mean pass number of 22.306. BLASR alignment software aligned 41,965 
ROIs to the reference sequence with a minimum percentage identity of 95%. The 
number of ROIs was decreased to 41,910 after fragments containing more than 3 
mutations were excluded. These ROIs were taken forward to secondary sequencing 
analysis. 
 	
Figure 5.15 shows the sequencing coverage of the plasmid in the Low generation DNA 
sample. The mean coverage of this sample was 10,525, ranging from 0 to 23,957. The 
coverage here is clearly different to the coverage in the plasmid stock and non-
integrated transfected samples. The pooling together of four separate PCR reactions 
resulted in four predominant plasmid sequence coverage frequencies. The coverage at 
the start of the sequence (positions 1-77) is approximately a 3-fold lower than the rest of 
the sequence from the same PCR reaction. The overlapping regions between the 
separate PCR-based sequences result in spikes of coverage, where plasmid regions are 
being covered by two PCR templates. Again, the coverage of plasmid positions 3,434 
and 4,653 are extremely low, being covered 0 and 4 times respectively. The vast 
majority of the plasmid positions within this data reside within the four predominant 
PCR-based frequency populations, which range in averages from 6,370 to 13,768.	
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Figure 5.15. Low Generation Sample Coverage	
The figure illustrates the coverage of each base pair across the 4966 bp – long GFP 
plasmid in the low generation recombinant plasmid DNA sample. 
 
 
Figure 5.16a shows the complete collection of point mutations detected by the 
secondary sequencing analysis platform in terms of plasmid location and frequency in 
the low generation genomic sample. Overall there were 2783 mutated plasmid positions 
detected. As was seen in previous samples, a C à T transition in the bacterial origin of 
replication (position 2539), was present in 16098 of 20676 fragments (16013 out of 
20016 after filtering). Again, we assume here that a mutation called at this frequency is 
genuine. As can be seen, the other detectable mutated plasmid positions in this sample 
have a much lower frequency. Figure 5.16b shows the same dataset, but scaled in for 
examination of the low frequency mutations. After quality score filtering (Figure 5.7c) 
2104 mutated plasmid positions were detected. With the exclusion of the mutation 
detected at position 2539, there were 2103 mutated plasmid positions, which had an 
accumulation of 4214 mutation events. After the data was filtered for mutations 
occurring more than once (Figure 5.7d) only 739 mutated bases were detected. 
Excluding mutation 2539, 738 mutated plasmid positions were detected, which had an 
accumulation of 2456 mutation events. Mutation seems to be randomly  
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Figure 5.16 Low Generation Recombinant Plasmid Mutation Frequency	
This figure shows the frequency and locations of detected point mutations in the low 
generation recombinant plasmid sample. All observed (A), low frequency (B), low 
frequency quality filtered (C) and low frequency quality filtered and >1 filtered (D) 
point mutations are shown.		
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distributed along the full range of the plasmid. The total number of called bases that 
passed the quality score filter was 51,635,389. Therefore, depending on filtering 
stringency, the mutation rates within the low frequency mutation dataset were 1 in 1.2 x 
104 and 1 in 2.1 x 104 for the quality score and >1 filters respectively.  These mutation 
rates are approximately 47-fold and 95-fold higher than those seen in the plasmid stock 
negative control for the Q score filter and >1 filter mutation rates respectively. There 
are mutations in more plasmid positions and with higher frequencies than seen in the 
plasmid stock control. This is strong evidence of mutations occurring during the 
generation of the stable GFP cell line and subsequent cell culture for ~57 generations. 
The coverage of plasmid bases in this sample was considerably higher than the plasmid 
stock negative control, but this does not impact on the differences found between the 
two datasets (Figure 5.5). Depending on filter stringency, the mutation rates given here 
suggest that 1 in every 2.4 or 4.2 of the 5 kb plasmids used here contain a point 
mutation. 
 
As stated previously, the >1 – filtered dataset is more likely to result in the detection of 
genuine mutations, because it overcomes the sources of error that are unique to 
individual ZMWs as well as being filtered for quality. The Q score – filtered dataset 
was considered sufficient to comment on mutation frequencies, but not for drawing 
conclusions regarding the type of the mutations detected, because inaccuracies here may 
skew the results.  Therefore, only the >1 – filtered dataset will be used for this purpose. 
 
Table 5.1 contains all the genetic elements of the phCMV C-GFP plasmid and the 
percentage of mutations that fall within each element from the >1 – filtered dataset. 
Where two or more elements overlap, a separate element is designated so not to count 
mutations more than once. If mutation is assumed to be random, then a base within one 
genetic element is equally likely to be mutated as a base within another genetic element. 
Therefore, the longer a genetic element, the more likely it is that it will have been 
mutated at some point along its length. In order to determine whether mutation is 
targeted towards particular genetic elements, mutation percentage was normalised to 
element length to correct for this potential bias. All but two of the sequence types noted 
here were mutated. The two mutation-free sequences were the polyadenylation signal 
sequences for the Kan / Neo GFP genes, which perhaps are conserved through natural 
selection. However, this may also be due to polyadenylation signals being short and are 
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less likely to be hit by random mutation. Of the mutated elements, there appears to be 
no substantial difference between coding and non-coding DNA, which may be an 
indication of random mutation, not greatly affected by natural selection. MCS’s in 
particular appear to be more heavily mutated than other sequences. 
 				
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1. Low Generation Sample: Mutated Genetic Elements 
The table contains the percentage of mutations that fall within each genetic element of 
the phCMV C-GFP plasmid and the normalized mutation value relative to the length of 
each genetic element. The sequence elements are as follows: Ampicillin resistance gene 
promoter, SV40 promoter, Kanamycin / Neomycin resistance gene, HSV Thymidine 
Kinase polyadenylation signal, pUC origin of replication, Human CMV promoter 
enhancer and intron, overlapping region of Human CMV promoter enhancer and intron 
plus the multiple cloning site upstream of the GFP open reading frame, T7 promoter 
priming for sequencing, multiple cloning site upstream of GFP open reading frame, 
GFP open reading frame, multiple cloning site downstream of GFP open reading frame, 
SV40 polyadenylation signal sequence and non-coding DNA. 				 	 		
 
 
Sequence Element Mutation Frequency 
(%) 
Mutation Frequency 
(Normalised by 
element length) 
pAmp 0.4 13.79 
pSV40 4.7 20.43 
Kan / Neo 16.9 21.26 
HSV_TK_PolyA 0 0 
Puc_Ori 13.7 21.27 
phCMV + Intron 14.9 21.72 
phCMV + Intron + MCS1 0.9 18.75 
pT7 0.3 18.75 
MCS1 1.5 30 
GFP ORF 18.4 25.56 
MCS2 3.1 44.29 
SV40 PolyA 0 0 
Non-Coding 25.2 15.68 
Chapter 5: Plasmid DNA Mutation Analysis 
	 162	
Table 5.2 shows the frequency of each type of point mutation, along with a total 
frequency of changed nucleotides, from the >1 – filtered dataset. There is a clear 
predominance in point mutations of G and C nucleotides, showing 41.96% and 43.98% 
of changes respectively. More specifically, by far the most frequent types of changes are 
G.C à A.T transitions (C à T (24.9%), G à A (19.22%)) and C.G à A.T 
transversions (C à A (18.54%), G à T (22.6%)). The GC content of the plasmid 
reference sequence is 50.7%, so will not have influenced these results.  	
	
Table 5.2. Low Generation Sample: Nucleotide Changes	
The table shows the percentages of each type of nucleotide change seen within this 
dataset, the sum of which are used to give the total percentage change for each 
nucleotide. 
 
 
 
The phCMV C-GFP plasmid contains two open reading frames (Kan / Neo and GFP). 
The >1 – filtered dataset was used to determine whether the observed DNA point 
mutations were synonymous or non-synonymous in terms of the resulting amino acids 
coded for. For the Kan / Neo open reading frame there were 105 (76%) non-
synonymous changes and 33 (24%) synonymous changes and for the GFP open reading 
frame there were 115 (75%) non-synonymous changes and 38 (25%) synonymous 
changes. Given that the probability of a random mutation causing a synonymous or non-
synonymous change is 24% and 76% respectively (generated by mathematical 
simulation), the data in this sample show that the observed amino acid changes are 
random. Despite these probabilities mutation studies, generally, do not usually uncover 
point mutations in line with the ratio of synonymous to non-synonymous mutations 
observed here. This is because non-synonymous mutations are more likely to be 
deleterious and result in changes that prohibit the natural selection of these mutation-
containing genes, and so it is more common to find synonymous mutations. Therefore, 
this would indicate that the mutations found in this study are not under the influence of 
	 	 To 	  A T C G Total 
 
From 
A -- 0.41 0.41 7.44 8.26 
T 0.81 -- 4.74 0.27 5.82 
C 18.54 24.9 -- 0.54 43.98 
G 19.22 22.6 0.14 -- 41.96 
Chapter 5: Plasmid DNA Mutation Analysis 
	 163	
natural selection. This is likely to be due to their extremely low frequency. It is highly 
likely that a given cell will contain more than one copy of recombinant plasmid DNA, 
because this is a trait that will be selected for through G418 resistance and FACS events 
and so if one of these plasmid copies contains a mutation that effects phenotype then it 
can be compensated for by other, unchanged, plasmid copies.  
 
5.2.7. Genome-Integrated Plasmid: High Generation Number 
 
High generation DNA samples were prepared using the same protocols as with the low 
generation sample, in which genomic DNA was purified, four recombinant plasmid 
DNA regions were amplified through PCR and pooled together into one sample. SMRT 
sequencing of this sample was carried out by GATC Biotech. Primary analysis filtering 
for ROIs with a minimum of 10 passes, 99% predicted accuracy and a minimum length 
of 800 bp generated 40,315 ROIs, with a mean length of 1336 bp, a mean quality of 
0.9935 and a mean pass number of 21.936. BLASR alignment software aligned 40,968 
ROIs to the reference sequence with a minimum percentage identity of 95%. The 
number of ROIs was decreased to 40,924 after fragments containing more than 3 
mutations were excluded. These ROIs were taken forward to secondary sequencing 
analysis. 
 
Figure 5.17 shows the sequencing coverage of plasmid DNA in the high generation 
DNA sample. The mean coverage of this sample was 10,253, ranging from 0 to 22,570. 
The coverage seen here is clearly different to the coverage seen in the plasmid stock and 
non-integrated transfected samples. Again, the pooling together of four separate PCR 
reactions resulted in four predominant plasmid sequence coverage frequencies. The 
coverage at the very start of the sequence (positions 1-77) is approximately a 2-fold 
lower than the rest of the sequence from the same PCR reaction. The overlapping 
regions between the separate PCR-based sequences result in spikes of coverage, 
because these plasmid regions are being covered by two PCR templates. Again, the 
coverage of plasmid positions 3,434 and 4,653 are extremely low, being covered 0 and 
2 times respectively. The vast majority of the plasmid positions within this data reside 
within the four main PCR-based frequency populations seen in figure 5.17, which range 
in averages from 7,521 to 13,290.	
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Figure 5.17. High Generation Sample Coverage	
The figure illustrates the coverage of each base pair across the 4966 bp – long GFP 
plasmid in the high generation recombinant plasmid DNA sample. 						
Figure 5.18a shows the complete collection of point mutations detected by the 
secondary sequencing analysis platform in terms of plasmid location and frequency in 
the high generation genomic sample. Overall there were 2550 mutated plasmid 
positions detected. As was seen in previous samples, a C à T transition in the bacterial 
origin of replication (position 2539), was present in 15,010 of 18,097 fragments (14,922 
out of 18,746 after filtering). Again, we assume here that a mutation called at this 
frequency is genuine. As can be seen, the other detectable mutated plasmid positions in 
this sample have a much lower frequency. Figure 5.18b shows the same dataset, but 
scaled in for examination of the low frequency mutations. After quality score filtering 
(Figure 5.18c) 1724 mutated plasmid positions were detected. With the exclusion of the 
mutation detected at position 2539, there were 1723 mutated plasmid positions, which 
had an accumulation of 3095 mutation events. After the data was filtered for mutations 
occurring more than once (Figure 5.7d) only 512  
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Figure 5.18 High Generation Recombinant Plasmid Mutation Frequency	
This figure shows the frequency and locations of detected point mutations in the high 
generation recombinant plasmid sample. All observed (A), low frequency (B), low 
frequency quality filtered (C) and low frequency quality filtered and >1 filtered (D) 
point mutations are shown.					
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mutated bases were detected. Excluding mutation 2539, 511 mutated plasmid positions 
were detected, which had an accumulation of 1590 mutation events. Mutation seems to 
be randomly distributed along the full range of the plasmid. The total number of called 
bases that passed the quality score filter was 50,279,121. Therefore, depending on 
filtering stringency, the mutation rates within the low frequency mutation dataset were 1 
in 1.6 x 104 and 1 in 3.2 x 104 for the Q score and >1 filters respectively.  These 
mutation rates are approximately 35-fold and 63-fold higher than those seen in the 
plasmid stock negative control for the Q score filter and >1 filter mutation rates 
respectively. Again, there are mutations in more plasmid positions and with higher 
frequencies than seen in the plasmid stock control. Mutation frequencies for both filters 
are approximately 1.3-fold lower in the high generation same when compared to the low 
generation sample. Figure 5.5 confirms that these trends are still apparent when 
mutation frequencies are normalised by sequence coverage. By number, using the >1 
filter, there are 227 more mutated plasmid positions in the low generation sample when 
compared to the high generation sample. This difference can be broken down into 251 
maintained mutated positions, 528 lost mutation positions and 278 gained mutation 
positions. This is further evidence of mutations occurring during ~76 generations 
between sampling over long-term cell culture. Depending on filter stringency, the 
mutation rates given here suggest that 1 in every 3.2 or 6.4 of these 5 kb plasmids 
contain a point mutation. The average rate of mutation found across the two genomic 
samples is 1 in 4 plasmids (5 kb). 
 
Table 5.3 contains all the genetic elements of the phCMV C-GFP plasmid and the 
percentage of mutations that fall within each element from the >1 – filtered high 
generation dataset. As with the low generation dataset, where two or more elements 
overlap, a separate element is designated so not to count mutations more than once. 
Mutation percentage was normalised to element length to correct for the potential bias 
of element sequence length. In this sample mutations were detected in all element types, 
apart from the Kan / Neo polyadenylation sequence. Again, there was not a substantial 
difference in mutation frequencies between coding and non-coding DNA. MCS 2 had a 
substantially higher mutation frequency than other plasmid sequence elements. 
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Sequence Element Mutation Frequency 
(%) 
Mutation Frequency 
(Normalised by 
element length) 
pAmp 0.2 6.9 
pSV40 6.8 29.57 
Kan / Neo 15.6 19.62 
HSV_TK_PolyA 0 0 
Puc_Ori 14.8 22.98 
phCMV + Intron 17 24.78 
phCMV + Intron + MCS1 0.6 12.5 
pT7 0.6 37.5 
MCS1 1 20 
GFP ORF 14.3 19.86 
MCS2 3.7 52.86 
SV40 PolyA 0.8 15.69 
Non-Coding 24.6 15.31 		
Table 5.3. High Generation Sample: Mutated Genetic Elements 
The table contains the percentage of mutations that fall within each genetic element of 
the phCMV C-GFP plasmid and the normalised mutation value relative to the length of 
each genetic element. The sequence elements are as follows: Ampicillin resistance gene 
promoter, SV40 promoter, Kanamycin / Neomycin resistance gene, HSV Thymidine 
Kinase polyadenylation signal, pUC origin of replication, Human CMV promoter 
enhancer and intron, overlapping region of Human CMV promoter enhancer and intron 
plus the multiple cloning site upstream of the GFP open reading frame, T7 promoter 
priming for sequencing, multiple cloning site upstream of GFP open reading frame, 
GFP open reading frame, multiple cloning site downstream of GFP open reading frame, 
SV40 polyadenylation signal sequence and non-coding DNA. 			
Table 5.4 shows the frequency of each type of point mutation, along with a total 
frequency of changed nucleotides, from the >1 – filtered high generation dataset. Again 
there is a clear predominance in point mutations of G and C nucleotides, showing 
42.19% and 41.21% of changes respectively. Upon closer inspection, the frequency of 
mutation types seen here differ from those in the low generation sample. G.C à A.T 
transitions were predominant, but G.C à A.T transition (C à T (29.3%) and G à A 
(29.69%)) mutations were more common than C.G à A.T transversion (C à A 
(11.13%) and G à T (11.91%)) mutations. Again, it should be noted that the GC 
content of the plasmid reference sequence is 50.7%, so will not have influenced these 
results.  
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Table 5.4. High Generation Sample: Nucleotide Changes 
The table shows the percentages of each type of nucleotide change seen within this 
dataset, the sum of which are used to give the total percentage change for each 
nucleotide. 		
The >1 – filtered high generation dataset was used to determine whether the observed 
DNA point mutations were synonymous or non-synonymous in terms of the resulting 
amino acid sequences coded for by the two open reading frames, Kan / Neo and GFP. 
For the Kan / Neo open reading frame there were 54 (67%) non-synonymous changes 
and 27 (33%) synonymous changes and for the GFP open reading frame there were 55 
(71%) non-synonymous changes and 22 (29%) synonymous changes. The ratio of 
synonymous to non-synonymous mutations deviates slightly more from the ratio 
expected from completely random mutation (24%:76%) than the low generation sample, 
but still vastly deviates from ratios commonly found in mutational studies, which 
indicates that natural selection has not solely impacted upon the mutation frequencies 
observed here. However, the increase in the percentage of synonymous mutations may 
indicate that natural selection is slowly acting upon this population, but this could be a 
result of random fluctuations between samples. 
 
5.2.7. PCR-based error 
 
Overall, the results here have shown that point mutations predominantly occur after 
plasmid integration. However, sample preparation of genome-integrated samples 
involved PCR, whereas the pre-integration samples did not. Therefore, PCR error 
needed to be eliminated as a potential source of these observed mutations. The reported 
error rate of the Phusion polymerase when using the High Fidelity buffer is 1 in 4.4 x 
107 (Ingman and Gyllensten, 2009). Using the ThermoFisher Scientific online PCR 
Fidelity Calculator (Thermo Fisher Scientific, n.d.), with inputs of the length of the 
PCR product (an average of 1338 and 1336 bp for the low and high generation samples 
respectively) and the number of PCR cycles (40) used, the approximate PCR error rate 
	 	 To 	  A T C G Total 
 
From 
A -- 0.2 1.37 7.62 9.19 
T 0.59 -- 6.84 0 7.43 
C 11.13 29.3 -- 0.78 41.21 
G 29.69 11.91 0.59 -- 42.19 
Chapter 5: Plasmid DNA Mutation Analysis 
	 169	
was calculated for the two genomic samples. It was calculated that approximately 
2.35% of ROIs in the low and high generation samples would contain 1 error. This 
percentage was used in comparison with the Q-score-filtered dataset. For the low 
generation recombinant sample, an error rate of 2.35% in 51,635,389 bases from ROIs 
with an average length of 1338 would yield 907 PCR-originating point mutations. For 
the high generation recombinant sample, an error rate of 2.35% in 50,279,121 bases 
from ROIs with an average length of 1336 would yield 884 PCR-originating point 
mutations. The mutation frequencies observed in these samples are 4.7-fold and 3.5-fold 
higher than the estimated level of PCR-based errors, for low and high generations 
respectively, and so are likely to be a result of genuine occurrences of point mutation. 
Even though the majority of mutations uncovered in this study are likely not to be a 
result of PCR error, PCR-based errors may still be frequent enough to skew the dataset. 
A previous study regarding the fidelity of the Phusion polymerase, which confirmed the 
reported manufacturer error rate, revealed that errors were predominantly transitions 
(~60%) rather than transversions (Kinde et al., 2011) and further manufacturer in-house 
data has revealed a predominance of C à T and G à A transitions (personal 
correspondence with New England Bioscience technical support), which is the same 
predominance shown in this study. However, various studies have shown that these 
types of mutations are also predominant in CHO and other mammalian cell DNA 
replication (Dejong et al., 1988, Gojobori et al., 1982, Hauser et al., 1987). Therefore, 
although it may be exacerbated by PCR, the trends found in base-pair bias are likely to 
be genuine trends of point mutation occurrence in CHO cells over long-term cell 
culture. 
 
 
5.3. Discussion 
 
5.3.1 Summary and Conclusions 
 
As stated in the introduction to this chapter, recombinant protein-producing CHO cell 
lines have been shown to produce product variants in the form of amino acid sequence 
changes. Many of these changes have been attributed to non-synonymous point 
mutations in the recombinant DNA sequence (Harris et al., 1993, Ren et al., 2011). A 
number of these point mutations have been shown to originate during long-term cell 
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culture of stable cell lines after the plasmid, coding for the protein of interest, has 
integrated into the host genome (Zhang et al., 2015). Other studies have shown that 
point mutations were found to occur in plasmid DNA immediately after transfection 
into mammalian cells, before genome integration (Hauser et al., 1987, Lebkowski et al., 
1984, Lechardeur et al., 1999). Therefore, it is possible that point mutation-derived 
product variants in recombinant CHO cell lines could result from DNA polymerase 
replication error of genomic DNA or the potential mutative environment of the cell 
cytosol or nucleus.  
 
To our knowledge only one study (Zhang et al., 2015) has investigated point mutations 
in recombinant CHO cell lines using NGS without prior knowledge of sequence 
variants. The Zhang et al. (2015) study was carried out on 11 CHO cell populations, 
derived from limited dilution transfectant, clones, and subclones, in which 3 mutations 
were identified. So, although the Zhang et al (2015) study provides insight into 
recombinant DNA point mutations in CHO cell populations and a novel use for RNA-
seq in mutation identification, the restrictions in cell heterogeneity (dilution, cloning 
and subcloning) limit the number of observable mutations. The use of clonal, or nearly 
clonal, cell populations in these types of studies ensure the frequency of a unique 
mutation is high enough to be detected by NGS technologies, because it ensures that 
DNA samples contain many copies of the same ‘version’ of a plasmid. There have been 
reports of Illumina-based sequencing detecting mutations at < 5% frequency (Spencer et 
al., 2014) and the Pacific Biosciences lower limit to PacBio standard variant calling is 
reportedly 1% (Dilernia et al., 2015). Previous studies, presumably, have been devised 
around these reported detection sensitivities. Without the imposition of cell 
heterogeneity restrictions (e.g. in a non-diluted transfectant pool), many more 
recombinant plasmid ‘versions’ would be sequenced. Indeed, the frequency of any 
given mutation would be lower, but there would be a higher number of unique 
mutations present. This was the premise behind the analysis platform devised in this 
study, which can detect these low frequency mutations and provide a more in-depth 
characterisation of them. This study aimed to push the limits of SMRT sequencing by 
maximising the accuracy in the sequencing of individual molecules. Consensus 
sequence generation between molecules was avoided, so that rare mutations were not 
diluted to the extent that they could not be detected. 
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Sequencing was carried out on DNA from linearised plasmid stocks, transfected but not 
integrated linearised plasmid, and genome integrated plasmid from two time points in 
long-term cell culture (low and high generation). SMRT sequencing was carried out on 
fragments (through fragmentation or PCR) of the ph-CMV C-GFP vector. Primary 
analysis generated ROIs with a minimum predicted accuracy of 99% and a minimum 
length of 800 bp. This was carried out for a range of minimum pass numbers (0, 5, 10, 
15, 20) required to generate a consensus sequence. Using BLASR, sequences were 
aligned to a plasmid reference sequence with 95% matched identity, generating data on 
sequences, sequence coverage, and sequence quality. A novel secondary analysis 
platform was then used to report all called nucleotides at each plasmid position, using 
various stringencies of error-eliminating filters (Removal or error-prone ROIs, Q score 
filtering and > 1 filtering). Plasmid mutation was then assessed for frequency, position, 
type and impact on amino acid sequences. Final analysis and conclusions were drawn 
from the 10 – pass datasets, because they delivered the highest coverage from the 
datasets deemed to have low error frequencies.  
 
The average coverage of samples varied: linearised plasmid stock – 6,600; transfected / 
non-integrated plasmid – 4,319; Low genomic sample – 10,525; High genomic sample 
– 10,253. These values of coverage are derived from 10 – pass ROIs and so arguably 
are more accurate than 1x coverage in other sequencing methods. The discrepancy 
between total ROIs (30,824) and aligned ROIs (15,063) in the transfected / non-
integrated sample is the reason for the lower coverage seen in this sample. This was due 
to the inability of the Blue Pippin instrument (Sage Science, MA, USA) to remove non-
plasmid DNA from the sample. Carrying out Blue Pippin purification using the same 
conditions as the validation study would be more likely to remove a greater proportion 
of non-plasmid DNA and result in increased sequence coverage. Coverage from PCR-
derived samples was noticeably different from non-PCR-derived samples, in that the 
four PCR-fragments had distinct coverages, presumably due to the their relative 
concentrations within the pooled samples. Interestingly, two plasmid positions (3434 
and 4653) were consistently covered at low frequencies (ranging 0 to 4), which could be 
due to an inherent issue with sequencing at this position. 
All samples were found to have a high frequency C à T transition in the bacterial 
origin of replication (plasmid position 2539) in > 99.9% of fragments covering this 
position. The same plasmid stock was used throughout this study. We assume here that 
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this mutation was present in the initial plasmid stock from the manufacturer. However it 
is possible that the mutation originated from a DNA replication error during E. coli cell 
divisions during plasmid cloning, but the error would have had to of occurred during an 
extremely early plasmid replication. 
 
Other than the 2539 mutation, the observed mutation frequency in the linearised 
plasmid stock sample was extremely low (Q score filter: 1 in 5.6 x105, >1 filter: 1 in 2 x 
106). Although it is possible that here we are observing genuine low frequency mutation 
as a result of rare E. coli DNA replication errors, it was deemed more likely that these 
were representative of false positive call rates within this sequencing analysis platform. 
Therefore, this sample was used as a negative control sample for point mutations in this 
study.  
 
The level of mutation observed in the transfected / non-integrated plasmid sample (Q 
score filter: 1 in 4.7 x105, >1 filter: 1 in 1.1 x 107) did not substantially surpass the level 
seen in the negative control and so the conclusion drawn here is that the pre-integration 
cellular environment did not cause point mutations in plasmid DNA. However, previous 
studies investigating the putative mutagenic environment of a mammalian cell utilised 
protocols, in which transfected plasmid extracts were then transformed into a bacterial 
host to identify mutations. It was hypothesised that mutations are a result of DNA 
damage in the mammalian cell environment, such as Cytosine damination, depurination 
of Guanine residues or through nuclease attack (Hauser et al., 1987, Lebkowski et al., 
1984). These transformed DNA molecules are presumably replicated or transcribed by a 
DNA polymerase before assessing the DNA for mutation. Theoretically, a mutation will 
only be present once this DNA damage is misread by a replicase or polymerase. In this 
study the DNA in the transfected / non-integrated sample was deliberately left 
unamplified due to concerns that PCR-based errors may be at a greater frequency than 
mutation itself, which may have only been present as a single copy. However, perhaps 
there were DNA damage events, which had, in essence, marked a given nucleotide for 
point mutation, but there was a lack of replication to consolidate this change before 
sequencing and so they were left undetected. The PacBio sequencing polymerase will 
not have served this purpose, because a DNA damage repair step in sample preparation 
removes DNA damages such as cytosine deamination and oxidative damages, so that 
the polymerase does not stall during sequencing (Pacific-Bioscience, 2010). Therefore, 
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these mutations were unlikely to have been detected in the transfected / non-integrated 
sample in this experimental design. It might be the case that some mutations detected in 
the genome-integrated samples (Low and High) were caused by pre-integration damage. 
So, although the sequencing of this sample determined that there is no observable point 
mutation occurring before genome integration, it was unable to address the hypothesis 
that DNA is somehow marked for mutation upon replication.  
 
As mentioned in chapter 4 in regards to cell viability and average cell diameter 
responses to transfection, electroporation of plasmid DNA has a substantial impact on 
cell health in that it is known to cause apoptosis, which is presumed to be due to a 
cellular response in line with the response to a viral attack (Shimokawa et al., 2000). 
One observation of this apopotic response is genomic DNA fragmentation, which gives 
rise to gel banding patterns not dissimilar to the unidentified contaminant DNA in the 
transfected non-integrated sample (Nagata, 2000, Ioannou and Chen, 1996). This is a 
heavy indication that a proportion of cells in this study were undergoing apoptosis. Not 
all cells undergo apoptosis-mediated cell death as a result of DNA electroporation, but it 
might be the case that cells elicit a response as a result of electroporation stress. Indeed, 
it could be worthwhile to investigate the global cellular response to electroporation. 
Mammalian cells are known to detect the presence of foreign DNA and have been 
shown to silence transfected plasmid DNA (Orzalli and Knipe, 2014). Furthermore, the 
redox state of the cell is known to change as a result of apoptosis (Slater et al., 1996, 
Bustamante et al., 1997). Changes such as this to the cellular environment could play a 
role in the putative mutations that occur as a result of pre-integration damage, meaning 
point mutation is an indirect cellular response to electroporation. 
 
The level of mutation observed in the genome-integrated plasmid copies was 
considerably greater than in the linearised plasmid stock negative control. Mutation 
frequency was higher in the low generation sample (Q score filter: 1 in 1.2 x 104, >1 
filter: 1 in 2.1 x 104) than in the high generation sample (Q score filter: 1 in 1.6 x 104, 
>1 filter: 1 in 3.2 x 104). The mutations observed here were predominantly observed 
between 1 and 20 times and were shown to be well above the level of mutation expected 
from PCR-based errors alone. Indeed, the assumption that these mutations are genuine 
is made more likely by the fact that the 11% error rate of a single pass in SMRT 
sequencing is predominantly due to indel errors (Carneiro et al., 2012). Upon closer 
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inspection, this difference was a result of hundreds of mutation gains and losses, and so 
it is difficult to establish whether the difference in mutation frequency between these 
two samples is due anything other than random fluctuations of observed mutations in a 
given sample. The data here clearly show strong evidence of mutation in recombinant 
plasmid DNA, which are most likely a result of DNA replication errors. Generally, it 
would appear that there is no evidence to strongly suggest that mutation is anything 
other than randomly distributed across the plasmid, with genetic elements and non-
coding regions showing no observable difference in mutation frequency. Mutations 
were observed in all genetic elements other than the polydenylation signal sequence 
(HSV_TK_PolyA) for the Kanamycin / Neomycin resistance gene, which could be a 
result of sequence conservation through natural selection. On the other hand, this 
sequence is only 19 bp long and may not have been mutated due to the random 
distribution of mutations across the length of the plasmid. MCS sequences appeared to 
be mutated to a greater extent than other sequences, but again, this could be down to 
chance. There was a clear bias in the type of mutation seen in these samples. G and C 
residues (~85%) were mutated to a far greater extent than A and T residues (~15%). In 
the low generation sample G.C à A.T (19.22%, 24.9%) transitions and G.C à T.A 
(22.6%, 18.54%) transversions were the predominant mutations observed, whereas in 
the high generation sample the G.C à A.T (29.69%, 29.3%) transitions became more 
predominant than G.C à T.A (11.91%, 11.13%) transversions. A and T residue 
changes also showed a higher level of transition mutation than transversion mutation. 
The rates of mutation type seen here are in line with mutation occurrences reported in 
other mammalian cells, both as a result of genome replication and pre-integration 
mutation (Dejong et al., 1988, Gojobori et al., 1982, Hauser et al., 1987).  
 
The observed point mutations were then used to determine the subsequent amino acid 
sequences of the Kan / Neo and GFP ORFs. The Kan / Neo ORF was subject to 138 and 
81 mutations, of which 76% and 67% were non-synonymous changes, for low and high 
generation numbers respectively. The GFP ORF was subject to 153 and 77 mutations, 
of which 75% and 71% were non-synonymous changes, for low and high generation 
numbers respectively. Generally speaking, in most mutation studies the rate of 
synonymous mutation is far higher than the rate of non-synonymous mutation, because 
non-synonymous mutations are likely to be deleterious and as such are selected against 
evolutionarily. On the other hand synonymous mutations are neutral, or at least nearly 
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neutral, and so their rate of prevalence and fixation is subject only to random genetic 
drift (Nei and Gojobori, 1986, Kimura, 1979). Indeed, a recent study into CHO cell 
SNPs revealed that only 0.15% of discovered SNPs were non-synonymous (Lewis et 
al., 2013). The raw probabilities of the occurrence of non-synonymous and synonymous 
mutations are 76% and 24% respectively. The mutations identified in this study seem to 
adhere closely to the raw probabilities of non-synonymous and synonymous mutation 
occurrence and are apparently not being affected by natural selection. This is most 
likely explained by the extremely low frequency that these mutations reside within the 
total population. It is likely that many of the cells harvested for recombinant plasmid 
contain more than one copy of plasmid DNA, because these cells are more likely to 
have been included in the high producers that were selected during FACS. Therefore, if 
one of these copies contained a non-synonymous point mutation, any deleterious affects 
could be compensated by other gene copies. Moreover, after these sorting events the 
only genes on which a selection pressure is imposed code for elements influencing cell 
growth.  Therefore, after FACS, changes to the GFP ORF are not influenced by natural 
selection. In theory, the Kan / Neo ORF sequence should be constantly fixed by natural 
selection, because it is essential to the growth and survival of the cell in G418 media. 
However, as was shown during stable cell line generation, G418 selection was not 
sufficient for cell line selection. Either, cells had become resistant to G418 irrespective 
of plasmid copies or the resistance achieved by a proportion of cells could provide 
resistance to many of the remaining cells of the population. This could due to resistance 
protein secretion. Therefore, as long as there is plentiful supply of resistance protein 
within the population, cells can tolerate deleterious mutations.  
 
In summary, this study has shown that ~25% of the plasmid copies used in this study 
were mutated over long-term cell culture and that there was no evidence of mutation 
occurring before integration. Due to their low frequency, natural selection does not 
impact strongly on the prevalence or fixation of these mutations, which means they can 
reside anywhere along the length of the plasmid and result in non-synonymous changes 
more often than would be expected (~72% of the time). G and C residues were found to 
be mutated more frequently than A and T residues, with G.C à A.T transitions being 
predominant. This appears to be in line with mutation patterns that have been found to 
occur in other studies into mammalian cell mutation. The novel analysis platform used 
in this study adeptly identified mutations at a resolution beyond what is generally 
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reported in NGS studies, using careful and logical elimination wherever possible. Due 
to the necessity for high resolution accuracy is sacrificed, despite this error elimination. 
However, the conclusions here were made using trends on the dataset as a whole, which 
adds a certain level of confidence to the findings. This study has confirmed the need for 
sequence variant screens in cell line development. Despite the success of this high-
resolution platform, it is far more practical in terms of cost and time to screen clonal cell 
line candidates, which need lower resolution sequencing technologies. However, this 
platform could find other avenues for application, such as checking the homogeneity of 
gene therapy DNA stocks or for a higher resolution analysis of cancer genetic 
heterogeneity. 
 
5.3.2. Future Work 
 
The DNA sequencing secondary analysis platform outlined in this chapter has been 
shown to effectively detect extremely rare mutations. However, there are experiments 
that could be carried out to further validate its efficacy. The calculations to rule out 
PCR-based error in this study showed that the mutation detected in the low and high 
genomic samples was genuine. However, a plasmid stock negative control, which has 
undergone PCR would more effectively quantify the exact level of PCR-based error that 
made it through the error filters put in place. Changes to the PCR process, such as the 
use of less PCR cycles or the use of a more high fidelity DNA polymerase, such as Q5 
polymerase (New England Biolabs, UK), would also help quantify this source of error 
more accurately. 
 
Further validation of this platform could be carried out through mutagenesis studies, 
whereby DNA mutations are deliberately induced to different extents, using techniques 
such as UV radiation or error-prone DNA polymerases. Different samples would have 
different levels of random mutation, which, in theory, should be quantified using this 
analysis platform. Moreover, a study could be conducted using a similar format to 
(Spencer et al., 2014), in which a DNA template is synthesised with a range of known 
mutations along its length in comparison to the non-mutated reference. Through 
dilution, samples are then made from these sequences, with varying proportions of the 
mutated version. This would offer a precise evaluation of platform accuracy. Although 
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this would not involve the discovery of unknown mutations, it would offer a more 
accurate insight into the top end of resolution that can be achieved using this platform.   
 
A mutation detection analysis of the dataset used in this study with the Pacific 
Bioscience variant caller would provide an accurate evaluation of the difference in 
resolution between the platform devised in this study and the standard platform used for 
SMRT sequencing. 
 
As discussed in this chapter, the experimental setup in this study may not have been 
sufficient to identify mutations that were caused as a result of DNA damage before 
plasmid integration into the host genome, because the DNA used was unreplicated and 
was subjected to DNA repair before sequencing. A future study could consist of 
purifying plasmid DNA from CHO cells as it was done in this chapter, but then 
transforming the DNA into E. coli DH5α cells for replication, which was shown to be 
relatively error-free in the sequencing of the plasmid stock sample. If multiple clones 
from this transformation were pooled together to prepare DNA for sequence then a large 
collection of these putative mutations could be detected. 
 
Finally, as was discussed in this chapter, it is difficult to discern whether an individual 
mutation discovered in this study is genuine or a result of sequencing or PCR-based 
error. To characterise genuine mutations, a number of clones or extremely diluted 
cultures could be generated from the working cell banks of the low and high generation 
stable GFP cell line samples. These clones / cultures would contain a much smaller 
number of plasmid versions compared to the whole cell population. Sequencing of the 
plasmid DNA derived from these cultures would lead to the identification of genuine 
mutations, because they are present at a much higher frequency. 
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Chapter 6 
 
Concluding Remarks 
 
This chapter will give a brief summary of the findings, conclusions and the impact of the 
work presented in this thesis. 
 
 
6.1. Chapter 3 – Genomic Instability 
 
Genetic instability is an inherent feature of CHO cells lines. The lack of evolutionary 
constraint within the cell culture environment leads to genetic drift within the CHO 
genome, whereby genomic sequences that do not directly influence growth 
characteristics are not heavily influenced by natural selection in terms of their 
consistency through generations of cell culture (Kim et al., 2011, Kimura, 1955, 
Kimura, 1979). Therefore allele frequencies will gradually change and the propagation 
of, potentially detelerious, genetic changes is more likely. This instability means that 
CHO cells can be moulded into cell factories with a range of desirable phenotypes, 
which is put to good use through evolution and engineering strategies in the generation 
of commercial cell lines (Sinacore et al., 2000, Prentice et al., 2007). However, this 
phenotype, whilst desirable for these evolutionary strategies, becomes problematic in 
the long-term cell culture of productive cell lines. Phenotypic drift causes these 
desirable cell lines to deviate from the phenotypes by which they were once selected. 
Indeed, this instability means that it is difficult to maintain consistent phenotypes for the 
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duration of the production process. Despite undergoing cloning procedures, cell 
heterogeneity an inherent feature of CHO cell lines, which often leads to a decline in 
productivity and concerns over product quality (Barnes et al., 2006, Kim et al., 2011, 
Ren et al., 2011, Davies et al., 2013). CHO cells have been said to have a mutator 
phenotype (Kim et al., 2011), which has been shown to be the case at the chromosome 
level (Yoshikawa et al., 2000, Derouazi et al., 2006), through recombinant gene copy 
loss (Kim et al., 2011), and at the base pair level through the appearance of sequence 
variants and a plethora of SNPs (Zhang et al., 2015, Lewis et al., 2013). If 
understanding of these genetic changes was further elucidated, then there could be 
potential for engineering strategies to generate more stable cell lines, such as to bolster 
proof reading capabilities or to select slower adapting cell lines in an attempt to select 
for genetic fidelity. On the other hand, instability may not be trait of cells in culture that 
is easy, or even possible, to eliminate. In this case, efficient screening tools to quickly 
identify unstable or error-containing cells lines may be able to eliminate candidate cell 
lines from production pipelines. In this chapter genetic instability was measured at the 
base pair level, via microsatellite analysis and at the chromosomal level via karyotype 
analysis.  
 
The microsatellite analysis showed the slow, progressive change in allele frequencies by 
genetic drift and allowed for the relatedness of cell lines to be established through 
microsatellite allele similarities and differences. There was an indication, but no 
conclusive evidence, of a physical change to microsatellite length through replication 
slippage. Therefore, it could not be concluded that this selection of microsatellites were 
able to be used as a successful marker for changes at the base pair level. There was no 
correlation between cell line genetic drift and changes in cell specific productivity. 
Microsatellites differed in their level of change, which shows that different genomic loci 
are more changeable than others. For microsatellite analysis to be validated as a useful 
marker and screening tool for base pair level genetic instability and drift, a greater 
number of microsatellites, spanning the whole genome, at a high resolution would need 
to be used. 
 
Karyotype analysis revealed that chromosomal instability is substantial, with changes in 
chromosome number and chromosome breakage / fusion events both contributing to 
this instability. Over long-term cell culture 70% of cell lines were shown to change in 
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karyotype, which included the generation of 18 chromosome types that were not seen in 
parental cell lines. Karyotype analysis is not quantitative, so we were unable to establish 
whether chromosomal instability correlated with observed changes to cell specific 
productivity. Some chromosomes or chromosomal regions, such as chromosome 1, 
remained unaltered for the duration of the study, which could be due to an evolutionary 
conservation effect. Perhaps targeted integration to these, stable, regions might lead to 
greater phenotypic stability in important production process attributes. Again, further 
study here may lead to evolution, engineering or screening / selection strategies to 
facilitate the use of more stable cell lines for production pipelines. 
 
6.2. Chapter 4 – Electroporation Optimisation 
 
Chapter 4 presented a complete optimisation of plasmid DNA delivery into CHOK1SV 
cells by electroporation. Electroporation is a key part of the bioprocess, because it 
marks the start point of the generation of a stably producing cell line. It is also used in 
bioprocess development, whereby new therapeutics are tested for performance attributes 
in transient production platforms (Jayapal et al., 2007, Wurm, 2004, Makrides, 1999). 
Therefore, techniques that deliver the ability to fine tune this process for the bespoke 
requirements of any given therapeutic production platform could be put to good use in 
an academic or industrial setting. The need for bespoke parameters become apparent 
when comparing the requirements of different stages of bioprocesses. For example, in 
the generation of a stable cell line an increase in plasmid copy numbers entering the cell 
could lead to an increased number of integration events, which in turn could lead to a 
greater probability of generating high producing cell lines from a cloning procedure.  
Moreover, with TGE, increasing the number of plasmid copies entering the cell will 
increase the level of plasmid copies capable of gene expression. However, during the 
SGE process, cells are allowed the time to recover from electroporation during 
recombinant cell selection and enrichment, whereas in transient platforms cells are 
required to achieve high culture densities and productivities immediately (Wurm, 2004, 
Rita Costa et al., 2010). Therefore, optimum TGE platforms will require higher levels of 
cell viability and growth post-electroporation, whereas a lag time in electroporation 
recovery might be a worthwhile sacrifice in SGE platforms. Moreover, cells are 
typically transfected with linear DNA for the generation of stable cell lines, whereas 
TGE is carried out with circular plasmid. Linear DNA is more difficult to transfect, and 
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so electroporation parameters will likely differ between the two platforms (Schmidt et 
al., 2004).  
 
When optimising a bioprocess for a new therapeutic candidate, in many cases a number 
of variables will differ compared to other therapeutics, such as vector elements and size, 
cell type, product expression and product impact on growth and viability (Wurm, 2004, 
Jordan et al., 2007, Jordan et al., 2008, Kim et al., 2011). Therefore, an electroporation 
optimisation platform that enables the quick and easy assessment of protocol 
permutations will allow for the easy implementation of bespoke conditions for each new 
candidate. This study clearly provides such a platform. Using a simple DoE strategy, a 
range of parameters (310 – 320 V, 25-28 ms, exponential day time constant protocol) 
resulting in positive range of transfection response activity, was discovered for the 
phCMV C-GFP plasmid being used.  After this range was tested experimentally, one 
parameter setting was clearly seen to offer the best response (320-26). These conditions 
resulted in an improvement of 17% transfection efficiency, which was achieved without 
greatly sacrificing on the health of the transfected cells. These optimised conditions 
were shown to be successful in chapter 5 when generating a stable cell line for DNA 
sequencing analysis. Not only were conditions improved, but a DoE analysis allowed 
for the interactive nature of the different electroporation parameters to be identified. 
Indeed, field strength, pulse length and DNA load were all found to interact in their 
effect on the transfection response. Moreover, the relationship between transfection 
efficiency and cell viability was reasonably well defined, to the extent that cell viability 
alone was able to successfully predict a design space that would yield a high level of 
gene expression. If this work was to be taken further, whereby a number of different 
protein products, cell types and DNA vectors were used then, not only would the 
relationships discussed in this study be more acutely understood, but a certain level of 
predictability may be possible for the optimisation of future platforms. For example, the 
optimisation process for a new therapeutic gene, contained within a well defined vector 
of a particular size, being transected into a well characterised cell type could be started 
within a much narrower range of electroporation parameters, because a model-based 
information repository could accurately provide the predicted parameter range that 
would yield positive results. Indeed, this narrow range of parameters may only need to 
be assessed using a cell viability output, because the relationship between cell viability 
and gene expression could be characterised to the extent that it is completely predictive. 
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A scenario such as this would lead to a high-throughput and cost-effective platform for 
electroporation optimisation. 
 
6.3 Chapter 5 – Recombinant DNA Sequence Analysis 
 
Regulatory bodies require that the therapeutics produced by bioprocess platforms are of 
a certain quality. Therefore, product variants, such as aggregates, charge variants, 
glycosylation variants and sequence variants must be reduced to minimal levels, 
because of concerns over product safety and efficacy (Zhang et al., 2015, Ren et al., 
2011, Zhu, 2012). As discussed in chapter 4, genetic instability is a regularly observed 
phenomenon in CHO cells, and this is seen to manifest in point mutations. These point 
mutations have been shown to occur in recombinant DNA (Zhang et al., 2015) and in 
CHO genomic DNA, through the appearance of SNPs (Lewis et al., 2013). Non-
synonymous point mutations in recombinant DNA cause sequence variants, which 
result in unwanted heterogeneous protein products. Mostly, these sequence variants 
have been identified at the protein level, and traced back to DNA sequence changes 
(Zeck et al., 2012, Victoria et al., 2010). Zhang et al. (2015) used NGS to identify DNA 
point mutations without prior knowledge of protein sequence changes, but this was only 
carried out in clonal or diluted cell populations. Therefore, only a small range of 
mutations were identified, and so detailed information on mutation position, type and 
raw frequency is lacking. The reported resolution of NGS does not allow for analysis on 
non-diluted or non-clonal cell populations, because mutations need to be at a certain 
frequency within a DNA sample to be detected (Spencer et al., 2014, Dilernia et al., 
2015).   
 
In this study SMRT sequencing was used with an altered analysis platform, in which 
high-coverage CCS reads were used in order to generate information on point mutations 
from individual molecules. Various filtering strategies were employed to eliminate 
error-prone ROIs and individual nucleotide reads. One point mutation, a C à T 
transition in the bacterial origin of replication, was found to be present at high levels in 
all samples, which was presumed to have been present in the initial plasmid stock 
received from the manufacturer, or was a result of a point mutation occuring in an early 
generation of bacterial cloning. Other than this mutation, it was concluded that plasmid 
stocks showed no substantial evidence of mutation. The low frequency changes 
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observed in the plasmid stock sample were used as a base level of error for this 
sequencing analysis platform. There was no evidence of mutation in samples derived 
from transfected, non-integrated, plasmid DNA. However, further investigation might 
reveal that DNA is damaged within this pre-integration period, but converted into a 
mutation upon DNA replication, and so would not be called as a mutation in the 
experimental platform used here. Other studies have shown that point mutation of 
plasmid DNA within this period does occur in mammalian cells (Hauser et al., 1987, 
Lebkowski et al., 1984), so this might be a worthwhile avenue for research. A 
substantial level of low-frequency point mutation was covered after sequencing 
recombinant DNA, sampled from two time points in long-term cell culture. On average, 
25% of 5 kb plasmid molecules were found to contain at least one point mutation. 
Mutations were found to be randomly distributed along the length of the plasmid 
sequence, showing no bias towards coding or non-coding localisation.  85% of point 
mutations occurred with G and C nucleotides, with G.C à A.T transitions being the 
predominant type of change observed. This bias is in line with mutation frequency 
observations of mammalian cell DNA replication (Dejong et al., 1988, Gojobori et al., 
1982). On average, within the two plasmid open reading frames, Kan / Neo and GFP, 
72.25% of mutations were non-synonymous. This proportion of non-synonymous 
mutations is in line with the raw probability of a non-synonymous mutation occurring, 
rather than with the proportion of non-synonymous mutations found in nature (Lewis et 
al., 2013). The results presented here indicate that natural selection does not greatly 
impact upon these low-frequency point mutations, but rather that their existence and 
prevalence is random.  
 
Overall, this chapter showed the preliminary validation of a novel SMRT sequencing 
secondary analysis platform in the identification of low-frequency mutations from 
individual DNA molecules. This validation could be built upon with a small set of 
quantitative controls. Moreover, protein sequence variant-causing DNA point mutations 
were characterised at a frequency and resolution that, to our knowledge, has not been 
seen previously. 
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6.4 Future Directions for Genetic Instability 
 
As has been discussed throughout this thesis, genetic instability of CHO cells poses a 
threat to cell line development processes and biopharmaceutical production. This 
instability causes phenotypic drift in cell lines that have been carefully selected for 
attributes suitable for bioprocesses, such as fast growth rates and high productivity. 
Instability, gives rise to heterogeneous cell populations, which is clearly an undesirable 
trait for a ‘clonal’ cell line. One form of phenotypic drift commonly encountered is a 
decline in cell productivity over long-term cell culture (Wurm, 2004). This has been 
shown to be due to epigenetic changes as well as genetic changes, such as changes in 
recombinant gene copy number (Kim et al., 2011). The seemingly random nature of a 
cell line’s disposition to decline in productivity makes it extremely difficult, if not 
impossible, to predict. Moreover, it is not the case that genetic instability can be traced 
back to a specific point mutation in DNA replication / repair machinery or a common 
chromosome breakage, but rather genetic instability seems to be an almost inevitable 
global attribute of an immortalized cell line and so prediction or elimination of genetic 
instability is not straightforward. This is because an immortalized cell line growing in 
culture is almost in a state of evolutionary freefall, whereby the only genes to be 
monitored by natural selection are those which contribute to growth and cell division. 
Other genes, which do not directly impact upon growth and division, are neutral, or at 
least nearly neutral, in the context of evolution and so are relatively free to change. 
Therefore, continuous cell culture facilitates an environment in which DNA replication 
becomes a process that is not constrained to high standards of fidelity and so over time 
DNA replication becomes an error-prone process and genetic change is commonplace 
(Kimura, 1955, Kimura, 1979). Conceivably, this process is quickened by cell line 
evolution and engineering strategies guide cells towards desirable attributes, such as 
growth, productivity, growth in serum-free media, and adaptation to growth in a late-
stage culture environment (Sinacore et al., 2000; Prentice et al., 2007). This is because 
genetic instability is likely to also be a heterogeneous phenotype and so when a 
particular cell is selected for a desirable trait it is because that cell has changed 
genetically to present this phenotype. Therefore, genetic change is being selected for 
and so the process of selection is likely to increase the likelihood of a genetic instability 
phenotype. It is perhaps unsurprising that these types of cells would lose the ability to 
produce recombinant protein, because these cells are simply adapting towards a more 
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desirable phenotype, such that they are able to thrive and grow in a given environment 
without the metabolic burden of producing a complex protein, such as a Mab (Kim et 
al., 2011). 
 
The karyotype analysis in chapter 3 and sequencing analysis in chapter 5 illustrate the 
high frequency and randomness of this genetic instability phenotype at the 
chromosomal and sequence level respectively. It seems unfeasible that such a global 
and consistent phenomenon could be targeted by any direct genetic engineering strategy 
that might attempt to reconstitute a cells ability to accurately segregate chromosomes 
upon cell division, limit chromosome form changes or increase the fidelity of DNA 
replication, because it is likely to be a phenotype that has a different origin in any given 
case and is likely to persist regardless of any tinkering to gene content. It seems far 
more pertinent to try and development genetically stable cell populations through 
selection strategies, because selection, as opposed to engineering, is likely to draw upon 
a whole-cell-based solution. Of course, the ability to select for a pool of genetically 
stable cells would depend upon a set of robust selection markers for genetic stability. 
One such marker, as proven in chapter 3, is cell karyotyping (Derouazi et al., 2006). 
Selection for cells that are less changeable in their karyotype could be a method for 
generating cell populations better able to maintain a homogenous cell number and that 
are less subject to changes in chromosome form. As well as a method for generating 
novel, genetically stable cell lines, periodic karyotype screens during cell line 
development could serve as a quality control step to prevent or detect the onset of 
chromosomal instability. Chapter 5 showed that NGS can serve as a selection marker 
for the fidelity of DNA replication and DNA damage repair. Perhaps a strategy 
involving the selection of cell populations containing fewer of the low frequency 
mutations detected in this study would serve to generate cell populations with an 
improved accuracy in DNA replication. Moreover, sequencing throughout cell line 
development could serve as a useful supplementary tool for protein sequencing methods 
to ensure that product quality is maintained. Despite progress being made in enabling 
high-throughput sequencing of recombinant DNA at a cheaper price (Zhang et al., 
2015), NGS is an expensive and relatively time consuming process and so development 
of cheaper tools, using markers that could stand as proxy for point mutation would 
make this a much more feasible ambition. Chapter 3 attempted to do this using 
microsatellite analysis, but was unable to prove its worth as a marker for genomic 
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instability. However, as mentioned in section 3.3.4 further investigation with a larger 
number of microsatellites, or microsatellites within a recombinant plasmid may be more 
informative.  
 
As mentioned above, it is could be the case that genetic instability within CHO cell 
lines is an inevitable bi-product of continuous cell culture and so perhaps attempts to 
generate cell lines that have a higher level of inherent stability is a futile exercise. 
Therefore, perhaps a more promising direction would be to accept the unstable 
landscape of the CHO genome and try to work around it. For example, the karyotype 
analysis in chapter 3 found that chromosome 1 was unchanged throughout the study and 
it was postulated that this likely to be because it contains essential genes. There is 
progress being made into targeted integration of plasmid DNA into genomic sites that 
are more likely to facilitate high gene expression (Wurm, 2004). Perhaps attempts to 
target genetically stable sites would lead to the development of cell lines more likely to 
maintain consistent productivity over long-term cell culture. Strategies like this, in 
combination with regular quality control measures, such as the karyotype and sequence 
screens mentioned above, would help to decrease genomic instability manifesting in 
changes to product yields or quality. 
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Table A1: Sample Volume Transfection Efficiency Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS. 
 
 
 
 
 
 
 
 
 
Table A2: Sample volume Transfection Efficiency ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
Figure A1: Sample Volume Transfection Efficiency Normal Plot of Residuals 
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Table A3: Sample Volume Cell Viability Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
Table A4: Sample volume Cell Viability ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
Figure A2: Sample Volume Cell Viability Normal Plot of Residuals 
Design-Expert® Software
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Table A5: Exponential Decay: Wide – Transfection Efficiency Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A6: Exponential Decay: Wide – Transfection Efficiency ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3: Exponential decay: Wide – Transfection Efficiency Normal Plot of 
Residuals 
Design-Expert® Software
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Figure A4. Exponential Decay: Wide – Transfection Efficiency Response Surface 
Response surfaces of the transfection efficiency response to changes in field strength 
and pulse length at different levels of DNA load: Low Factorial (A), Center point (B) 
and Upper Factorial (C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) DNA load: 41.34 ug/ml B) DNA load: 100.5 ug/ml 
C) DNA load: 159.66 ug/ml 
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Table A7: Exponential Decay: Wide – Median Fluorescence Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A8: Exponential Decay: Wide – Median Fluorescence ANOVA table 
Table of ANOVA output statistical terms and values. 
Appendix  
	 215	
 
 
Figure A5. Exponential Decay: Wide – Median Fluorescence Data Manipulation 
The figure shows the identification of non-normality (A) and the outlier responsible (B) 
as highlighted by a data point falling outside of a threshold level difference (red line). 
The Box-Cox plot (C) highlights a recommended transformation (green line). After 
ignoring the outlier and transformation the data residuals are normally distributed (D). 
 
A B 
C D 
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Figure A6. Exponential Decay: Wide – Median Fluorescence Response Surface 
Response surfaces of the median fluorescence response to changes in field strength and 
pulse length at different levels of DNA load: Low Factorial (A), Center point (B) and 
Upper Factorial (C). 
 
A) DNA load: 41.34 ug/ml B) DNA load: 100.5 ug/ml 
C) DNA load: 159.66 ug/ml 
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Table A9: Exponential Decay: Wide – Cell Viability Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A10: Exponential Decay: Wide – Cell Viability ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7: Exponential decay: Wide – Cell Viability Normal Plot of Residuals 
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Figure A8. Exponential Decay: Wide – Cell Viability Response Surface 
Response surfaces of the cell viability response to changes in field strength and pulse 
length at different levels of DNA load: Low Factorial (A), Center point (B) and Upper 
Factorial (C).  
 
A) DNA load: 41.34 ug/ml B) DNA load: 100.5 ug/ml 
C) DNA load: 159.66 ug/ml 
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Table A11: Exponential Decay: Wide – ACD Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A12: Exponential Decay: Wide – ACD ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure A9: Exponential decay: Wide – ACD Normal Plot of Residuals 
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Figure A10. Exponential Decay: Wide – ACD Response Surface 
Response surfaces of the ACD response to changes in field strength and pulse length at 
different levels of DNA load: Low Factorial (A), Center point (B) and Upper Factorial 
(C).  
 
C) DNA load: 159.66 ug/ml 
B) DNA load: 100.5 ug/ml A) DNA load: 41.34 ug/ml 
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Table A13: Square Wave: Wide – Transfection Efficiency Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A14: Square Wave: Wide – Transfection Efficiency ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
Figure A11: Square Wave: Wide - Transfection Efficiency Normal Plot of 
Residuals 
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Figure A12. Square Wave: Wide – Transfection Efficiency Response Surface 
Response surfaces of the transfection efficiency response to changes in field strength, 
pulse length, at different levels of DNA load (A&B, C&D, E&F) and with one (A,C,E) 
or two (B,D,F) pulses. 
2 Pulses	 1 Pulse	 
DNA load: 41.34 ug/ml 
 DNA load: 100.5 ug/ml 
 DNA load: 159.66 ug/ml 
B A 
C D 
E F 
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Table A15: Square Wave: Wide – Cell Viability Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A16: Square Wave: Wide – Cell Viability ANOVA table 
Table of ANOVA output statistical terms and values. 
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Figure A13. Square Wave: Wide – Cell Viability Data Manipulation 
The figure shows the identification of non-normality (A) and the outlier responsible (B) 
as highlighted by a data point falling outside of a threshold level of residual (red line). 
The Box-Cox plot (C) highlights a recommended transformation (green line). After 
ignoring the outlier and the power transformation the data is normal (D). 
A B 
C D 
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Figure A14. Square Wave: Wide – Cell Viability Response Surface 
Response surfaces of the cell viability response to changes in field strength, pulse 
length, at different levels of DNA load (A&B, C&D, E&F) and with one (A,C,E) or two 
(B,D,F) pulses. Transformation had to be carried out manually, so the Y-axis is the 
transformed data scale.  
 
2 Pulses	 1 Pulse	 
DNA load: 41.34 ug/ml 
 DNA load: 100.5 ug/ml 
 DNA load: 159.66 ug/ml 
B A 
C D 
E F 
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Table A17: Exponential Decay: Narrow – Transfection Efficiency Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A18: Exponential Decay: Narrow – Transfection Efficiency ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A15: Exponential Decay: Narrow – Transfection Efficiency Normal Plot of 
Residuals 
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Table A19: Exponential Decay: Narrow – Median Fluorescence Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A20: Exponential Decay: Narrow – Median Fluorescence ANOVA table 
Table of ANOVA output statistical terms and values. 
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Figure A16. Exponential Decay: Narrow – Median Fluorescence Data 
Manipulation 
The figure shows the identification of non-normality (A) and the outlier responsible (B) 
as highlighted by a data point falling outside of a threshold level of residual (red line). 
The Box-Cox plot (C) highlights a recommended transformation (green line). After 
ignoring the outlier and transformation the data is normal (D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
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Table A21: Exponential Decay: Narrow – Cell Viability Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A22: Exponential Decay: Narrow – Cell Viability ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A17: Exponential Decay: Narrow – Cell Viability Normal Plot of Residuals 
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Table A23: Exponential Decay: Narrow – ACD Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
Table A24: Exponential Decay: Narrow – ACD ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A18: Exponential Decay: Narrow – ACD Normal Plot of Residuals 
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Table A25: Square Wave: Narrow – Transfection Efficiency Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A26: Square Wave: Narrow – Transfection Efficiency ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A19: Square Wave: Narrow – Transfection Efficiency Normal Plot of 
Residuals 
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Table A27: Square Wave: Narrow – Median Fluorescence Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table A28: Square Wave: Narrow – Median Fluorescence ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A20: Square Wave: Narrow – Median Fluorescence Normal Plot of 
Residuals 
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Table A29: Square Wave: Narrow – Cell Viability Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A30: Square Wave: Narrow – Cell Viability ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A21: Square Wave: Narrow – Cell Viability Normal Plot of Residuals 
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Table A31: Square Wave: Narrow – ACD Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A32: Square Wave: Narrow – ACD ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A22: Square Wave: Narrow – ACD Normal Plot of Residuals 
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Table A33: Exponential Decay: Narrow 2 – Transfection Efficiency Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A34: Exponential Decay: Narrow 2 – Transfection Efficiency ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A23: Exponential Decay: Narrow 2 – Transfection Efficiency Normal Plot 
of Residuals 
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Table A35: Exponential Decay: Narrow 2 – Median Fluorescence Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS. 
 
 
 
 
 
 
 
 
 
 
 
 
Table A36: Exponential Decay: Narrow 2 – Median Fluorescence ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A24: Exponential Decay: Narrow 2 – Median Fluorescence Normal Plot of 
Residuals 
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Table A37: Exponential Decay: Narrow 2 – Cell Viability Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A38: Exponential Decay: Narrow 2 – Cell Viability ANOVA table 
Table of ANOVA output statistical terms and values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A25: Exponential Decay: Narrow 2 – Cell Viability Normal Plot of 
Residuals 
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Table A39: Exponential Decay: Narrow 2 – ACD Fit Summary 
Showing suggested model fit summary data for A) SMSS, B) Lack of fit and C) MSS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A40: Exponential Decay: Narrow 2 – ACD ANOVA table 
Table of ANOVA output statistical terms and values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A26: Exponential Decay: Narrow 2 – ACD Normal Plot of Residuals 
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MS Passage Allele W-statistic P-value Normally_Distributed 
BAT25 High 1 0.895646285 0.034199133 FALSE 
 GNAT High 1 0.955992723 0.467212562 TRUE 
 GT23 High 1 0.971771309 0.588696645 TRUE 
 MS.10.1 High 1 0.936382757 0.204689835 TRUE 
 MS.11.1 High 1 0.899093069 0.055405989 TRUE 
 MS.21.1 High 1 0.994787502 0.999987622 TRUE 
 BAT25 Low 1 0.96528812 0.653911998 TRUE 
 GNAT Low 1 0.980223251 0.936951501 TRUE 
 GT23 Low 1 0.95515801 0.2318533 TRUE 
 MS.10.1 Low 1 0.897088704 0.036380816 FALSE 
 MS.11.1 Low 1 0.984519137 0.984522183 TRUE 
 MS.21.1 Low 1 0.978412725 0.91199442 TRUE 
 BAT25 High 2 0.997320982 0.999999986 TRUE 
 GNAT High 2 0.953212688 0.418500308 TRUE 
 GT23 High 2 0.927206732 0.041412929 FALSE 
 MS.10.1 High 2 0.94470569 0.293768813 TRUE 
 MS.11.1 High 2 0.985465071 0.98880964 TRUE 
 MS.21.1 High 2 0.968981519 0.733234678 TRUE 
 BAT25 Low 2 0.944752948 0.294362489 TRUE 
 GNAT Low 2 0.948800272 0.349245936 TRUE 
 GT23 Low 2 0.976101988 0.715171958 TRUE 
 MS.10.1 Low 2 0.952588214 0.408093338 TRUE 
 MS.11.1 Low 2 0.901202793 0.060299815 TRUE 
 MS.21.1 Low 2 0.949498502 0.359541652 TRUE 
 BAT25 High 3 0.973529861 0.82695169 TRUE 
 GNAT High 3 0.961268927 0.569501156 TRUE 
 GT23 High 3 0.986332045 0.957634808 TRUE 
 MS.10.1 High 3 0.761632736 0.000244157 FALSE 
 MS.11.1 High 3 0.942050863 0.314051686 TRUE 
 MS.21.1 High 3 0.97229543 0.802428827 TRUE 
 BAT25 Low 3 0.949802048 0.364094987 TRUE 
 GNAT Low 3 0.971701901 0.790342261 TRUE 
 GT23 Low 3 0.947660783 0.1463017 TRUE 
 MS.10.1 Low 3 0.990947843 0.999047513 TRUE 
 MS.11.1 Low 3 0.989889003 0.998695 TRUE 
 MS.21.1 Low 3 0.97305754 0.817676017 TRUE 
 BAT25 High 4 0.924725022 0.122193565 TRUE 
 GT23 High 4 0.980311649 0.833781078 TRUE 
 MS.10.1 High 4 0.883302838 0.020295718 FALSE 
 MS.11.1 High 4 0.991767305 0.999688775 TRUE 
 BAT25 Low 4 0.940775101 0.247997664 TRUE 
 GT23 Low 4 0.940063733 0.091318917 TRUE 
 MS.10.1 Low 4 0.933929475 0.183729819 TRUE 
 MS.11.1 Low 4 0.981347061 0.962832437 TRUE 
 GT23 High 5 0.969105742 0.515004932 TRUE 
 MS.11.1 High 5 0.980370064 0.953750386 TRUE 
 GT23 Low 5 0.949635713 0.165302526 TRUE 
 MS.11.1 Low 5 0.971079941 0.817737857 TRUE 
 GT23 High 6 0.978254395 0.77748186 TRUE 
 MS.11.1 High 6 0.988504169 0.997050654 TRUE 
 GT23 Low 6 0.92262145 0.031384188 FALSE 
 MS.11.1 Low 6 0.956221066 0.530639633 TRUE 
  
Table A41: Shapiro Wilk Test for Normality 1 
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MS Passage Allele W-statistic P-value Normally_Distributed 
BAT25 High 1 0.914534023 0.077807028 TRUE 
 GNAT High 1 0.955992723 0.467212562 TRUE 
 GT23 High 1 0.971771309 0.588696645 TRUE 
 MS.10.1 High 1 0.940145989 0.241308698 TRUE 
 MS.11.1 High 1 0.899093069 0.055405989 TRUE 
 MS.21.1 High 1 0.994787502 0.999987622 TRUE 
 BAT25 Low 1 0.96528812 0.653911998 TRUE 
 GNAT Low 1 0.980223251 0.936951501 TRUE 
 GT23 Low 1 0.95515801 0.2318533 TRUE 
 MS.10.1 Low 1 0.990640822 0.993910437 TRUE 
 MS.11.1 Low 1 0.984519137 0.984522183 TRUE 
 MS.21.1 Low 1 0.978412725 0.91199442 TRUE 
 BAT25 High 2 0.997320982 0.999999986 TRUE 
 GNAT High 2 0.953212688 0.418500308 TRUE 
 GT23 High 2 0.96471322 0.641622583 TRUE 
 MS.10.1 High 2 0.937627722 0.216181175 TRUE 
 MS.11.1 High 2 0.985465071 0.98880964 TRUE 
 MS.21.1 High 2 0.968981519 0.733234678 TRUE 
 BAT25 Low 2 0.944752948 0.294362489 TRUE 
 GNAT Low 2 0.948800272 0.349245936 TRUE 
 GT23 Low 2 0.976101988 0.715171958 TRUE 
 MS.10.1 Low 2 0.952588214 0.408093338 TRUE 
 MS.11.1 Low 2 0.901202793 0.060299815 TRUE 
 MS.21.1 Low 2 0.949498502 0.359541652 TRUE 
 BAT25 High 3 0.973529861 0.82695169 TRUE 
 GNAT High 3 0.961268927 0.569501156 TRUE 
 GT23 High 3 0.986332045 0.957634808 TRUE 
 MS.10.1 High 3 0.944002359 0.285058017 TRUE 
 MS.11.1 High 3 0.942050863 0.314051686 TRUE 
 MS.21.1 High 3 0.97229543 0.802428827 TRUE 
 BAT25 Low 3 0.949802048 0.364094987 TRUE 
 GNAT Low 3 0.971701901 0.790342261 TRUE 
 GT23 Low 3 0.947660783 0.1463017 TRUE 
 MS.10.1 Low 3 0.990947843 0.999047513 TRUE 
 MS.11.1 Low 3 0.989889003 0.998695 TRUE 
 MS.21.1 Low 3 0.97305754 0.817676017 TRUE 
 BAT25 High 4 0.924725022 0.122193565 TRUE 
 GT23 High 4 0.980311649 0.833781078 TRUE 
 MS.10.1 High 4 0.892273963 0.029615721 FALSE 
 MS.11.1 High 4 0.991767305 0.999688775 TRUE 
 BAT25 Low 4 0.940775101 0.247997664 TRUE 
 GT23 Low 4 0.940063733 0.091318917 TRUE 
 MS.10.1 Low 4 0.933929475 0.183729819 TRUE 
 MS.11.1 Low 4 0.981347061 0.962832437 TRUE 
 GT23 High 5 0.969105742 0.515004932 TRUE 
 MS.11.1 High 5 0.980370064 0.953750386 TRUE 
 GT23 Low 5 0.949635713 0.165302526 TRUE 
 MS.11.1 Low 5 0.971079941 0.817737857 TRUE 
 GT23 High 6 0.978254395 0.77748186 TRUE 
 MS.11.1 High 6 0.988504169 0.997050654 TRUE 
 GT23 Low 6 0.95041019 0.173390193 TRUE 
 MS.11.1 Low 6 0.956221066 0.530639633 TRUE 
  
Table A42: Shapiro Wilk Test for Normality 2 
 	
 
Figure A27: GNAT2 Box Plots for Allele Percentage 
 	
 
Figure A28: 10.1 Box Plots for Allele Percentage 
 	
 
Figure A29: 21.1 Box Plots for Allele Percentage 
 	
 
Figure A30: 11.1 Box Plots for Allele Percentage 
 	
 
Figure A31: GT-23 Box Plots for Allele Percentage 
 	
 
Figure A32: BAT25 Box Plots for Allele Percentage
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Microsatellite Allele 
 Variance 
Ratio P-value 
BAT25 1 1.053519542 0.910714013 
GNAT 1 1.168340239 0.738009019 
GT23 1 2.180148051 0.039847612 
MS.10.1 1 1.794863861 0.211487385 
MS.11.1 1 2.221055888 0.109459607 
MS.21.1 1 1.13393719 0.78694436 
BAT25 2 1.345976545 0.523510817 
GNAT 2 1.216823155 0.673184772 
GT23 2 1.456597188 0.316784346 
MS.10.1 2 2.089612921 0.116870231 
MS.11.1 2 2.481139237 0.069350219 
MS.21.1 2 0.983106051 0.970765138 
BAT25 3 1.178428529 0.724121937 
GNAT 3 1.203642153 0.690330612 
GT23 3 2.060195742 0.056227015 
MS.10.1 3 0.358176031 0.030520912 
MS.11.1 3 1.519576052 0.396990224 
MS.21.1 3 0.984898839 0.973890062 
BAT25 4 1.192579588 0.704995678 
GT23 4 1.610278191 0.205559438 
MS.10.1 4 1.007585909 0.987030567 
MS.11.1 4 1.091005427 0.859576507 
GT23 5 1.47114654 0.304239528 
MS.11.1 5 1.589758002 0.348423574 
GT23 6 1.692691268 0.162388698 
MS.11.1 6 2.062425191 0.145617444 
 
Table A43: F Test for Variance Comparison 
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Microsatellite Allele Cluster Variance Ratio P-value 
BAT25 1 B 6.383817457 0.010896608 
GNAT 1 B 3.792108002 0.059966717 
MS.11.1 1 B 0.055724458 0.006565282 
MS.21.1 1 B 3.526929437 0.192822575 
BAT25 2 B 1.960644011 0.330298003 
GNAT 2 B 0.816529564 0.767626887 
MS.11.1 2 B 0.034675437 0.00215426 
MS.21.1 2 B 0.437317369 0.385135243 
BAT25 3 B 1.629828318 0.478147605 
GNAT 3 B 0.959709717 0.952157213 
MS.11.1 3 B 0.028750666 0.001376396 
MS.21.1 3 B 0.200640004 0.102565016 
BAT25 4 B 7.278209634 0.006822434 
MS.11.1 4 B 0.03878704 0.002810799 
MS.11.1 5 B 0.061016215 0.008091691 
MS.11.1 6 B 0.02484157 0.000968192 
BAT25 1 A 3.02136691 0.115060971 
GNAT 1 A 0.300187716 0.087627839 
GT23 1 A 2.180148051 0.039847612 
MS.10.1 1 A 1.794863861 0.211487385 
MS.11.1 1 A 6.04734176 0.005890824 
MS.21.1 1 A 5.009211792 0.006584751 
BAT25 2 A 0.949020826 0.939151236 
GNAT 2 A 0.298619757 0.086328269 
GT23 2 A 1.456597188 0.316784346 
MS.10.1 2 A 2.089612921 0.116870231 
MS.11.1 2 A 1.183059249 0.785348098 
MS.21.1 2 A 1.881562855 0.267458264 
BAT25 3 A 0.896757427 0.873710087 
GNAT 3 A 0.247367721 0.049372885 
GT23 3 A 2.060195742 0.056227015 
MS.10.1 3 A 0.358176031 0.030520912 
MS.11.1 3 A 0.371301268 0.115100147 
MS.21.1 3 A 1.7198411 0.340459352 
BAT25 4 A 2.63592155 0.164966524 
GT23 4 A 1.610278191 0.205559438 
MS.10.1 4 A 1.007585909 0.987030567 
MS.11.1 4 A 0.868286166 0.818976664 
GT23 5 A 1.47114654 0.304239528 
MS.11.1 5 A 0.506560007 0.2746497 
GT23 6 A 1.692691268 0.162388698 
MS.11.1 6 A 3.32393671 0.058192121 
 
Table A44: F Test for Variance Comparison by Cluster 
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Microsatellite	 Cell.line	 Allele	 P	Value	
BAT25	 2	 1	 0.012674149	
BAT25	 2	 2	 0.058691898	
GT23	 2	 4	 0.012387279	
GT23	 2	 5	 0.072504019	
GNAT	 3	 3	 0.074524779	
MS.21.1	 3	 2	 0.099746573	
MS.21.1	 3	 3	 0.07776738	
GNAT	 6	 1	 0.023002864	
GNAT	 6	 2	 0.023002864	
GNAT	 6	 3	 0.023002864	
GNAT	 7	 2	 0.083405626	
GT23	 9	 3	 0.072477286	
GT23	 9	 6	 0.072477286	
MS.11.1	 9	 1	 0.056022967	
MS.11.1	 9	 2	 0.056022967	
MS.11.1	 9	 3	 0.056022967	
MS.11.1	 9	 4	 0.040308138	
MS.11.1	 9	 5	 0.056022967	
MS.11.1	 9	 6	 0.04256647	
MS.11.1	 10	 6	 0.057723343	
 
Table A45: TTEST Results (p < 0.1) 
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Figure A33: Parental Cell Line Karyotype 
Karyotype: 
19: 1,+1,2,4,5,8,9, der(X), +der(4), der(6), der(7), +der(8),+z13,+z4, +z8, +z2, +Mar1, 
+Mar2, +Mar3. 
Appendix 
	 251	
 
 
 
 
Table A46: List of Karyotypes. 
Table containing all the karyotypes seen in the investigation and which cell line / 
generation they were in. The ‘karyotype’ column presents chromosomes that differ from 
wild type hamster. In cases where there are subpopulations of a cell line with differing 
karyotypes, both are listed with a ‘/’ to separate them. Numbers at the start of each 
karyotype refer to the number of chromosomes there are. Numbers in square brackets 
show how many cells had a particular karyotype. The ‘karyotype change as compared to 
parental line’ column shows how cell lines differed from the standard CHO karyotype. 
The ‘karyotype change from late to early’ column shows differences between early and 
late generation cell lines. 
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Figure A34: Example Heavily Mutated ROI Region 
When ROIs were found to contain many mismatches, generally these matches were 
found to be within error-prone regions, containing both mismatches and indels. It was 
assumed that this phenomenon was likely to be due to sequencing error in a given ZMW 
and so a threshold filter was imposed, whereby ROIs with >3 mismatches were 
eliminated from analysis.  
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Figure A35: R scripts for the SMRT secondary analysis platform. # precedes 
explanatory information or acts to split up separate script phases. Red script 
refers to file names or directory names unique to this study and should be changed 
when using a different computer or file name. 
 
 
 
Figure A35a: The following R script is used to convert BLASR Human readable 
format output into a useable CSV file containing information regarding query 
sequence, matches, target sequence, ROI name and positional information. 
###################################################################### 
###################################################################### 
# This Script converts BLASR output into readable csv file 
# Inputs: 1) CSV file the raw output from BLASR with header limited to Query, 
QueryRange, TargetRange 
# Output: 1) CSV named in input 2 that contains the query header information and 
concatonated  
# sequences for target query and match. 
###################################################################### 
###################################################################### 
 
###################################################################### 
# Set working directory and clear the working directory and load required packages. 
setwd("/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts") 
rm (list=ls()) 
###################################################################### 
 
###################################################################### 
# Load in inputs and set input variables 
data=read.csv("BLASR CSVs/High_20pass.csv",head=F) 
output_name="processed_data/New CSVs/new_High_20_800_2.csv" 
###################################################################### 
 
###################################################################### 
#Set some empty variables and counting variables used in out for loop 
Query_list=c() 
QueryRange_list=c() 
TargetRange_list=c() 
Query_seq_list=c() 
Match_seq_list=c() 
Target_seq_list=c() 
Full_Query_seq_list=c() 
Full_Match_seq_list=c() 
Full_Target_seq_list=c() 
l=1 
Query_count=0 
Current_Query_count=0   
###################################################################### 
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###################################################################### 
# Initiate for loop taking data line by line. Assuming the start of a sequence entry extract 
the header information into variable lists. Skipping though the next two header lines 
with an empty else if recognise the start of the sequence section by setting query count 
being out of sync and set l to 1 to identify the start of the three lines of sequence match 
information. 
for(i in 1:nrow(data)){ 
    if (grepl("Query:",data[i,])){ 
    Query_list=c(Query_list,as.character(data[i,])) 
    QueryRange_list=c(QueryRange_list,as.character(data[(i+1),])) 
    TargetRange_list=c(TargetRange_list,as.character(data[(i+2),])) 
    Query_count=Query_count+1 
  }else if(grepl("QueryRange:",data[i,])){ 
  }else if(grepl("TargetRange:",data[i,])){ 
  }else if(l==1 & Query_count!=Current_Query_count){ 
###################################################################### 
   
###################################################################### 
# Add the concatenated sequence derived from the previous sequence entry to the list of 
all sequence entries and empty these variables. 
    Full_Query_seq_list=c(Full_Query_seq_list,Query_seq_list) 
    Full_Match_seq_list=c(Full_Match_seq_list,Match_seq_list) 
    Full_Target_seq_list=c(Full_Target_seq_list,Target_seq_list) 
    Query_seq_list=c() 
    Match_seq_list=c() 
    Target_seq_list=c() 
###################################################################### 
 
###################################################################### 
# Increase Current Query count ready to identify next sequence entry. Using Reg 
expression to identify the start point of the sequence information rather than the numeric 
point as this varies with the number whether the total sequence length is greater than 
1000 or less. Last two lines of this section fix an error occuring if there are none of any 
of the possible start point characters. 
    Current_Query_count=Current_Query_count+1  
    first_character=c(regexpr("A",as.character(data[i,])), 
                      regexpr("C",as.character(data[i,])), 
                      regexpr("T",as.character(data[i,])), 
                      regexpr("G",as.character(data[i,])), 
                      regexpr("-",as.character(data[i,]))) 
    first_character[first_character==-1]=NA 
    first_character=min(first_character,na.rm = T) 
###################################################################### 
     
###################################################################### 
# Having prepped for concatonation of the three sequences the first sequence is added to 
the appropriate variable then progresses on through the else if for the rest of the three 
sequence as Query_count was set to equal current query count. This continues until a 
new sequence entry is recognised by the header information. 
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Query_seq_list=paste(Query_seq_list,substring(as.character(data[i,]),first_character),se
p="") 
                l=2 
  }else if(l==1 & 
Query_count==Current_Query_count){Query_seq_list=paste(Query_seq_list, 
                                      substring(as.character(data[i,]),first_character),sep="") 
                 l=2 
  }else if(l==2){Match_seq_list=paste(Match_seq_list, 
                                      substring(as.character(data[i,]),first_character),sep="") 
                l=3 
  }else if(l==3){Target_seq_list=paste(Target_seq_list, 
                                       substring(as.character(data[i,]),first_character),sep="") 
                l=1 
  }} 
###################################################################### 
 
###################################################################### 
#Add the final concatenated sequence to the list of sequneces. 
Full_Query_seq_list=c(Full_Query_seq_list,Query_seq_list) 
Full_Match_seq_list=c(Full_Match_seq_list,Match_seq_list) 
Full_Target_seq_list=c(Full_Target_seq_list,Target_seq_list) 
###################################################################### 
 
###################################################################### 
# Bind together all the extracted data into a dataframe and store as named input 2 
new_data=cbind(Query_list,QueryRange_list,TargetRange_list,Full_Query_seq_list,Ful
l_Match_seq_list, 
               Full_Target_seq_list) 
write.csv(new_data,output_name) 
###################################################################### 
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Figure A35b: The following R script converts CSV information generated by the 
script in figure A27b into three matrices for sequence, match and quality 
information, respectively. The matrices contain information for individual 
nucleotides in individual matrix cells. 
###################################################################### 
###################################################################### 
# This Script creates a binary system for mismatches and aligns to whole plasmid 
sequence so that mutations can be counted at each position and creates a query sequence 
matrix for base calling 
# Inputs: 1) Formatted output from 'alignment conversion to fasta' R script (Figure 
A27a) 
#             2) List of Target strand orientations for each query sequence  
#             3) SAM output from BLASR, containing Quality score information 
# Output: 1) CSV named in input 3 that contains the match/mismatch matrix 
#              2) CSV named in input 3 that contains the sequence matrix 
#              3) CSV named in input 3 that contains the Quality matrix 
###################################################################### 
###################################################################### 
 
###################################################################### 
# Set working directory and clear the working directory and load required packages. 
setwd("/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts") 
 
rm (list=ls()) 
###################################################################### 
 
###################################################################### 
# Load in inputs and set input variables & bind target strand data to main dataframe 
data.1=read.csv("processed_data/New CSVs/new_Ecoli_15_800_2.csv") 
data2=read.csv("Target CSVs/Ecoli_15passTARGET.csv", header=F) 
data3=cbind(data.1,data2[,3]) 
names(data3)=c(names(data.1),"Target_Strand") 
FASTQ=read.delim("FASTQ BLASR/Ecoli_15_Q",header = F,quote="") 
FASTQ=FASTQ[5:nrow(FASTQ),] 
data=cbind(data3,FASTQ[,11]) 
names(data)=c(names(data3),"Q-scores") 
output_name="processed_data/Matrix CSVs/Ecoli_15/matrix_Ecoli_15_800_2.csv" 
output_name2="processed_data/Matrix 
CSVs/Ecoli_15/QUERY_matrix_Ecoli_15_800_2.csv" 
output_name3="processed_data/Matrix 
CSVs/Ecoli_15/Q_matrix_Ecoli_15_800_2.csv" 
###################################################################### 
 
###################################################################### 
# Taking the data line by line create variables a and b containing the sequence for the 
'Query' and 'Match' respectively. These are then separated into strings with one base 
reported per element 
# If query sequence is in opposite orientation it is converted into the proper orientation 
and 
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# complement and match data is reversed 
Perc=seq(from=1, to=nrow(data),by=100) 
Perc2=c(Perc,nrow(data)) 
i=1 
j=1 
full_matrix=matrix(,nrow=nrow(data),ncol=4965) 
full_matrix2=matrix(,nrow=nrow(data),ncol=4965) 
full_matrix3=matrix(,nrow=nrow(data),ncol=4965) 
matrix=matrix(,nrow=1,ncol=4965) 
matrix2=matrix(,nrow=1,ncol=4965) 
matrix3=matrix(,nrow=1,ncol=4965) 
for(i in 1:nrow(data)){ 
  a=as.character(data[i,5]) 
  b=as.character(data[i,6]) 
  c=as.character(data[i,9]) 
  if (data[i,8]==0){ 
    a=as.character(substring(a,c(1:nchar(a)),c(1:nchar(a)))) 
    b=as.character(substring(b,c(1:nchar(b)),c(1:nchar(b)))) 
    c=as.character(substring(c,c(1:nchar(c)),c(1:nchar(c))))} 
  if (data[i,8]==1){ 
    a=as.character(rev(substring(a,c(1:nchar(a)),c(1:nchar(a))))) 
    b=as.character(rev(substring(b,c(1:nchar(b)),c(1:nchar(b))))) 
    c=as.character(substring(c,c(1:nchar(c)),c(1:nchar(c))))} 
  if (data[i,8]==1){ 
    a=(unname(sapply(a, switch,  "A"="T.", "T"="A.","G"="C.","C"="G.","-"="-")))} 
  if (data[i,8]==0){ 
    a=unname(sapply(a, switch,  "A"="A.", "T"="T.","G"="G.","C"="C.","-"="-"))} 
     
###################################################################### 
 
###################################################################### 
# having created stings for each sequence this loop looks at each element in the 
sequence and asks the question is it a match thus scoring 0, a mismatch scoring 1, a 
deletion scoring NA, or a insertion scoring nothing (to avoid matrix misalignment) this 
score is built up into x_list. 
# The same information is used to create y_list and z_list, containing the query 
sequence without insertions. 
x_list=c() 
for(n in 1:  length(b)){ 
  #i=1} 
  if (b[n]=="|"){x=0 
  }  else if (b[n]=="*"){x=1 
  }  else if (b[n]==" "&a[n]=="-"){x=NA 
  }  else if (b[n]==" "&a[n]!="-"){x="X"} 
   
  if (is.na(x)){x_list=c(x_list,x) 
  }  else if (x==0|x==1){ 
  x_list=c(x_list,x)} 
} 
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  y_list=c() 
  for(n in 1:  length(b)){ 
    #i=1} 
    if (b[n]=="|"){y=(a[n]) 
    }  else if (b[n]=="*"){y=(a[n]) 
    }  else if (b[n]==" "& a[n]=="-"){y=NA 
    }  else if (b[n]==" "& a[n]!="-"){y="Y"} 
     
    if (is.na(y)){y_list=c(y_list,y) 
    }  else if (y=="A."|y=="T."|y=="C."|y=="G."){ 
      y_list=c(y_list,y)} 
  } 
   
  z_list=c() 
  k=1 
  for(n in 1:  length(b)){ 
    if (b[n]=="|"){z=(c[k]);k=k+1 
    }  else if (b[n]=="*"){z=(c[k]);k=k+1 
    }  else if (b[n]==" "& a[n]=="-"){z=NA 
    }  else if (b[n]==" "& a[n]!="-"){z="NULL"} 
     
    if (is.na(z)){z_list=c(z_list,z) 
    }  else if (z!="NULL"){ 
      z_list=c(z_list,z)}   
  } 
###################################################################### 
 
###################################################################### 
# Start and end positions relative to the target are calculated for the query sequence and 
matches.  This determines the number of NA's to be added to the front and the end of 
the sequence to give full length comparable to the full target sequence. The full 
sequence length is made of 'head' NA's at the start of the sequence, the sequence itself, 
and then 'tail' NA's until the end of the sequence. This is carried out for matches and 
query sequences to generate full matrices for all match and sequencing data 
 
start=c() 
end=c() 
  if (data[i,8]==0){ 
   start=as.numeric(strsplit(as.character(data[i,4])," ")[[1]][4]) 
   end=as.numeric(strsplit(as.character(data[i,4])," ")[[1]][6])} 
  if (data[i,8]==1){ 
    start=4965-as.numeric(strsplit(as.character(data[i,4])," ")[[1]][6]) 
    end=4965-as.numeric(strsplit(as.character(data[i,4])," ")[[1]][4])} 
    
 
head_NA=start 
tail_NA=4965-end 
matrix=c(rep(NA,head_NA),x_list,rep(NA,tail_NA)) 
matrix2=c(rep(NA,head_NA),as.character(y_list),rep(NA,tail_NA)) 
matrix3=c(rep(NA,head_NA),as.character(z_list),rep(NA,tail_NA)) 
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full_matrix[i,]=matrix 
full_matrix2[i,]=matrix2 
full_matrix3[i,]=matrix3 
 
if (i==Perc2[j]){ 
  print(i/nrow(data)*100,digits = 3);j=j+1} 
} 
 
full_data_frame=as.data.frame(cbind(data[,2],full_matrix)) 
full_data_frame2=as.data.frame(cbind(data[,2],full_matrix2)) 
full_data_frame3=as.data.frame(cbind(data[,2],full_matrix3)) 
###################################################################### 
 
###################################################################### 
# Save the compiled matrices to csv files 
write.csv(full_data_frame,output_name) 
write.csv(full_data_frame2,output_name2) 
write.csv(full_data_frame3,output_name3) 
###################################################################### 
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Figure A35c: The following R script removes error-prone ROIs from the analysis 
pipeline and provides a preliminary analysis on the extent of fragment mutation 
###################################################################### 
###################################################################### 
# This Script creates a modified matrices with removed error prone fragments and 
analyses the number of fragments that are mutated 
# Inputs: 1) Sequence matrix 
#             2) Match/mismatch matrix 
#             3) Quality matrix 
# Output: 1) Sequence matrix with error-prone fragments removed 
#              2) Match/mismatch matrix with error-prone fragments removed 
#              3) Quality matrix with error-prone fragments removed 
#              4) Statistics regarding the frequency of mutations in the fragments 
###################################################################### 
###################################################################### 
 
###################################################################### 
# Set working directory and clear the working directory and load required packages. 
setwd("/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts") 
rm (list=ls()) 
###################################################################### 
 
###################################################################### 
# Load in inputs and set input variables 
data=read.csv("processed_data/Matrix CSVs/High_10/matrix_High_10_800_2.csv") 
Query.data=read.csv("processed_data/Matrix 
CSVs/CHO_10/QUERY_matrix_CHO_10_800_2.csv") 
Q.data=read.csv("processed_data/Matrix 
CSVs/CHO_10/Q_matrix_CHO_10_800_2.csv") 
output_name="processed_data/Matrix CSVs/CHO_10/matrix_CHO_10_800_3.csv" 
output_name2="processed_data/Matrix 
CSVs/CHO_10/Query_matrix_CHO_10_800_3.csv" 
output_name3="processed_data/Matrix 
CSVs/CHO_10/Q_matrix_CHO_10_800_3.csv" 
output_name4="processed_data/Mutated Fragment 
Data/MUTFRAG_CHO_10_800_2.csv" 
###################################################################### 
 
###################################################################### 
#Remove unwanted columns 
# Remove all rows whose sum is greater than 3 - fragments seem to show sequencing 
error 
data2=data[,-c(1,2)] 
rSUMS=rowSums(data2,na.rm=T) 
data3=cbind(data,rSUMS) 
data4=data3[data3[,4968]<=3,] 
data5=data4[,-4968] 
 
Query.data2=Query.data[,-c(1,2)] 
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Query.data3=Query.data2[data3[,4968]<=3,] 
 
Q.data2=Q.data[,-c(1,2)] 
Q.data3=Q.data2[data3[,4968]<=3,] 
###################################################################### 
 
###################################################################### 
# Write altered dataset to csv 
write.csv(data5,output_name) 
write.csv(Query.data3,output_name2) 
write.csv(Q.data3,output_name3) 
###################################################################### 
 
###################################################################### 
# View deleted fragments in terms of number of detected mutations 
delsum=sort(data3[,4968], decreasing = T) 
head(delsum, n = 10) 
###################################################################### 
 
###################################################################### 
# calculate number mutated fragments, their % of total and the number of fragments 
with 1,2 or 3 mutations. Bind together. 
Mutated_Fragments=nrow(data4[data4[,4968]>0,]) 
Percent_Mutated_Fragments=Mutated_Fragments/nrow(data4)*100 
Mutated_Fragments1=nrow(data4[data4[,4968]==1,]) 
Mutated_Fragments2=nrow(data4[data4[,4968]==2,]) 
Mutated_Fragments3=nrow(data4[data4[,4968]==3,]) 
MUTFRAG=cbind(Mutated_Fragments,Percent_Mutated_Fragments,Mutated_Fragme
nts1,Mutated_Fragments2,Mutated_Fragments3) 
###################################################################### 
 
###################################################################### 
# write csv for mutated fragment data 
write.csv(MUTFRAG,output_name4) 
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Figure A35d: The following R script generates statistics and plots for mutation 
frequency along the length of the plasmid sequence. It also calculates nucleotide 
coverage 
###################################################################### 
###################################################################### 
# This Script generates statistics and plots for plasmid mutation frequency and plasmid 
position 
# Inputs: 1) Match/mismatch matrix 
# Output: 1) Table containing number of mutations and coverage at each target position. 
#              2) Statistics regarding plasmid mutation 
#              3) Plots for plasmid mutation and coverage 
###################################################################### 
##################################################################### 
 
###################################################################### 
# Set working directory and clear the working directory and load required packages. 
setwd("/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts") 
rm (list=ls()) 
###################################################################### 
 
###################################################################### 
# Load in inputs and set input variables 
data=read.csv("processed_data/Matrix CSVs/High_10/matrix_High_10_800_3.csv") 
output_name="processed_data/Mutation Tables/mutations_MOD_High_10_800_2.csv" 
output_name2="processed_data/Mutated Plasmid 
Data/MUTPLAS_MOD_High_10_800_2.csv" 
output_name3="processed_data/Mutated Plasmid Data/Av_COV_High_10_800_2.csv" 
PDFPath = "/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts/processed_data/Plots/plots_MOD_High_10_800_2.pdf" 
###################################################################### 
 
###################################################################### 
#Remove unwanted columns 
data2=data[,-c(1:3)] 
###################################################################### 
 
###################################################################### 
# Calculate the sum for all base pairs across the plasmid length.  
# Create data frame of sums where 0 = NA for clarity in plots 
# Create subset dataframe of this, only including obserbed mutations 
# Calculate the Coverage at each base pair position 
SUMS=colSums(data2,na.rm=T) 
 
COVER=c() 
for (i in 1:ncol(data2)){ 
  x=data2[,i] 
  cove=length(na.omit(x)) 
  COVER=c(COVER,cove)} 
Av.cov=mean(COVER) 
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write.csv(Av.cov,output_name3) 
plasmid=c(1:4965) 
MFREQ=as.data.frame(cbind(SUMS,plasmid,COVER)) 
MFREQ[MFREQ==0]=NA 
 
Mutations=as.data.frame(MFREQ[complete.cases(MFREQ),]) 
names(Mutations)=c("Mutations","Base number","Coverage") 
 
Coverage_T_Test=t.test(MFREQ[,3],Mutations[,3]) 
Coverage_Mean_Difference=mean(MFREQ[,3],na.rm = T)-mean(Mutations[,3]) 
###################################################################### 
 
###################################################################### 
#calculate minimum and maximums of SUMS and COVER datasets to establish y axis 
limits for plots 
max(SUMS) 
min(SUMS) 
max(COVER) 
min(COVER) 
head(sort(MFREQ[,1],decreasing=T)) 
###################################################################### 
 
###################################################################### 
# Plot coverage and sums and write out to pdf 
# For sum plots create one for overall and another for lower frequencies (higher 
resolution plot) 
# Write mutations to csv 
pdf(file=PDFPath) 
par(mfrow=c(1,1)) 
plot(COVER,pch="*",ylim=c(0,11000),ylab="Base Coverage",xlab="Base Pair 
Number") 
plot(MFREQ[,1]~MFREQ[,2],pch="*",ylim=c(1,7000),ylab="Mutation 
Frequency",xlab="Base Pair Number") 
plot(MFREQ[,1]~MFREQ[,2],pch="*",ylim=c(1,30),ylab="Mutation 
Frequency",xlab="Base Pair Number") 
dev.off() 
write.csv(Mutations,output_name) 
###################################################################### 
 
###################################################################### 
# Calculate the number of mutated positions of plasmid 
# Does coverage differ between mutated positions compared to all positions 
# Normalise number of mutated positions by sequence coverage 
# Write this data to csv 
Mutated_Positions=nrow(Mutations) 
Coverage_Mutation_Significance=Coverage_T_Test$p.value 
Normalised_Mutated_Positions=Mutated_Positions/mean(na.omit(MFREQ$COVER)) 
MUTPLAS=cbind(Mutated_Positions,Coverage_Mean_Difference,Coverage_Mutation
_Significance,Normalised_Mutated_Positions) 
write.csv(MUTPLAS,output_name2) 
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Figure A35e: The following R script generates an annotated list of mutations with 
mutation frequencies for all, Q score filtered and >1 filtered mutation sets. 
###################################################################### 
###################################################################### 
# This Script provides an annotated list of observed mutations for all, Q score filtered 
and >1 filtered data 
# Inputs: 1) sequence matrix 
#             2) Quality matrix 
#             3) GFP target sequence 
#             4) Quality character --> Phred score key 
#             5) List of mutations from mutation frequency table 
#             6) Mutation table generated in Analysis 2 
# Output: 1) Base type count at each plasmid position and corresponding target 
sequence 
#              2) Updated Mutation table containing the base changes. 
#              3) Updated Mutation table containing the base changes (Q score filtered). 
#              4) Updated Mutation table containing the base changes (>1 filtered). 
###################################################################### 
###################################################################### 
 
###################################################################### 
# Set working directory and clear the working directory and load required packages. 
setwd("/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts") 
rm (list=ls()) 
###################################################################### 
 
###################################################################### 
# Load in inputs and set input variables 
data=read.csv("processed_data/Matrix 
CSVs/High_10/QUERY_matrix_High_10_800_3.csv") 
data3=read.csv("processed_data/Matrix 
CSVs/High_10/Q_matrix_High_10_800_3.csv") 
GFP=read.csv("processed_data/GFP.csv",header = F, stringsAsFactors = F, colClasses 
= c("character")) 
Mutations=read.csv("processed_data/Mutation 
Tables/mutations_MOD_High_10_800_2.csv") 
FASTQ.CHAR=read.csv("FASTQ.VALUES.csv") 
output_name="processed_data/Base counts/BASE_High_10_800.csv" 
output_name2="processed_data/Mutation 
Tables/FINALmutations_MOD_High_10_800_2.csv" 
output_name3="processed_data/Mutation 
Tables/FINALmutations_MOD.Q_High_10_800_2.csv" 
output_name4="processed_data/Mutation 
Tables/FINALmutations_MOD.Q_>1_High_10_800_2.csv" 
PDFPath = "/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts/processed_data/Plots/plots_Q_High_10_800.pdf" 
###################################################################### 
 
###################################################################### 
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# remove information that is not sequence 
data2=(data[,-1]) 
qmat=(data3[,-1]) 
rm(data) 
rm(data3) 
###################################################################### 
 
###################################################################### 
# Alter the quality score matrix, so that each quality character is replaced by 
corresponding Phred score value 
 
FASTQ.CHAR=as.matrix(FASTQ.CHAR) 
 
QMAT2=as.matrix(qmat) 
QMAT3=matrix(,nrow=nrow(qmat),ncol=ncol(qmat)) 
for (j in 1:nrow(QMAT2)){ 
  QMATM=QMAT2[j,] 
  for (i in 1:nrow(FASTQ.CHAR)){ 
    x=FASTQ.CHAR[i,1] 
    y=FASTQ.CHAR[i,2] 
    QMATM=replace(QMATM,QMATM==x,y) 
  } 
  QMAT3[j,]=QMATM 
  print(j) 
} 
 
### Anything with Phred score lower than 25 (99.5% accuracy) changed to NA 
### Corresponding base in nucleotide matrix replaced with NA so it is not counted. 
 
data3=as.matrix(data2) 
QMAT4=QMAT3 
QMAT4[QMAT4<25]=NA 
 
for (i in 1:nrow(data3)){ 
  x=data3[i,] 
  x[is.na(QMAT4[i,])]=NA 
  data3[i,]=x 
  print(i) 
} 
###################################################################### 
 
###################################################################### 
# Base_count table created from number of A's, T's, C's or G's at each postion, along 
with the target sequence. 
# Save this as CSV file 
Adenosine=c() 
Thymine=c() 
Cytosine=c() 
Guanine=c() 
ad=c() 
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th=c() 
gu=c() 
cy=c() 
for (i in 1:ncol(data2)){ 
    ad=as.data.frame(summary(as.factor(data3[,i])))["A.",1] 
    th=as.data.frame(summary(as.factor(data3[,i])))["T.",1] 
    cy=as.data.frame(summary(as.factor(data3[,i])))["C.",1] 
    gu=as.data.frame(summary(as.factor(data3[,i])))["G.",1] 
  Adenosine=cbind(Adenosine,ad) 
  Thymine=cbind(Thymine,th) 
  Cytosine=cbind(Cytosine,cy) 
  Guanine=cbind(Guanine,gu)} 
 
GFP=as.matrix(GFP[1,]) 
 
Base_counts=rbind(Adenosine,Thymine,Cytosine,Guanine,GFP) 
rownames(Base_counts)=c("A","T","C","G","Seq")   
colnames(Base_counts)=c(1:4965) 
 
write.csv(Base_counts,output_name) 
###################################################################### 
 
###################################################################### 
# Create an updated mutation table containing the target base changed and the base it 
has changed to create 3 of these tables: 
#           1) Containing all mutations observed 
#           2) Mutations removed by quality filtering 
#           3) Mutations occuring only once removed 
# plots for these 
# save to CSV 
 
Basenames=as.numeric(colnames(Base_counts)) 
 
Targ=c() 
Target=c() 
for (i in 1:nrow(Mutations)){ 
  Targ=Base_counts[5,Basenames[Mutations[i,3]]] 
  Target=rbind(Target,Targ)} 
Mutations2=cbind(Mutations,Target[,1]) 
 
Empty.changes=matrix(0,nrow=nrow(Mutations2),ncol=4) 
colnames(Empty.changes)=c("A","T","C","G") 
for (i in 1:nrow(Mutations)){ 
  if(is.na(Base_counts[1,Basenames[Mutations[i,3]]])==F & Mutations2[i,5]!="A"){ 
Empty.changes[i,1]=as.numeric(Base_counts[1,Mutations[i,3]])} 
  if(is.na(Base_counts[2,Basenames[Mutations[i,3]]])==F & Mutations2[i,5]!="T"){ 
Empty.changes[i,2]=as.numeric(Base_counts[2,Mutations[i,3]])} 
  if(is.na(Base_counts[3,Basenames[Mutations[i,3]]])==F & Mutations2[i,5]!="C"){ 
Empty.changes[i,3]=as.numeric(Base_counts[3,Mutations[i,3]])} 
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  if(is.na(Base_counts[4,Basenames[Mutations[i,3]]])==F & Mutations2[i,5]!="G"){ 
Empty.changes[i,4]=as.numeric(Base_counts[4,Mutations[i,3]])}} 
 
Mutations2=cbind(Mutations2,Empty.changes) 
Mutations.2=rowSums(Mutations2[,c(6:9)]) 
Mutations2=cbind(Mutations2[,c(1:2)],Mutations.2,Mutations2[,c(3:9)]) 
Mutations3=Mutations2[,c(7:10)] 
Mutations3[Mutations3==1]=0 
Mutations.3=rowSums(Mutations3) 
Mutations3=cbind(Mutations2[,c(1:3)],Mutations.3,Mutations2[,c(4:6)],Mutations3) 
Mutations4=Mutations3[Mutations3[,3]>0,] 
Mutations5=Mutations4[Mutations4[,4]>0,] 
 
for (i in 1:nrow(Mutations3)){ 
  if (Mutations3[i,5]==2539) 
    RM=i} 
for (i in 1:nrow(Mutations4)){ 
  if (Mutations4[i,5]==2539) 
    RM2=i} 
for (i in 1:nrow(Mutations5)){ 
  if (Mutations5[i,5]==2539) 
    RM3=i} 
 
YLIM1=round(sort(Mutations3[,2],decreasing=T)[2]+5,-1) 
 
pdf(file=PDFPath)    
par(mfrow=c(1,1)) 
plot(Mutations3[-RM,2]~Mutations3[-RM,5],xlim=c(1,5000),ylim=c(0,YLIM1),xlab = 
"Base Pair Number", ylab = "Mutation Frequency",pch="*") 
plot(Mutations4[-RM2,3]~Mutations4[-RM2,5],xlim=c(1,5000),ylim=c(0,YLIM1),xlab 
= "Base Pair Number", ylab = "Mutation Frequency",pch="*") 
plot(Mutations5[-RM3,4]~Mutations5[-RM3,5],xlim=c(1,5000),ylim=c(0,YLIM1),xlab 
= "Base Pair Number", ylab = "Mutation Frequency",pch="*") 
dev.off() 
 
write.csv(Mutations3,output_name2) 
write.csv(Mutations4,output_name3) 
write.csv(Mutations5,output_name4) 
###################################################################### 
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Figure A35f: The following R script calculates the amount of mutation in each 
element of the plasmid. It also calculates the proportion of each type of mutation 
that was observed. It then generates various statistics regarding mutation 
frequency and  an overall mutation rate. 
###################################################################### 
###################################################################### 
# This Script calculates the percentage of mutation that falls within each genetic 
element of the plasmid sequence and calculates the number of each mutation type. Then 
mutation information is normalised by the average coverage of the sample. Overall 
mutation rates are then calculated. 
# Inputs: 1) Mutation table for all mutations 
#             2) Mutation table for Q score filtered mutations 
#             3) Mutation table for >1 filtered mutations 
#             4) Base counts table 
#             5) Average coverage for the sample 
# Output: 1) A table containing the percentage mutation of each plasmid genetic 
element 
#              2) A table containing the percentage of each mutation type 
#              3) A table containing mutation frequency information 
###################################################################### 
###################################################################### 
 
###################################################################### 
# Set working directory and clear the working directory and load required packages. 
setwd("/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts") 
rm (list=ls()) 
###################################################################### 
 
###################################################################### 
# Load in inputs and set input variables 
Mutation1=read.csv("processed_data/Mutation 
Tables/FINALmutations_MOD_High_10_800_2.csv") 
Mutation2=read.csv("processed_data/Mutation 
Tables/FINALmutations_MOD.Q_High_10_800_2.csv") 
Mutation3=read.csv("processed_data/Mutation 
Tables/FINALmutations_MOD.Q_>1_High_10_800_2.csv") 
Base_counts=read.csv("processed_data/Base counts/BASE_High_10_800.csv") 
Av.cov=read.csv("processed_data/Mutated Plasmid 
Data/Av_COV_High_10_800_2.csv") 
output_name1="processed_data/Mutation Annotation/High_10_position.csv" 
output_name2="processed_data/Mutation Annotation/High_10_Bases.csv" 
output_name3="processed_data/Mutated Plasmid 
Data/High_10_MUTPLAS_NEW.csv" 
###################################################################### 
 
###################################################################### 
# Create dataframe with plasmid annotations 
# Use dataframe to create a table regarding the plasmid positions percentages of 
mutations 
Appendix 
	 269	
# Standardise these numbers by dividing by the number of bases in a given element 
Emat=matrix(,nrow=4965,ncol=12) 
colnames(Emat)=c("pAmp","pSV40","Kan/Neo","HSV_TK_PolyA","Puc_Ori","phCM
V_and_Intron","phCMV_and_Intron_MCS.1","pT7","MCS.1","GFP_ORF","MCS.2","
SV40_PolyA") 
Emat[c(527:555),1]="pAmp";Emat[c(639:868),2]="pSV40";Emat[c(990:1784),3]="Ka
n/Neo";Emat[c(2020:2038),4]="HSV_TK_PolyA";Emat[c(2369:3012),5]="Puc_Ori"; 
Emat[c(3153:3838),6]="phCMV_and_Intron";Emat[c(3839:3852),7]="phCMV_and_In
tron_MCS.1";Emat[c(3853:3868),8]="pT7";Emat[c(3869:3902),7]="phCMV_and_Intro
n_MCS.1"; 
Emat[c(3903:3952),9]="MCS.1";Emat[c(3953:4672),10]="GFP_ORF";Emat[c(4673:47
42),11]="MCS.2"; 
Emat[c(4878:4928),12]="SV40_PolyA" 
 
Element=matrix(,nrow=nrow(Mutation3),ncol=1) 
for (i in 1:nrow(Mutation3)){ 
  x=Emat[Mutation3[i,6],] 
  Y=c() 
  for (j in 1:ncol(Emat)){ 
    y=c() 
    if (is.na(x[j])==F){ 
      y=x[j]} 
      Y=c(Y,y)} 
  if (length(Y)==0){ 
    Y="Non-coding"} 
  Element[i,]=Y} 
Mutation.A=cbind(Mutation3,Element)     
names(Mutation.A)=c(names(Mutation3),"Element") 
  
Element_percentages=matrix(,nrow=3,ncol=13) 
colnames(Element_percentages)=c("pAmp","pSV40","Kan/Neo","HSV_TK_PolyA","P
uc_Ori","phCMV_and_Intron","phCMV_and_Intron_MCS.1","pT7","MCS.1","GFP_O
RF","MCS.2","SV40_PolyA","Non-coding") 
 
for (i in 1:ncol(Element_percentages)){ 
Element_percentages[1,i]=round(summary(Mutation.A$Element)[colnames(Element_p
ercentages)[i]]/nrow(Mutation.A)*100,digits=1)} 
 
Element_percentages[1,][is.na(Element_percentages[1,])]=0 
Elengths=matrix(,nrow=1,ncol=12) 
for (i in 1:ncol(Elengths)){ 
  Elengths[i]=length(na.omit(Emat[,i]))} 
NC=4965-sum(Elengths) 
Elengths2=cbind(Elengths,NC) 
Element_percentages[2,]=Elengths2 
 
Enorm=Element_percentages[1,]/Element_percentages[2,]*1000 
Element_percentages[3,]=Enorm 
Element_percentages=round(Element_percentages,digits=2) 
rownames(Element_percentages)=c("Percentage","Element_Bases","Normalised") 
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write.csv(Element_percentages,output_name1) 
###################################################################### 
 
###################################################################### 
# Create a table illustrating the percentage mutation frequency of each base change type 
Base_percentages=matrix(,nrow=4,ncol=5) 
rownames(Base_percentages)=c("A","T","C","G") 
colnames(Base_percentages)=c("A","T","C","G","Total") 
 
Mutation_base=Mutation3[9:12] 
Mutation_base[Mutation_base==0]=NA 
 
Y=c() 
for (i in 1:nrow(Mutation_base)){ 
  x=Mutation_base[i,] 
  y=c() 
  for (j in 1:length(x)){ 
  if (is.na(x[j])==F){ 
    y=colnames(Mutation_base)[j]}} 
    Y=rbind(Y,y)} 
colnames(Y)=c("Change") 
Mutation3=cbind(Mutation3,Y[,1])   
   
A_to_T=Mutation3[Mutation3[,8]=="A" & 
Mutation3[,13]=="T",];Base_percentages[1,2]=round(nrow(A_to_T)/nrow(Mutation3)*
100,digits=2)   
A_to_C=Mutation3[Mutation3[,8]=="A" & 
Mutation3[,13]=="C",];Base_percentages[1,3]=round(nrow(A_to_C)/nrow(Mutation3)
*100,digits=2)   
A_to_G=Mutation3[Mutation3[,8]=="A" & 
Mutation3[,13]=="G",];Base_percentages[1,4]=round(nrow(A_to_G)/nrow(Mutation3)
*100,digits=2)   
T_to_A=Mutation3[Mutation3[,8]=="T" & 
Mutation3[,13]=="A",];Base_percentages[2,1]=round(nrow(T_to_A)/nrow(Mutation3)
*100,digits=2)   
T_to_C=Mutation3[Mutation3[,8]=="T" & 
Mutation3[,13]=="C",];Base_percentages[2,3]=round(nrow(T_to_C)/nrow(Mutation3)*
100,digits=2)   
T_to_G=Mutation3[Mutation3[,8]=="T" & 
Mutation3[,13]=="G",];Base_percentages[2,4]=round(nrow(T_to_G)/nrow(Mutation3)
*100,digits=2)     
C_to_A=Mutation3[Mutation3[,8]=="C" & 
Mutation3[,13]=="A",];Base_percentages[3,1]=round(nrow(C_to_A)/nrow(Mutation3)
*100,digits=2)   
C_to_T=Mutation3[Mutation3[,8]=="C" & 
Mutation3[,13]=="T",];Base_percentages[3,2]=round(nrow(C_to_T)/nrow(Mutation3)*
100,digits=2)   
C_to_G=Mutation3[Mutation3[,8]=="C" & 
Mutation3[,13]=="G",];Base_percentages[3,4]=round(nrow(C_to_G)/nrow(Mutation3)
*100,digits=2)   
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G_to_A=Mutation3[Mutation3[,8]=="G" & 
Mutation3[,13]=="A",];Base_percentages[4,1]=round(nrow(G_to_A)/nrow(Mutation3)
*100,digits=2)   
G_to_T=Mutation3[Mutation3[,8]=="G" & 
Mutation3[,13]=="T",];Base_percentages[4,2]=round(nrow(G_to_T)/nrow(Mutation3)*
100,digits=2)   
G_to_C=Mutation3[Mutation3[,8]=="G" & 
Mutation3[,13]=="C",];Base_percentages[4,3]=round(nrow(G_to_C)/nrow(Mutation3)
*100,digits=2) 
 
Base_percentages[1,5]=sum(na.omit(Base_percentages[1,c(1:4)])) 
Base_percentages[2,5]=sum(na.omit(Base_percentages[2,c(1:4)])) 
Base_percentages[3,5]=sum(na.omit(Base_percentages[3,c(1:4)])) 
Base_percentages[4,5]=sum(na.omit(Base_percentages[4,c(1:4)])) 
write.csv(Base_percentages,output_name2) 
###################################################################### 
 
###################################################################### 
#Create a table summarising the mutation frequencies observed and normalise using 
coverage. 
Mutated_positions=nrow(Mutation1) 
Mutated_positions_Q=nrow(Mutation2) 
Mutated_positions_1=nrow(Mutation3) 
Mutation_number_Q=sum(Mutation2$Mutations.2) 
Mutation_number_1=sum(Mutation3$Mutations.3) 
Mutated_positions_norm=Mutated_positions/Av.cov[1,2] 
Mutated_positions_Q_norm=Mutated_positions_Q/Av.cov[1,2] 
Mutated_positions_1_norm=Mutated_positions_1/Av.cov[1,2] 
Mutation_number_Q_norm=Mutation_number_Q/Av.cov[1,2] 
Mutation_number_1_norm=Mutation_number_1/Av.cov[1,2] 
Plasmid_mutations=cbind(Mutated_positions,Mutated_positions_Q,Mutated_positions_
1,Mutated_positions_norm,Mutated_positions_Q_norm,Mutated_positions_1_norm) 
write.csv(Plasmid_mutations,output_name3) 
###################################################################### 
 
###################################################################### 
# Overall mutation rates 
zxc=Base_counts[c(1:4),c(2:4966)] 
z=0 
for (i in 1:nrow(zxc)){ 
  x=zxc[i,] 
  y=0 
  for (j in 1:ncol(x)){ 
    if (is.na(as.numeric(as.character(x[1,j])))==F){ 
      y=y+as.numeric(as.character(x[1,j]))}} 
  z=z+y} 
 
Q_mut_rate=z/(sum(Mutation2$Mutations.2)-Mutation2[Mutation2[,6]==2539,4]) 
once_mut_rate=z/(sum(Mutation3$Mutations.3)-Mutation3[Mutation3[,6]==2539,4]) 
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Figure A35f: The following R script calculates the number of synonymous and 
non-synonymous mutations in the GFP and Kan / Neo ORFs. It then calculates the 
general probability of a non-synonymous or synonymous mutation occurring. 
###################################################################### 
###################################################################### 
# This Script calculates the percentage of synonymous and non-synonymous mutations. 
It then simulates the raw probability of these occuring for comparison 
# Inputs: 1) Base_counts table 
#             2) Mutation table (>1 filtered) 
#             3) Codon sequence key 
###################################################################### 
###################################################################### 
 
###################################################################### 
# Set working directory and clear the working directory and load required packages. 
setwd("/Users/josephcartwright/Google Drive/shared folder-JLongworth & 
JCartwright/R scripts") 
rm (list=ls()) 
###################################################################### 
 
###################################################################### 
# Load in inputs and set input variables 
Mutation1=read.csv("processed_data/Mutation 
Tables/FINALmutations_MOD.Q_>1_High_10_800_2.csv") 
Base_counts=read.csv("processed_data/Base counts/BASE_High_10_800.csv") 
Codons=read.csv("Amino acid codons.csv",header = F) 
names(Codons)=c("Amino_acid","1","2","3") 
###################################################################### 
 
###################################################################### 
# Create dataframes for open reading frame positions 
Kan_Neo=seq(990:1784)+989 
GFP=seq(3953:4672)+3952 
 
# Create mutation dataframe for Kan/Neo gene only 
Kan_mut=c() 
for (i in 1:length(Kan_Neo)){ 
  x=Mutation1[Mutation1[,6]==Kan_Neo[i],] 
  Kan_mut=rbind(Kan_mut,x)} 
 
# Create mutation dataframe for GFP gene only 
GFP_mut=c() 
for (i in 1:length(GFP)){ 
  x=Mutation1[Mutation1[,6]==GFP[i],] 
  GFP_mut=rbind(GFP_mut,x)} 
 
# Isolate ORF sequences       
Plasmid=Base_counts[5,c(2:4966)]     
Kan_seq=Plasmid[c(990:1784)]     
GFP_seq=Plasmid[c(3953:4672)] 
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names(Kan_seq)=c(Kan_Neo[1:length(Kan_Neo)]) 
names(GFP_seq)=c(GFP[1:length(GFP)]) 
###################################################################### 
 
###################################################################### 
#KAN/NEO GENE 
# Split Kan/Neo ORF into codons by row 
Kan_pos=seq(0,length(Kan_seq)-1, by=3) 
Kan_cod=matrix(,nrow=length(Kan_pos),ncol=3) 
for (i in 1:length(Kan_pos)){ 
  x=as.matrix(Kan_seq[c((1+Kan_pos[i]):(3+Kan_pos[i]))]) 
  Kan_cod[i,]=x} 
Kan_cod=as.data.frame(Kan_cod) 
 
# Annotate each codon with amino acid it codes 
b=c() 
for (i in 1:nrow(Kan_cod)){ 
  x=Kan_cod[i,1]      
  y=Kan_cod[i,2]   
  z=Kan_cod[i,3]    
  a=as.character(Codons[Codons[,2]==x & Codons[,3]==y & Codons[,4]==z,1])  
  b=rbind(b,a) 
  } 
  Kan_cod=cbind(Kan_cod,b[,1])   
 
# Change all base annotations that are 0 to NA in Kan_mut dataframe    
Kan_mut.x=Kan_mut[,c(9:12)]  
Kan_mut.x[Kan_mut.x==0]=NA   
Kan_mut[,c(9:12)]=Kan_mut.x   
 
# add in extra rows to Kan_mut where two mutation types are seen and label each 
change - named Kan_mut2 
Kan_mut2=c() 
for (j in 1:nrow(Kan_mut)){ 
z=Kan_mut[j,c(9:12)] 
y=c() 
for (i in 1:length(z)){ 
  if (is.na(z[i])==F){ 
    x=z[i] 
    y=c(y,x)}} 
 
if (length(y)==1){w=Kan_mut[j,]} 
if (length(y)==2){w=rbind(Kan_mut[j,],Kan_mut[j,])} 
if (length(y)==3){w=rbind(Kan_mut[j,],Kan_mut[j,],Kan_mut[j,])} 
if (length(y)==4){w=rbind(Kan_mut[j,],Kan_mut[j,],Kan_mut[j,],Kan_mut[j,])} 
 
N=names(y) 
u=cbind(w,N) 
Kan_mut2=rbind(Kan_mut2,u) 
} 
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#create a matrix containing all mutated versions of the Kan/Neo seqeunce 
Kan_changes=matrix(,nrow=nrow(Kan_mut2),ncol=ncol(Kan_seq)) 
for (i in 1:nrow(Kan_mut2)){ 
  Kan_changes[i,]=as.matrix(Kan_seq)} 
colnames(Kan_changes)=names(Kan_seq) 
for (i in 1:nrow(Kan_mut2)){ 
  
Kan_changes[i,colnames(Kan_changes)==Kan_mut2[i,6]]=as.character(Kan_mut2[i,13
])} 
 
# Create a numerical position dataframe to mirror codons 
Kan_Neo2=as.data.frame(Kan_Neo) 
Kan_Neo3=t(Kan_Neo2) 
Kan_pos=seq(0,length(Kan_seq)-1, by=3) 
Kan_Neo4=matrix(,nrow=length(Kan_pos),ncol=3) 
for (i in 1:length(Kan_pos)){ 
  x=as.matrix(Kan_Neo3[c((1+Kan_pos[i]):(3+Kan_pos[i]))]) 
  Kan_Neo4[i,]=x} 
Kan_Neo4=as.data.frame(Kan_Neo4) 
 
# Create a dataframe containing reference amino acids and the amino acid seen as a 
result of mutation 
# Append this to Kan_mut dataframe and create an extra Synonymous vs Non-
synonymous column 
Kan_amino_changes=c() 
colnames(Kan_amino_changes)=c(colnames(w)) 
for (i in 1:nrow(Kan_changes)){ 
  a=matrix(,nrow=length(Kan_pos),ncol=3) 
  b=Kan_changes[i,] 
  for (j in 1:length(Kan_pos)){ 
    c=as.matrix(b[c((1+Kan_pos[j]):(3+Kan_pos[j]))]) 
    a[j,]=c} 
  a=as.data.frame(a) 
   
  d=c() 
  z=c() 
  for (k in 1:nrow(a)){ 
    e=a[k,1] 
    f=a[k,2] 
    g=a[k,3] 
    h=as.character(Codons[Codons[,2]==e & Codons[,3]==f & Codons[,4]==g,1]) 
    z=rbind(z,h) 
  } 
  a=cbind(a,z[,1]) 
   
  y=as.character(a[Kan_Neo4[,1]==Kan_mut2[i,6] | Kan_Neo4[,2]==Kan_mut2[i,6] | 
Kan_Neo4[,3]==Kan_mut2[i,6],4]) 
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  x=as.character(Kan_cod[Kan_Neo4[,1]==Kan_mut2[i,6] | 
Kan_Neo4[,2]==Kan_mut2[i,6] | Kan_Neo4[,3]==Kan_mut2[i,6],4]) 
  w=cbind(x,y) 
  colnames(w)=c("Reference","Sample") 
   
  Kan_amino_changes=rbind(Kan_amino_changes,w)} 
   
Kan_mut3=cbind(Kan_mut2,Kan_amino_changes) 
 
 
Kan_change_type=c() 
for (i in 1:nrow(Kan_mut3)){ 
  if (as.character(Kan_mut3[i,14])==as.character(Kan_mut3[i,15])){ 
    x="Synonymous"} 
  else{x="Non-Synonymous"} 
  Kan_change_type=rbind(Kan_change_type,x)} 
 
Kan_mut3=cbind(Kan_mut3,Kan_change_type) 
 
summary(Kan_mut3$Kan_change_type) 
###################################################################### 
 
###################################################################### 
#GFP GENE 
# Split GFP ORF into codons by row 
GFP_pos=seq(0,length(GFP_seq)-1, by=3) 
GFP_cod=matrix(,nrow=length(GFP_pos),ncol=3) 
for (i in 1:length(GFP_pos)){ 
  x=as.matrix(GFP_seq[c((1+GFP_pos[i]):(3+GFP_pos[i]))]) 
  GFP_cod[i,]=x} 
GFP_cod=as.data.frame(GFP_cod) 
 
# Annotate each codon with amino acid it codes 
b=c() 
for (i in 1:nrow(GFP_cod)){ 
  x=GFP_cod[i,1]      
  y=GFP_cod[i,2]   
  z=GFP_cod[i,3]    
  a=as.character(Codons[Codons[,2]==x & Codons[,3]==y & Codons[,4]==z,1])  
  b=rbind(b,a) 
} 
GFP_cod=cbind(GFP_cod,b[,1])   
 
# Change all base annotations that are 0 to NA in GFP_mut dataframe    
GFP_mut.x=GFP_mut[,c(9:12)]  
GFP_mut.x[GFP_mut.x==0]=NA   
GFP_mut[,c(9:12)]=GFP_mut.x   
 
# add in extra rows to GFP_mut where two mutation types are seen and label each 
change - named GFP_mut2 
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GFP_mut2=c() 
for (j in 1:nrow(GFP_mut)){ 
  z=GFP_mut[j,c(9:12)] 
  y=c() 
  for (i in 1:length(z)){ 
    if (is.na(z[i])==F){ 
      x=z[i] 
      y=c(y,x)}} 
   
  if (length(y)==1){w=GFP_mut[j,]} 
  if (length(y)==2){w=rbind(GFP_mut[j,],GFP_mut[j,])} 
  if (length(y)==3){w=rbind(GFP_mut[j,],GFP_mut[j,],GFP_mut[j,])} 
  if (length(y)==4){w=rbind(GFP_mut[j,],GFP_mut[j,],GFP_mut[j,],GFP_mut[j,])} 
   
  N=names(y) 
  u=cbind(w,N) 
  GFP_mut2=rbind(GFP_mut2,u) 
} 
 
 
#create a matrix containing all mutated versions of the GFP seqeunce 
GFP_changes=matrix(,nrow=nrow(GFP_mut2),ncol=ncol(GFP_seq)) 
for (i in 1:nrow(GFP_mut2)){ 
  GFP_changes[i,]=as.matrix(GFP_seq)} 
colnames(GFP_changes)=names(GFP_seq) 
for (i in 1:nrow(GFP_mut2)){ 
  
GFP_changes[i,colnames(GFP_changes)==GFP_mut2[i,6]]=as.character(GFP_mut2[i,1
3])} 
 
# Create a numerical position dataframe to mirror codons 
GFP2=as.data.frame(GFP) 
GFP3=t(GFP2) 
GFP_pos=seq(0,length(GFP_seq)-1, by=3) 
GFP4=matrix(,nrow=length(GFP_pos),ncol=3) 
for (i in 1:length(GFP_pos)){ 
  x=as.matrix(GFP3[c((1+GFP_pos[i]):(3+GFP_pos[i]))]) 
  GFP4[i,]=x} 
GFP4=as.data.frame(GFP4) 
 
# Create a dataframe containing reference amino acids and the amino acid seen as a 
result of mutation 
# Append this to GFP_mut dataframe and create an extra Synonymous vs Non-
synonymous column 
GFP_amino_changes=c() 
colnames(GFP_amino_changes)=c("Reference","Sample") 
for (i in 1:nrow(GFP_changes)){ 
  a=matrix(,nrow=length(GFP_pos),ncol=3) 
  b=GFP_changes[i,] 
  for (j in 1:length(GFP_pos)){ 
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    c=as.matrix(b[c((1+GFP_pos[j]):(3+GFP_pos[j]))]) 
    a[j,]=c} 
  a=as.data.frame(a) 
   
  d=c() 
  z=c() 
  for (k in 1:nrow(a)){ 
    e=a[k,1] 
    f=a[k,2] 
    g=a[k,3] 
    h=as.character(Codons[Codons[,2]==e & Codons[,3]==f & Codons[,4]==g,1]) 
    z=rbind(z,h) 
  } 
  a=cbind(a,z[,1]) 
   
  y=as.character(a[GFP4[,1]==GFP_mut2[i,6] | GFP4[,2]==GFP_mut2[i,6] | 
GFP4[,3]==GFP_mut2[i,6],4]) 
  x=as.character(GFP_cod[GFP4[,1]==GFP_mut2[i,6] | GFP4[,2]==GFP_mut2[i,6] | 
GFP4[,3]==GFP_mut2[i,6],4]) 
  w=cbind(x,y) 
  colnames(w)=c("Reference","Sample") 
   
  GFP_amino_changes=rbind(GFP_amino_changes,w)} 
 
GFP_mut3=cbind(GFP_mut2,GFP_amino_changes) 
 
 
GFP_change_type=c() 
for (i in 1:nrow(GFP_mut3)){ 
  if (as.character(GFP_mut3[i,14])==as.character(GFP_mut3[i,15])){ 
    x="Synonymous"} 
  else{x="Non-Synonymous"} 
  GFP_change_type=rbind(GFP_change_type,x)} 
 
GFP_mut3=cbind(GFP_mut3,GFP_change_type) 
 
summary(GFP_mut3$GFP_change_type)   
 
###################################################################### 
 
###################################################################### 
# Calculate the probability of synonymous vs non-synonymous mutations 
 
Codons2=Codons 
Codons3=Codons 
Codons4=Codons 
Codons5=Codons 
 
Total=c() 
for (i in 1:nrow(Codons2)){ 
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  x=Codons2[i,] 
  for (j in 2:4){ 
    r=c();Codons3=Codons;Codons4=Codons;Codons5=Codons 
    if 
(as.character(x[1,j])=="A"){Codons3[i,j]="T";Codons4[i,j]="C";Codons5[i,j]="G"}  
    if 
(as.character(x[1,j])=="T"){Codons3[i,j]="A";Codons4[i,j]="C";Codons5[i,j]="G"} 
    if 
(as.character(x[1,j])=="C"){Codons3[i,j]="T";Codons4[i,j]="A";Codons5[i,j]="G"} 
    if 
(as.character(x[1,j])=="G"){Codons3[i,j]="T";Codons4[i,j]="C";Codons5[i,j]="A"} 
    
a=as.character(Codons3[i,2]);b=as.character(Codons3[i,3]);c=as.character(Codons3[i,4]
) 
    
d=as.character(Codons4[i,2]);e=as.character(Codons4[i,3]);f=as.character(Codons4[i,4]
) 
    
g=as.character(Codons5[i,2]);h=as.character(Codons5[i,3]);k=as.character(Codons5[i,4]
) 
    l=as.character(Codons[Codons[,2]==a & Codons[,3]==b & Codons[,4]==c,1]) 
    m=as.character(Codons[Codons[,2]==d & Codons[,3]==e & Codons[,4]==f,1]) 
    n=as.character(Codons[Codons[,2]==g & Codons[,3]==h & Codons[,4]==k,1]) 
    if (as.character(Codons3[i,1])==l){o="Synonymous"}else{o="Non-Synonymous"} 
    if (as.character(Codons4[i,1])==m){p="Synonymous"}else{p="Non-Synonymous"} 
    if (as.character(Codons5[i,1])==n){q="Synonymous"}else{q="Non-Synonymous"} 
    r=rbind(o,p,q) 
    Total=rbind(Total,r)}} 
 
Syn=0 
Non=0 
for (i in 1:nrow(Total)){ 
  if (Total[i,1]=="Non-Synonymous"){Non=Non+1}else{Syn=Syn+1}} 
 
